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Abstract 
 
Chapter one is split into three sections, providing general overviews of synthetic retinoids 
and their biology, Pd-catalysed C-C bond forming reactions and transition metal-
catalysed borylation of aromatic and vinylic C-H bonds, respectively.  
 
Chapter two details the application of sequential Ir-catalysed aromatic C-H borylations, 
Pd-catalysed C-C bond forming reactions and Rh-catalysed vinylic C-H borylations for 
the stereo-controlled synthesis of stilbene-based TTNPB retinoids. 
 
Chapter three details the application of Ir-catalysed aromatic C-H borylations, 
Sonogashira cross-couplings and Suzuki-Miyaura cross-couplings for the synthesis of 
tolan-, and biaryl-based retinoids. 
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Chapter four details the development and applications of new Rh
I
 catalyst precursors for 
the dehydrogenative borylation of unactivated olefins. The dehydrogenative borylation 
reactions were utilised in one-pot, single solvent syntheses of 2-arylindenes from indene 
and arylhalides through C-H borylation and subsequent Suzuki-Miyaura cross-couplings. 
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1.1 Retinoids 
 
1.1.1 Natural retinoids and their biology 
 
The retinoids are a class of over 4000 natural and synthetic molecules structurally and/or 
functionally related to all-trans-retinoic acid (ATRA), a metabolite of vitamin A 
(retinol).
1
 Endogenous ATRA regulates a range of essential processes during chordate 
embryogenesis and adult homeostasis including; embryonic development,
2 
vision,
3
 and 
cellular differentiation, proliferation and apoptosis.
4
 Retinoids are successfully used to 
treat certain dermatological conditions
5 
and have the potential to act as chemo-
preventative and chemotherapeutic agents, although toxicity issues have prevented their 
more widespread use.
6,7
 ATRA isomerises under laboratory and physiological conditions
 
 
to give mixtures of ATRA, 9-cis-retinoic acid (9cRA), 13-cis-retinoic acid (13cRA) 
(Figure 1.1) and other species.
8,9,10,11,12 
 
CO2H
ATRA
CO2H
13cRA
CO2H
9cRA
 
Figure 1.1 Natural retinoids. 
 
The structure of retinoids can be thought of as comprising three units, (as shown in 
Figure 1.2 for ATRA) a bulky, hydrophobic region, a linker unit and a polar terminus, 
which is usually a carboxylic acid group. 
 
Hydrophobic 
unit
Linker unit
Polar 
terminus
Hydrophobic 
unit
Linker unit Polar 
terminus
CO2H
Retinoid structural units Generic retinoid structure  
Figure 1.2 Retinoid structure. 
25 
 
Vitamin A (retinol, Figure 1.3) cannot be synthesised by any animal species and is 
obtained through the diet, either from pro-vitamin A carotinoids in plants (such as 
β-carotenoid) or directly from other animals. Ingested vitamin A is stored as retinyl esters 
in the liver until needed, at which time it is transported bound to retinol binding protein 
(RBP).
13 
Retinol is reversibly oxidised by retinol dehydrogenases (ROLDH) to give 
retinal which may then be irreversibly oxidised to ATRA
14
 by retinal dehydrogenases 
(RALDH), or by cytochrome P450 enzymes in hepatic tissue.
15 
ATRA can cross the 
plasma membrane passively and is translocated by cellular retinoic acid binding proteins 
(CRABP-I & II) to the nucleus where it binds to nuclear receptors. Otherwise, free 
ATRA can be stored by binding to retinoic acid binding protein I (CRABP-I), a process 
which inhibits its biological activity
16
 or can be oxidised by cytochrome P450 enzymes in 
conjunction with CRABP-I to give polar metabolites such as 4-hydroxy-retinoic acid and 
18-hydroxy-retinoic acid.
17
 
 
CHO
retinal
CH2OH
retinol-carotene
CO2H
ATRA  
 
Figure 1.3 ATRA biosynthesis precursors and ATRA. 
 
Retinoid activity results primarily from the transcriptional regulation of specific genes 
which is regulated by the binding of retinoids to receptors belonging to the 
steroid/thyroid superfamily of nuclear receptors.
1
 There are two classes of retinoid 
nuclear receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), with 
each subfamily being structurally and functionally distinct. In both cases the nuclear 
receptors act as ligand inducible transcriptional regulation factors.
18
 Both the RAR and 
RXR subfamilies are further separated into three isotypes,  and with the different 
RAR isotypes possess differing amino acid sequences in their ligand binding domains 
26 
 
(LBDs). In addition, RAR and RXR isotypes are further separated into different isoforms. 
For each isotype, the LBDs of the different isoforms are identical, but domains that are 
not involved in ligand binding are not conserved between the differing isoforms.
19,20 
In 
order to be functional, both RARs and RXRs must dimerise with other nuclear receptors. 
RARs predominantly heterodimerise with RXRs allowing for the binding of their specific 
nuclear DNA sequences known as retinoic acid response elements (RAREs), while RXRs 
form both homodimers and heterodimers
21,22,23 with RARs and other nuclear receptors 
including peroxisome-proliferation-activated-receptors (PPARs)
24
 and vitamin D3 
receptor (VDR).
25 
The endogenous ligands for retinoid receptors are ATRA and 9cRA, 
respectively. ATRA binds and activates the three RAR isotypes andwith similar 
affinities, while 9cRA acts as a pan-agonist for all six retinoid receptor isotypes, binding 
and activating both the RARs and RXRs.
26,27
 Crystallographic studies of both RAR and 
RXR ligand binding pockets (LBPs) bound to a variety of ligands have shown that the 
shape of the LBP differs markedly between RARs and RXRs.
28,29 ,30
 Crystal structures of 
the LBPs of RARand RXR have shown that RAR possesses a linear „„I‟‟ shaped 
LBP, whereas that of RXR is a shorter and more restrictive „„L‟‟ shape. As a result, the 
linear retinoid ATRA can act as a ligand only for RARs while the flexible 9cRA can 
adopt both the linear and twisted conformations required for binding to both RARs and 
RXRs respectively.
31 
The transcriptional activities of RAR agonists are mediated by 
ligand binding to the RAR LBP of RAR/RXR heterodimers (Figure 1.4A). The RXR 
partner may also bind to ligands, depending on the occupation of the RAR LBP and on 
the particular DNA-response element to which the heterodimer is bound.
32,33
 
Heterodimers of RXRs with RARs, thyroid receptor (TR) and vitamin D3 receptor (VDR) 
cannot be activated by the binding of RXR agonists alone and thus are termed „non-
permissive‟ heterodimers. However, RXR agonists can allosterically increase the efficacy 
of RAR agonists (retinoid synergism), and can activate „permissive‟ heterodimers34 of 
RXRs with numerous orphan nuclear receptors (OR) such as PPAR, liver X receptor 
(LXR), farnesoid X receptor (FXR) and pregnane X receptor (PXR) without the binding 
of agonists for the partner receptors (Figure 1.4C).
24,35 
Thirdly, RXRs can homodimerise 
on directly repeated sequences which are separated by one nucleotide. These homodimers 
27 
 
are transcriptionally activated by the binding of an RXR agonist such as 9cRA (Figure 
1.4B).
36
 
B C
RXR RAR RXR RXR RXR OR?
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Figure 1.4 Multiple retinoid signalling pathways. 
 
Activation of transcription from RAREs occurs in three stages or levels.
36 
In the absence 
of agonists, RARs bind to DNA via their DNA binding domains (DBDs) and recruit 
co-repressors, such as SMRT and NCoRT, leading to suppression of transcription from 
the response element (Figure 1.5A). Binding of RAR agonists, such as ATRA, to the 
ligand binding domain (LBD) of the RAR causes a conformation change of the RAR.  
This conformational change dislodges the bound corepressors, resulting in basal 
transcription levels (Figure 1.5B). Recruitment of transcriptional coactivators, such as 
SRC-1, COACT-X, CBP (steroid receptor coactivator-1, coactivator-X and CREB 
binding protein, respectively) or P-300, by the RAR-agonist complex results in an 
activated transcription complex and maximum levels of transcription from the RARE 
(Figure 1.5C). Deactivation of transcription from RAREs may be achieved through the 
use of RAR antagonists. Binding of RAR antagonists reversibly blocks the LBP without 
inducing the conformation change in the RAR required to dislodge the bound 
corepressors (Figure 1.5D).
36 
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Figure 1.5 Levels of transcriptional activation of RARE via RAR binding and activation and repression of 
transcription from RAREs by RAR antagonism. 
 
1.1.2 Receptor specificity in retinoids. 
 
The RAR/RXR isotypes differ in both their tissue distribution and in the biological 
processes mediated.
37
 RARis ubiquitous in its distribution, is involved in the 
differentiation therapy of acute human promyelocytic leukaemia
38
 and is associated with 
elevated triglyceride levels.
39
 RARis expressed predominantly in the heart, lungs and 
spleen
37
 and RARsubtypes exhibit suppressive effects on certain cell types40 and thus 
29 
 
constitute a possible target for the treatment of breast and other cancers.
41
 RAR is 
primarily expressed in the skin and bone
37,42 
and is associated with skin photoaging,
43
 
dermatological diseases
44
 and carcinogenesis.
45
 The wide ranging effects of non-isotype 
specific retinoids have so far limited their medical use. Thus, the preferential binding to 
the LBP of specific receptor isotypes is necessary if the high biological activities of the 
retinoids are to be harnessed for clinical use. 
 
1.1.2.1 RAR Selectivity 
 
Through sequence alignment of the RAR isotypes, it has been shown that the LBPs are 
highly conserved in the RARs with only 3 LBP residues differing between the 3 
isotypes
28b,31,46
 on the 3, 5 and 11 helices. Géhin et al. have demonstrated that ligand 
interaction with these non-conserved residues is crucial for determining RAR isotype 
selectivity (Table 1.1).
20 
 
 
1.1.2.2 RAR selectivity 
 
The LBP of RARdiffers from that of the  andisotypes by the presence on H3 of a H-
bond donor residue Ser232, in contrast to lipophilic Ala225 and Ala234 residues present 
in the LBPs of RARβ and RARγ, respectively. The formation of strong H-bonds between 
synthetic retinoids possessing H-bond acceptors, such as amide groups, in the linker 
region (i.e. AM 580,
47
 AGN 193836
48
 and AM 555S
49
) and this residue results in 
RARselectivity (Figure 1.6). 
Table 1.1 Divergent residues in the RAR isotype ligand binding pocket. 
 Helices 
Receptor H3 H5 H11 
RAR Ser232 Ile270 Val395 
RAR Ala225 Ile263 Val388 
RAR Ala234 Met272 Ala397 
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Figure 1.6 Synthetic RAR selective retinoids. 
 
1.1.2.3 RAR selectivity 
 
The RARLBP lacks the H-bond donor residue Ser232 which is present in the RAR 
LBP and thus, cannot interact selectively with ligands via H-bonding. Instead, 
RARselectivity is conferred by steric effects, with the smaller Ala225 and Ile263 
residues distinguishing the RARLBP from that of RAR and RAR respectively. The 
less sterically demanding residues in the LBP allow for the binding of larger retinoids, 
especially those possessing larger lipophilic regions than the widely used 1,1,4,4-
tetramethyl-2,2,3,3-tetrahydronaphthalene (Figure 1.7).  
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Figure 1.7 Synthetic retinoids. 
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This can be observed in the crystal structure of the complex of human RARβ (hRARβ) 
ligand binding domain with the RAR pan-agonist TTNPB
50
  (Figures 1.8 & 1.9),
28a 
in 
which an additional cavity in the hydrophobic region of the LBP is observed due to the 
smaller H3 Ala225 residue.  
 
CO2H
TTNPB  
 
Figure 1.8 Synthetic retinoid TTNPB. 
 
 
 
Figure 1.9 Crystal structure of the hRARβ LBP–TTNPB complex revealing an additional cavity in the 
LBP. Reproduced with permission of the copyright holder. 
 
    
 
 
 
 
 
 
 
 
Figure 1.10 Model structure of the docking of RARβ agonist / RARγ agonist BMS 453 into the RARβ 
(left) and RARγ LBP (right). Reproduced with permission of the copyright holder.28a 
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The mixed agonist/antagonist behaviour of BMS 453
28a
 and AGN 193174
51
 results from 
the inability of BMS 453 and AGN 193174 to effectively induce the conformational 
change necessary to dislodge bound corepressors when bound into the smaller RARα and 
RARγ LBPs. This can be observed in the structure of the docking of the RARβ agonist 
BMS453 in the RARγ LBP, as modelled by VOIDOO and MSMS, which shows steric 
clashes between the BMS 453 phenyl ring and residues on H3 and H5 (Figure 1.10B).
28a
 
Altering the shape of the retinoid lipophilic unit from (Z)-3,3-dimethylbut-2-en-1-yl 
(BMS 987) to phenyl (BMS 453) reduces RARβ agonist activity suggesting that the 
phenyl ring may cause some weak interference with H12 positioning and recruitment of 
coactivator. Further increases in steric bulk lead to further decreased agonist activity for 
BMS 701 and a high affinity RARβ antagonist in the case of BMS 009.28a Similar effects 
are observed for the exchange of the thiophenyl moiety of RARβ agonist AGN 193174 
with p-tolyl to give AGN 193109 which exhibits pan RARβ antagonism.51 4‟-Octyl-4-
biphenylcarboxylic acid
52
 (AC-55649, originally of interest for its liquid crystal phase 
behaviour
52b
) and AC-261066 are highly selective agonists for the RARβ2 receptor 
isoform.
 
RAR isoform selectivity cannot be achieved via interaction with non conserved 
residues in the LBP (AF-2) as the four RARβ isoform LBPs are identical. Instead, the 
variation between the isoforms is located in the ligand-independent activation domain 
(AF-1),
53
 which cooperates with the ligand binding domain (AF-2) in a promoter context 
manner.
54
 AF-1 and AF-2 are activating function domains which are responsible for 
transcriptional activity of nuclear receptors and can interact with coactivators such as 
p300/CBP.
53a
 Thus, retinoids, such as AC-55649 and AC-261066, which significantly 
interact with AF-2 (Figure 1.11),
52a
 may induce differing interactions between conserved 
AF-2 and non conserved AF-1 regions in the RARβ isoforms, leading to isoform 
selectivity.
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Figure 1.11 Modelling of the interactions of ATRA, AC 55649 and AC 261066 with the AF-2 domain. 
Reproduced with permission of the copyright holder.
52a 
  
1.1.2.4 RARselectivity 
 
The RARLBP differs from that of  and  isotypes by the presence of the weakly polar 
Met272 residue. The formation of a weak H-bond between this residue and retinoids 
possessing an H-bond donor on, or adjacent to the hydrophobic region confers 
RARselectivity.31,55 This can be observed in the modelling of the structure of the CD 
666-hRARγ complex (Figure 1.13).56 In addition, the smaller Ala397 residue allows for 
the docking of larger hydrophobic moieties, such as the 2-adamantylphenol group of CD 
437 (Figure 1.12),
57
 against helix 11 of RARwhich is not the case for RAR/RAR
OH
CO2H
CD 666 CD 437
HO
CO2H
 
Figure 1.12 RAR selective retinoids.
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
 
Figure 1.13 Modelling of the CD 666-hRARγ complex. Reproduced with permission of the copyright 
holder.
56 
 
1.1.2.5 RXR selectivity 
 
 RXRs are expressed mainly in adult tissue, with RXR present in nearly all tissue types, 
while RXRand RXR are expressed mainly in the liver, kidney, spleen and skin and in 
the brain and muscle, respectively.
58 
The endogenous ligand for RXRs is 9cRA.
26,27
 
Crystallographic studies
29,31
 of 9cRA-RXR complexes show distortion of the ligand with 
the region past C9 twisted perpendicular to the plane of the hydrophobic cyclohexenyl 
ring. The 9-cis double bond in 9cRA allows it to adopt both linear and twisted 
conformations in comparison to ATRA, which can only adopt linear conformations. This 
allows 9cRA to act as an agonist for RARs, which possess an elongated LBP with an „I‟ 
like shape, and for RXRs with a twisted „L‟-like LBP. In contrast to the RAR LBPs, the 
LBP of the RXR isotypes does not differ for each isotype and as yet, no isotype selective 
retinoids have been reported.
59
 The crystal structures of 9cRA bound to RXR LBPs show 
that the 9cRA ligand does not completely fill the LBP with 31% of the available LBP 
volume unfilled, predominantly in two regions.
60
 By synthesising retinoids which favour 
twisted conformations, and by increasing the size of both the hydrophobic and 
35 
 
hydrophilic regions with respect to 9cRA, the selectivity for RXRs over RARs may be 
increased. Synthetic retinoids which show high selectivities for RXRs over RARs are 
usually shorter than RAR agonists, typically with one linker atom between the 
hydrophobic ring and carboxyl bearing ring.
 
In addition, the presence of ortho ring 
substituents on the hydrophobic ring, which enforce twisted conformations (by steric 
interactions with the carboxyl bearing ring), is a common feature of many RXR agonists 
(Figure 1.14). 
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Figure 1.14 RXR selective retinoids. 
 
This is demonstrated by 3-Me TTNPB,
18,61
 which activates both RAR and RXRs, while 
TTNPB
18,28,50
 shows no RXR activation. SR 11237,
62
 LGD 100268
63
 and LGD 1069
64 
are 
all potent RXR agonists with binding affinities in excess of that for 9cRA. The 3-Me 
groups of LGD 1069 and LGD 100268 both enforce the twisted conformations necessary 
for RXR selectivity. 
 
1.1.3 Design and structure of synthetic retinoids 
 
The activities of natural retinoids, such as ATRA and 9cRA, are limited by their 
isomerism into species which possess differing activities and their oxidative metabolism 
by cytochrome P450 enzymes. These destructive processes proceed via reactions of key 
functionalities in ATRA and 9cRA. By replacing these moieties with more robust 
pharmacophores, retinoids may be synthesised which exhibit similar efficacies as ligands 
36 
 
for RARs or RXRs, but with improved resistance to metabolism and thus improved 
activities. 
 
 
 
 
 
 
 
 
 
Figure 1.15 Retinoid numbering scheme.
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Figure 1.16 Products of ATRA oxidative metabolism. 
 
The oxidative metabolism of ATRA leads to 4-hydroxy-, and 4-oxo-ATRA via oxidation 
at the allylic 4-position and at the 18-position to give 18-hydroxy ATRA. In addition, a 
5,6-epoxy derivative is formed from epoxidation of the terminal double bond of the 
polyene chain (in the cyclohexane ring).
65
 By replacing the trimethylcyclohexenylvinyl 
unit (C1-C8) with a structurally similar 1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene 
moiety, which possesses no allylic protons or alkene double bonds, degradation via 
radical oxidation and epoxidation is reduced. In addition, by replacing two C=C double 
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bonds in the conjugated polyene by an arene ring, photo-induced isomerism is decreased, 
leading to greater stability. These synthetic retinoids which contain one or more aromatic 
rings are termed arotinoids. Further increases in photostability and resistance to oxidative 
metabolism may be achieved by constraining the flexible polyene chain by incorporating 
it into one or more aromatic rings. By means of these modifications the 
trimethylcyclohexenyl ring and the conjugated tetraene of the natural retinoids may be 
replaced by robust structural units such as stilbene, tolan, biaryl or biaryl amide to give 
retinoids which exhibit high activity and stability such as TTNPB,
50
 EC23,
12
 TTNN (SRI 
5898-52)
66
 and Am580,
47
 respectively (Figure 1.17). 
 
CO2H
CO2H O
N
H
CO2H
CO2H
TTNPB EC23
SRI 5898-52
(TTNN)
Am580
 
 
Figure 1.17 Arotinoids. 
 
1.1.3.1 Modification of the hydrophobic unit 
 
The effects of modification of hydrophobic unit on retinoid activity can be observed in 
the structure-activity relationships for a series of TTNPB analogues on the differentiation 
of cultured hamster trachea cells (TOC assay).
67
 Replacing the 1,1,4,4-tetramethyl-
1,2,3,4-tetrahydro-naphthalene in TTNPB with 1,2,3,4-tetra- methylnapthalene (SRI 
5193-55) led to a decrease in the activity by over 2 orders of magnitude, in comparison to 
TTNPB, suggesting that it is desirable for the methyl substituents on the hydrophobic unit 
to lie out of the plane of the aromatic ring. Removal of either of the C4 methyl groups 
needed to block oxidation metabolism at that position leads to a drop in activity, with the 
38 
 
S-isomer, SRI 6910-29, showing a reduction in activity of over one order of magnitude, 
compared to TTNPB. The R-isomer, SRI 6910-50, was found to be 4 times less active 
than the S-isomer, SRI 6910-29. Surprisingly a racemic mixture of SRI 6910-29 and SRI 
6910-50 displayed a lower activity than either of the isomers on their own. The decreased 
activity of SRI 6910-29, SRI 6910-50 and racemic mixtures in comparison to TTNPB 
indicates the need for two methyl groups at the C4 position for high biological activity.
68
  
 
 
 
Retinoid ED50 (M) 
ATRA 1 X 10
-11 
TTNPB 2 X 10
-12 
SRI 5193-55 8 X 10
-10 
SRI 6910-29 2.5 X 10
-11 
SRI 6910-50 1 X 10
-10 
SRI 5639-27 3 X 10
-11 
SRI 4445-86B 1 X 10
-9 
SRI 5387-12 2 X 10
-10 
SRI 5896-39 5 X 10
-11 
SRI 2965-38 2 X 10
-10 
 
 
 
 
           
 
Figure 1.18 Modification of the hydrophobic unit in TTNPB arotinoids and their activities in the TOC 
assay. 
 
This is reinforced by SRI 5639-27, lacking both C4 methyl groups, which possesses a 
similar activity to both SRI 6910-29 and ATRA, and by the dramatic decrease in activity, 
compared to TTNPB, of nearly 3 orders of magnitude for the benzonorbornenyl analogue 
SRI 4445-86B. SRI 2965-38, a C11-C14 benzofused analogue of ATRA, exhibits a 
biological activity over one order of magnitude less than SRI 5639-27, which also lacks 
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both methyl groups at C4. This suggests that incorporating the C5-C6 and C7-C8 double 
bonds into a benzene ring improves activity in this assay. SRI 2965-38 was also found to 
possess reduced activity, compared to both TTNPB and ATRA (results are summarised 
in Figure 1.18).
68 
 
Substitution of the C4 methylene group of aromatic retinoids with heteroatoms leads to a 
class of retinoids termed heteroarotinoids, which have demonstrated significant potential 
as anticancer agents due to their activity as inhibitors of the induction of orthinine 
decarboxylase (ODC)
69
 and their resultant ability to prevent or inhibit the transformation 
of healthy cells into cancerous cells.
70
 In addition, several heteroarotinoids exhibit much 
reduced toxicities,
69a,70a
 in comparison to their carbocyclic analogues, with the reduced 
toxicity believed to result from the incorporation of the heteroatom.
70a
 Both SRI 5387-12 
and its thia-analogue SRI 5896-39 exhibit diminished activity, in TOC assay, compared 
to the parent retinoid TTNPB, with the loss of activity resulting both from the lack of 
lipophilic bulk in the 4-position, and the increase in polarity of the hydrophobic unit 
caused by the substitution with more electronegative atoms. The lower activity of oxy-
TTNPB analogue SRI 5387-12, in comparison to SRI 5896-39, results from the increased 
electronegativity of the oxygen atom, which further reduces hydrophobic interactions 
with the non-polar residues present around the hydrophobic region of the LBP. Similar 
trends have been reported by Benbrook et al.
71
 for other oxygen and sulphur 
heteroarotinoids.  However, it must be noted that dihydrobenzothiapyran based retinoids 
such as SRI 5896-39 are oxidised to sulfones and sulfoxides which exhibit low activities 
in the TOC assay.
68
 This ease of oxidation and subsequent deactivation may explain low 
lower toxicities of sulphur heteroarotinoids in comparison to their carbocyclic 
analogues.
70a 
 
 
Although oxygen and sulphur are the most prevalent heteroatoms in heteroarotinoids, 
other elements have also been used, with Tacke et al. having reported the synthesis and 
binding to RARs and RXRs of 1,4-disila-analogues of the arotinoids TTNPB, 3-Me 
TTNPB
72
 and LGD 1069 (bexarotene).
73 
 
1.1.3.2 Modification of the polar terminus 
40 
 
 
In order to effectively bind to the RAR or RXR LBPs, the polar terminus of the retinoid 
must be capable of interacting favourably with the residues present in the „bottom‟ of the 
LBP. These interactions between the LBP and the „anchoring‟ group on the polar 
terminus can be observed in the crystal structures of 9cRA with RAR and RXR (Figure 
1.19).
74
 In the 9cRA-RAR complex, the carboxylate of 9cRA forms an ion pair with Arg 
278 and 3 hydrogen bonds with the main chain amide group, side chain hydroxyl group 
of Ser 289 and a bound water molecule of RAR. In the 9cRA-RXR complex, an ion pair 
is formed between the ligand carboxylate and Arg 316, as well as 2 hydrogen bonds 
between the carboxylate, the amide group of Ala 327 and a bound water molecule of 
RXR.
74
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Figure 1.19 Crystal structures of  9cRA-RAR (top) and 9cRA-RXR (bottom) complexes. Reproduced with 
permission of the copyright holder.
74 
 
Although not proven, it is believed that the highest oxidation state of vitamin A, ATRA, 
is responsible for controlling cellular differentiation. Thus, in order to display biological 
activity of this type, retinol and retinal must be oxidised to ATRA.
75
 As the hamster 
trachea organ culture (TOC) assay is based on a whole organ culture, it possesses the full 
complement of enzymes. As a result, retinoid amides, which are inactive in epidermal 
ODC assay, show high activities in the TOC assay, suggesting that the necessary 
enzymes for the hydrolysis of retinoid amides prodrugs to the active acid forms are 
present in the organ culture.
67,68
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Figure 1.20 Modifications of the polar terminus. 
 
Retinol, which is oxidised in vivo to give ATRA, is less active than its acid form in the 
TOC assay by over 2 orders of magnitude. Similar differences in biological activity were 
seen between TTNN and both its alcohol form SRI 5542-11 and the methyl ether SRI 
5442-12. The sulfonate analogue of TTNN, SRI 5942-92, possessed only a quarter of the 
activity of TTNN alcohol SRI 5542-11 in the TOC assay, suggesting that the sulfonate 
moiety does not interact with the receptor residues as effectively as the carboxylate 
moiety. Due to the full complement of enzymes present in the TOC assay, the methyl 
naphthalene derivative, SRI 5193-67, may be oxidised in vivo to give polar species which 
exhibit retinoid activity (including TTNN) and showed activity comparable to that of 
sulfonate SRI 5942-92. The naphthalene derivative, SRI 5193-71, which cannot be 
oxidised to TTNN, was not active in the TOC assay (Figure 1.20).
68
  
 
1.1.3.3 Modification of the linker unit 
 
Most arotinoids feature 1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene as the 
hydrophobic unit and a carboxylate-bearing aromatic ring as the polar terminus, with 
these two functionalities linked by a short linker unit of 1-3 atoms. Despite the small size 
of the linker unit, a wide variety of differing functionalities have been employed as 
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linkers in arotinoid structures, with changes in linker structure allowing for selectivity 
between RARs and RXRs as well as RAR isotypes to be controlled. The E-propenyl 
linker of TTNPB
50
 closely mimics the skip methylated chain of ATRA. TTNPB is one of 
the most active synthetic retinoids yet discovered, possessing an activity in the hamster 
TOC assay 5 times greater than that of ATRA.
68 
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Figure 1.21 Synthetic retinoids possessing varying linker units. 
 
Retinoids TTNN
66
 and SRI-6751-84
76
 can be considered as isomeric, benzo-fused 
analogues of TTNPB and display high biological activities, with that of TTNN 
comparable to TTNPB, and that of SRI-6751-84 showing equivalent activity to ATRA. 
Both TTNN and SRI-6751-84 are RAR selective agonists due to their rigid, linear 
structures, with TTNN showing a greater affinity for RARβ over RARα and RARγ. 
Other hydrocarbon linker units include; the biaryl groups of E-, and Z-cinnamate 
retinoids SRI 7101-27 and SRI 7101-53, respectively, which show limited biological 
activities in the TOC assay, and the triple bond of the photostable retinoid EC23, which is 
highly effective in the induction of neural differentiation in human TERA2.cl.SP12 
embryonal carcinoma cells, with activity greater than that of the native ligand ATRA.
12
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Other linker units not based upon hydrocarbons include; the amide linkages of Am 580,
47
 
the internal ester linkage of the RARβ agonist AGN 19367651 and the cyclic urea linkage 
of YR 105, an inducer of differentiation of HL-60 cells with activity comparable to that 
of ATRA, (structures are shown in Figure 1.21).
77
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Figure 1.22 RXR selective synthetic retinoids possessing varying linker units. 
 
Due to the differing shapes of the RAR and RXR LBPs, selectivity for RXRs over RARs 
requires ligands which adopt twisted conformations similar to the natural ligand 9cRA, 
rather than the linear conformations required for RAR binding. In RXR antagonist LGD 
100754,
78
 steric interactions between the 9-cis triene linker unit and an ortho-n-propyloxy 
substituent on the hydrophobic aromatic ring result in a twisted conformation. Polyene 
linker units can be effectively locked in the cis conformation by cyclopropanation of the 
cis double bond to give 1,2-cis-cyclopropane derivatives such as RXR agonist AGN 
194420
79 
or by addition of 1,1 disubstituted cyclopropanyl groups to the linker unit as in 
1 (Figure 1.22).
80
 
 
45 
 
Rigid, one atom linker units, usually in conjunction with ortho substituents on the 
hydrophobic aromatic ring, give RXR selectivity due to minimisation of steric 
interactions between the aromatic ring of the polar terminus and the ortho substituents on 
the hydrophobic aromatic ring. Examples (Figure 1.22)  of such rigid linker units include 
an alkene in LGD 1069 (Targetin
®
, bexarotene),
64
 which is currently licensed for the 
treatment of the treatment of cutaneous manifestations of T-cell lymphoma, a carbonyl 
group (e.g. 3-Me TTNCB),
63
 an oxime (e.g. 2),
81
 2,2-dioxanyl group (SR 11237)
62
 and a 
1,1-cyclopropanyl group (LGD 100268).
63
 Alternatively, the linker unit may be 
incorporated into a suitably functionalised benzo-fused ring system, as in the RXR 
agonist HX 600.
82
 
 
In conclusion, synthetic retinoids can offer many advantages over their endogenous 
analogues, ATRA and 9cRA, and would appear destined to play a significant role, both 
as tools for research and in medicine. Not only are synthetic retinoids typically more 
stable to light and to enzymatic metabolism, which usually leads to greater activity, but 
RAR isotype selective retinoids can offer a greater degree of control over their effects, 
which can prove to be beneficial in a clinical context, especially in regards to the 
reduction of toxicity. In addition, several selective retinoid-based treatments are currently 
in clinical trials for cancer therapy. 
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1.2 Palladium-catalysed cross-couplings 
 
Palladium-catalysed cross-coupling reactions play an important role in modern organic 
synthesis with many syntheses of large molecules featuring at least one Pd-catalysed 
cross-coupling step. 
 
Mechanistically, the various cross-coupling reactions (Suzuki-Miyaura,
83
 Stille,
84 
Negishi,
85
 Sonogashira,
86
 Hiyama,
87
 etc.) are all similar, with the basic catalytic cycle 
(assuming Ln represents two monodentate ligands) consisting of oxidative addition of a 
C-X (typically halide or triflate) bond to a zero valent metal centre to give a trans-Pd
II
 
species, transmetallation, and trans-cis isomerisation followed by reductive elimination 
yielding the cross coupled product and the original Pd
0
 species. 
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R-XLnPd
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LnPd
II XR
LnPd
II R'R
LnPd
II
R'
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oxidative
addition
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Scheme 1.1 Basic catalytic cycle for Pd-catalysed cross-couplings. 
 
1.2.1 Oxidative addition  
 
The first step of the catalytic cycle in Pd-catalysed cross-couplings is the oxidative 
addition of the C-X bond to the palladium centre, with reports suggesting that the active 
species is a coordinatively unsaturated Pd
0
 species bearing one (PdL), or two (PdL2) 
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dative ligands.
88,89,89,90,91,92 
For tetrakis(triphenylphosphine)palladium, phosphine 
dissociation gives rise to Pd(PPh3)3 and Pd(PPh3)2 in solution, with the latter initially 
considered to be the active species in the oxidative addition step.
90 
 A variety of 
mechanisms have been proposed for oxidative addition, with the exact pathway 
dependent on metal ion and oxidation state, ligand, substrate and conditions. For aryl 
halides, the three main pathways are shown in Scheme 1.2.
89b,91
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Scheme 1.2 Oxidative addition pathways from top to bottom: nucleophilic addition, single electron transfer 
and 3-centred concerted addition.  
 
Work by Fauvarque et al., and later by Amatore et al. showed that for the oxidative 
addition of aryl iodides to Pd(PPh3)4, the mechanisms in THF
89a,92 
and toluene
89b
 are 
identical and the slope of the Hammett plots are similar in the two solvents. The similar 
enthalpies and entropies of activation for the reaction in polar and non polar solvent 
shows that the transition state for the addition of aryl halides to the coordinatively 
unsaturated Pd
0
(PPh3)2 species has no significant ionic character suggesting that 
oxidative addition occurs via either a concerted three-centre reaction or by a radical 
mechanism. For oxidative addition of aryl halides, the order of reactivity is found to be I 
> Br >> Cl >> F with electron deficient aryl halides being more reactive than electron 
rich ones. This corresponds with a rate limiting step which involves the breaking of the 
C-X bond.
90
 For a three-centered concerted addition the oxidative addition leads to an 
initial cis adduct which then isomerises to give the thermodynamically more stable trans 
complex.
91 
Isomerisation may occur via a dissociative pathway with a trigonal 
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ArPd
II
PPh3X intermediate or by an associative pathway with a trigonal bipyramid 
ArPd
II
(PPh3)2XA intermediate formed by the coordination of either solvent or free halide 
anion (A) to ArPd
II
(PPh3)2X. 
      
 
Hartwig and coworkers have shown that for the addition of aryl bromides to Pd
0 
complexes bearing bulkier phosphine ligands such as P(o-tol)3 the active species is a 12e
-
 
monophosphine complex.
93
 This was supported by catalytic studies by Fu and coworkers 
employing Pd2dba3/PR3 mixtures in a 1:1 ratio to form the monoligated Pd species in 
situ.
94
 Well defined Pd
0
PR3 complexes were shown to be highly active for the 
Suzuki-Miyaura cross-coupling of aryl halides with phenylboronic acid by Beller and 
coworkers.
87j  
 
Further evidence for the role of monoligated PdL complexes was provided by the studies 
of ArX elimination, observed indirectly and directly by Hartwig and coworkers. P(o-tol)3 
ligated arylpalladium halides of the form [Pd(Ar)(μ-X)P(o-tol)3]2 eliminate ArX upon 
addition of an excess of P
t
Bu3 to give Pd(P
t
Bu3)2. In addition, well defined, three-
coordinate Pd
II
(P
t
Bu3)(Ar)X complexes were shown to undergo elimination of ArX upon 
the addition of P
t
Bu3 to give PR3-Pd
0
-P
t
Bu3 complexes and ArX in 60–98% yields.
95  
 
Jutand and co-workers have shown that the nature of the active Pd species for the 
oxidative addition reaction is sensitive to the bulk of the ligand L, with less bulky or 
bidentate ligands more likely to promote oxidative addition via PdL2 species while more 
bulky monodentate ligands such as P
t
Bu3 undergo oxidative addition via PdL.
 96 
 
Studies by Hartwig and coworkers on the oxidative additions of chloro-, bromo-, and 
iodobenzene to Pd(Q-phos-tol)2 (Q-phos-tol = (di-tert-butylphosphino)penta-p-
tolylferrocene) have shown that the mechanism of oxidative addition is dependent on the 
identity of the halide. For PhI, associative displacement of ligand by PhI, prior to 
oxidative addition was found to be rate determining, while for PhBr, ligand dissociation 
from Pd(Q-phos-tol)2 is rate determining. In contrast, for PhCl, oxidative addition was 
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rate determining and is preceded by reversible ligand dissociation. In all cases, the 
oxidative addition occurred via the monoligated Pd(Q-phos-tol) species.
 97
  
 
Lin and Marder carried out DFT studies on the oxidative addition of a range of 
p-Y-C6H4-X (Y = CN, H, OMe, X = Cl, Br, I) to Pd(PMe3)2 with both PdL and PdL2 
pathways investigated (Scheme 1.3).
98
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Scheme 1.3 Mono-, and bis-ligated pathways for oxidative addition of aryl halides to Pd
0
. 
 
For aryl chlorides, the monophosphine pathway is favoured with transition state TS5-6 
higher in energy than 4. Thus oxidation addition is expected to be the rate determining 
step with the nature of the para-substituents on ArX affecting the rate. This is consistent 
with the results of Hartwig and co-workers for the reaction of PhCl with Pd(Q-phos-tol)2. 
For aryl bromides, the monophosphine pathway is also favoured. The energy of 
monoligated palladium species 4 was found to be  similar to TS3-7 with TS3-7 being 
marginally higher in energy than 4 for PhBr and p-MeO-C6H4-Br, while for p-NC-C6H4-
Br 4 and TS3-7 are equal in energy. 
 
For aryl iodides PhI and p-MeO-C6H4-I, the monophosphine pathway is marginally 
favoured, with the barrier between 5 and 6 being lower than the barrier to phosphine 
dissociation from 3. This is consistent with the experimental findings of Hartwig and co-
workers for the reaction of PhI and Pd(Q-phos-tol)2. For p-NC-C6H4-I, the barrier to 
50 
 
oxidative addition to 3 is lower than the barrier to phosphine dissociation from 3 and thus 
the bisphosphine pathway is favoured. 
 
Pd
0
 complexes of π-acidic olefins such as dba (dibenzylideneacetone) are widely used in 
conjunction with donor ligands to generate “Pd0Ln” complexes in situ. Amatore and 
Jutand have studied the oxidative addition of “Pd0L2” generated from Pd2(dba)3 and 
monodentated ligands to aryl iodides. “Pd0L2”exists predominantly as Pd
0
(dba)L2 which 
is unreactive for oxidative addition, due to reduction in electron density on the palladium 
centre due to π-backbonding to dba. The active species, Pd0L2 is generated in low 
concentrations from Pd
0
(dba)L2, with which it is in an unfavourable equilibrium (Scheme 
1.4).
99
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Scheme 1.4 Reversible coordination of dba to Pd
0
 centres. 
 
Dissociation of dba from Pd
0
(dba)L2 to give Pd
0
L2 was shown to be the rate determining 
step. Therefore, the strength of dba binding controls the concentration of the active 
species for oxidative addition and thus the kinetics of this key step. Fairlamb and 
coworkers have employed a range of n,n‟-disubstituted dba analogues bearing a range of 
groups (OMe, 
t
Bu, H, CF3, NO2) as ligands in Pd2(dba)3 type catalyst precursors in a 
range of palladium catalysed cross-couplings.
100
 As expected, the use of Pd2(dba)3 
analogues bearing electron donating groups showed higher activity due to weaker 
π-backbonding between Pd0 and the dba analogue, which reduces ligation of the active 
species by the dba analogues.
101
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1.2.2 Transmetallation 
 
The predominant difference between the various cross-coupling reactions is the nature of 
the transmetallation step in which the halide or pseudohalide on Pd
II
 is replaced by the 
nucleophilic carbon centre of the transmetallating species M-R1. M may be a p-block 
element such as boron (Suzuki-Miyaura reaction), silicon (Hiyama reaction), tin (Stille 
reaction) or aluminium, a transition metal such as copper (Sonogashira reaction) or zinc 
(Negishi reaction) or s-block elements such as magnesium (Kumada-Tamao-Corriu 
reaction). The transmetallation steps in the Sonogashira and Suzuki-Miyaura reactions 
will be discussed in more detail in further sections. 
 
1.2.3 Reductive elimination 
 
The increased oxidation state of palladium and the high strength of the C-C bond make 
the formation of a C-C bond via reductive elimination of the two carbon centres on Pd
II
 
highly favoured. Due to the lack of polarisation in the bond formed, the elimination step 
occurs via a concerted mechanism. In order for reductive elimination to occur, the two 
substituents on palladium must be in a cis configuration. This is demonstrated by the two 
dimethyl palladium complexes shown in Figure 1.23. The differing bite angles of 1,2-
bis-diphenylphosphino-ethane (dppe) and 2,11-bis-[(diphenylphosphanyl)-methyl]-
benzo[c]phenanthrene enforce cis and trans conformations, respectively, in their 
dimethylpalladium complexes. Warming Pd(dppe)Me2 (8) in DMSO produces ethane due 
to reductive elimination,
102
 while no ethane production is observed from 
Pd(transphos)Me2 (9) under the same conditions. 
Ph2P PPh2Pd
H3C
CH3Ph2P
Pd
PPh2
H3C CH3
8 9  
Figure 1.23 Pd(dppe)Me2 and Pd(transphos)Me2 complexes. 
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Facile reductive elimination is important in all cross-coupling reactions but is especially 
so in the case of the cross-couplings of alkyl nucleophiles and/or electrophiles in which 
reductive elimination is usually slow and competes with β-hydride elimination. The use 
of π-acidic olefins either as additives or ligands can enhance reductive elimination rates 
by removing electron density from Pd
II
 and further favouring the formation of Pd
0
. For 
example, the coupling of allyl halides with allyl stannanes catalysed by 1 mol % of (3-
allyl)palladium chloride dimer required maleic anhydride as a co-catalyst (Equation 1.1). 
 
Br Bu3Sn
O OO
1 mol % [3-C3H5)PdCl]2
THF, 50 oC
(5 mol %)
40%
(+ 37% homocoupling)
Cl Bu3Sn
O OO
1 mol % [3-C3H5)PdCl]2
THF, 50 oC
(5 mol %)
64%
(+ 12% homocoupling)
 
 
Equation 1.1 Stille couplings of allyl stannanes and allyl halides with catalytic maleic anhydride. 
 
On the basis of stoichiometric experiments, the authors suggest that maleic anhydride is 
required to facilitate reductive elimination from the Pd
II
 bis-allyl intermediate.
103
 The 
coupling of allyl chloride with NaBPh4 catalysed by [Pd(
3
-C3H5)Cl(AsPh3)] gave 48 % 
of allylbenzene after 40 minutes at 50 
o
C in the absence of exogenous alkene. Addition of 
20 mol % dimethyl fumarate increased the yield to 90% under identical conditions 
(Equation 1.2).
104
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4 mol % [3-C3H5)}PdCl(AsPh3)]Cl NaBPh4
THF, 0oC, 40 min
+
Additive                         none                                     (20 mol %)                        
                                                                       
    
                                                                               
Yield                              48%                         90%
MeO2C
CO2Me
 
 
Equation 1.2 Suzuki-Miyaura reactions of allyl chloride and sodium tetraphenylborate with catalytic 
dimethyl fumarate. 
 
Although the use of olefin additives can enhance reductive elimination, when in large 
excesses, these additives may retard the oxidative addition step similar to the action of 
dba. To overcome this, Aiwen Lei and coworkers developed novel phosphines bearing an 
electron deficient olefin (Figure 1.24). Palladium complexes of these ligands have 
proven highly effective in both Negishi couplings involving dialkylzinc reagents 
possessing β-hydrides105 and in Cadiot-Chodkiewicz type cross-couplings of 
bromoalkynes and terminal alkynes.
106
 In both cases, undesirable side reactions 
(β-hydride elimination and alkyne homocoupling, respectively) are minimised, with 
preliminary kinetic studies into the sp-sp cross-coupling showing that the 
phosphine-olefin ligand facilitated reductive elimination. 
 
O
PPh2
O
PCy2
 
 
Figure 1.24 Phosphine-olefins ligands synthesised by Lei and co-workers. 
 
1.2.4 The Sonogashira reaction 
The formation of a  bond between terminal acetylenes and aryl or vinyl halides has been 
known since the development of the Castro-Stephens reaction over 40 years ago.
107
 
However, this reaction involves the use of stoichiometric amounts of potentially 
explosive Cu acetylides in a reaction with aryl halides. In 1975, both Heck
108
 and 
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Cassar
109
 reported the coupling of terminal acetylenes with aryl or vinyl bromides and 
iodides. Heck et al. employed catalytic Pd(PPh3)2(OAc)2  in the presence of base at 100 
o
C, while Cassar showed that Ni(PPh3)4 and Pd(PPh3)4 in the presence of base mediated 
similar reactions under milder conditions. Coordination of the alkyne to nickel restricted 
subsequent oxidative addition steps with Ni
0
(PPh3)4, while the use of Pd(PPh3)4 allowed 
the reaction to run catalytically. Sonagashira et al. later developed a mild coupling of 
terminal acetylenes and bromoalkenes, iodoarenes and bromopyridines with catalytic 
amounts of Pd(PPh3)2Cl2, and CuI in an amine solvent.
85 
 
1.2.5.1 Mechanism of the Sonogashira reaction 
The original catalytic cycle, as proposed by Sonogashira,
86
 features a precatalytic 
initiation step in which PdL2X2 undergoes double transmetallation to give a 
(bis-alkynyl)palladium complex which reductively eliminates homocoupled diyne and 
gives rise to the catalytically active Pd
0
L2 species (Scheme 1.5). This initial 
homocoupling has been quantified by Marder and coworkers.
110
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(PR3)2PdCl2
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0
CuX
2CuCl /  R'3NHI
transmetalation
reductive elimination
trans oxidative addition 
(via cis-trans isomerisation)
transmetallationtrans-cis isomerisation
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 catalytically
active species
catalyst initiation
/ CuI / R'3NHR1
R1
PdII
R3P
R3P Ar
R1
PdII
Ar
R3P PR3
Cu R1
X
PdII
Ar
R3P PR3
H2
main catalytic cycle
 
Scheme 1.5 Classical Sonogashira reaction mechanism. X = Br, I or TfO.  
Recently, detailed mechanistic studies via cyclic voltammetry and 
31
P NMR 
spectroscopy
110,111,112
 have suggested that the Pd
0
(PPh3)2 species generated by 
electrochemical reduction of Pd(PPh3)2Cl2 actually exists as a mixture of three active 
forms in rapid equilibrium: [Pd
0
(PPh3)2Cl]
-
, its dimer [Pd
0
(PPh3)2Cl]2
2-
 and 
[Pd
0
(PPh3)2Cl2]
2-
 with the dimeric species being present in trace levels. Two catalytic 
cycles operate with the dominant cycle dependent on halide and nucleophile 
concentration as well as the nature of the metal ion, M. When MX exists as ion pairs, or 
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there is a lack of free halide, anionic palladium complexes are unable to form and the 
much slower non anionic secondary cycle dominates (Scheme 1.6). 
CuX
Secondary
cycle
PPh3 Pd
II
Ar
PPh3
R
Ar PdII
PPh3
PPh3
R
PPh3 Pd
II
Ar
X
PPh3
CCRCu
PdII Ar
PPh3
PPh3
S
X
PdII Ar
PPh3
PPh3
X
X
PdII Ar
PPh3
PPh3
X
R
Pd0 X
PPh3
PPh3
RAr
+ S, -X-
+ X-, -S
Main anionic
cycle
PdII Ar
PPh3
PPh3
X
Cl
PdI0 Cl
PPh3
PPh3
+ Cl
- Cl
Pd(PPh3)2
ArX
+ S
- Cl-
+ Cl-
- S
-S
CCRCu+
 
Scheme 1.6 Recent proposal for the mechanism of the Sonogashira eaction. S = THF, X = halide. 
 
For conditions in which the halide anion is not bound or is present in large excess 
(normal reaction conditions), ligation of Pd
0
 by halide leads to the formation of 
Pd
0
(PPh3)2X
- 
and Pd
0
(PPh3)2X2
2-
 and the dominance of the anionic cycle. The highly 
transient Pd
II
(PPh3)2ArX2
-
 species can be considered the key catalytic species in both 
cycles. It is involved in a rapid equilibrium with the neutral penta-coordinated 
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Pd
II
(PPh3)2ArXS  which may either dissociate solvent to give trans-Pd
II
(PPh3)2ArX or 
undergo transmetallation to give Pd
II
(PPh3)2ArX(CCR). Pd
II
(PPh3)2ArXS  interconnects 
the two cycles and as a result the secondary cycle remains important.
111,112,113
 
 
1.2.5.2 Transmetallation in the Sonogashira reaction 
The transmetallation step involves the transfer of the nucleophilic acetylide moiety from 
Cu
I
 to Pd.
II
. The transmetallating species is believed to be a Cu-acetylide formed in situ 
by the abstraction of the acidic acetylenic proton by base (typically NR3 or HNR2) and 
coordination of the acetylide anion to Cu
I
. Subsequent transmetallation yielding Pd 
acetylide and Cu halide occurs with retention of configuration at Pd suggesting that a 
concerted mechanism is in operation. 
 
1.2.5.3 Recent developments in the Sonogashira reaction 
Recent developments in the Sonogashira reaction have sought to increase both its scope, 
in relation to potential coupling partners, and its efficiency, in relation to higher turnover 
numbers (TONs) and the use of milder conditions such as room temperature couplings of 
aryl bromides. In addition, both Cu and amine free protocols have been developed. 
Copper free Sonogashira reactions, also referred to as Heck alkynylation reactions, have 
been developed to reduce the formation of homocoupled diyne side product in the 
presence of O2 by Cu-catalysed Glaser type reactions
114
 or by Pd/Cu catalysed 
reactions.
109,115
 Amine free protocols have also been developed, but require the use of 
stoichiometric amounts of an alternative base to deprotonate the terminal alkyne and to 
trap the HX byproduct.
116
 
Palladium catalysts featuring bulky, electron rich phosphines have been shown to be 
highly active for a wide range of cross-coupling reactions. Pd(PhCN)2Cl2 / 
t
Bu3P / CuI in 
a 1:2:1.5 ratio was found to promote the room temperature couplings of both activated 
and deactivated aryl bromides with a range of terminal acetylenes at room temperature.
117
 
A Cu free procedure using 1:1 Pd2(dba)3 / 
t
Bu3P was also found to be effective.
118
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Palladacyclic catalyst precursors such as 10 and 11 (Figure 1.25) possess high thermal 
stability in comparison to traditional Pd(PR3)2X2 catalyst systems. This, and the high 
TONs often obtained, has led to the use of palladacyclic precursors in a range of cross-
couplings, especially for substrates requiring the use of elevated temperatures. 
P
Pd Pd
PO O
O O
RR
R R
R = o-tolyl
10 11
Pd
N
OH
Cl
Cl
Pd
N
HO
Cl
Cl
Cl
Cl
 
Figure 1.25 Palladacyclic catalyst precursors. 
 
The oxime derived palladacycle 10 was used by Alonso et al. for the Cu and amine free 
Sonagashira reaction of aryl iodides and bromides with a variety of terminal acetylenes. 
TONs as high as 72000 were observed with tetrabutylammonium acetate as the base in 
N-methylpyrrolidinone at 110 
o
C.
119
 Interestingly, the reactions were carried out in air 
suggesting that an alternative mechanism to the traditional Pd
0
/Pd
II
 cycle may be 
operating. Palladacycle 11, derived from P(o-tolyl)3 and Pd(OAc)2,  shows high catalytic 
activity for a range of  cross-couplings
 
at elevated temperatures, and has been shown to 
mediate the Sonogashira reaction in the absence of Cu co-catalyst with very low catalyst 
loadings. TONs of up to 8000 have been reported in the coupling of 4-
bromoacetophenone with phenylacetylene.
120 
 
N-heterocyclic carbenes (NHCs) have attracted considerable interest as potential ligands 
for homogeneous catalysis since their isolation by Arduengo et al.
121
 The strong -donor 
and weak -acceptor properties of these ligands and their reluctance to dissociate from 
the metal centre make them attractive alternatives to bulky phosphine ligands.  
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Figure 1.26 N-heterocyclic carbene (NHC) precursors and a Pd
II
 complex bearing an NHC ligand. 
 
Catalyst precursor 12 (Figure 1.26) was shown by Batey et al. to promote Sonogashira 
cross-coupling under mild conditions with PPh3 and CuI co-catalyst and NEt3 or Cs2CO3 
as a base.
122
 Ligand precursor 13 (Figure 1.26) was used in conjunction with Pd(OAc)2 
and CuI with base to give highly efficient couplings of o-iodohaloarenes in a one-pot 
synthesis of N-substituted indoles. The alkyne product intermediates were not isolated, 
but overall yields of up to 99% were obtained for the final products.
123
 
 
In a highly important development, Fu and coworkers employed a range of 
N-heterocyclic carbene precursors, including 14 (Figure 1.26), in conjunction with Pd(-
allyl)Cl2 and CuI for the couplings of a range of unactivated alkyl bromides and iodides 
possessing -hydrogens. Yields of up to 81% were reported showing that the catalyst 
system successfully circumvents the propensity of the oxidative addition products to 
undergo -hydride elimination.124 
 
1.2.5 The Suzuki-Miyaura reaction 
 
The Suzuki-Miyaura reaction
82 
involves the formation of a  bond between two carbon 
atoms via the cross-coupling of an organoboron compound and an organic halide or 
pseudohalide (e.g. TfO). The reaction is tolerant of a wide range of functional groups, 
and the coupling of aryl or 1-alkenyl boronic acids (or equivalent) proceeds smoothly for 
aryl, 1-alkenyl, 1-alkynyl, allyl, and benzylic halides. -Hydride elimination in trans-
RPdL2X complexes formed from oxidative addition of RX has limited the use of primary 
and secondary alkyl halides as coupling partners. The Suzuki-Miyaura reaction follows 
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an oxidative addition, transmetallation, reductive elimination pathway common to most 
palladium-catalysed cross-couplings (Scheme 1.7).  
 
R-XLnPd
0
LnPd
II XR
LnPd
II R'R
LnPd
II
R'
R
oxidative addition
transmetallation
trans-cis isomerism
reductive 
elimination
R-R'
R'-B(OR)2 / ROM
B(OR)3 + MX  
Scheme 1.7 Mechanism of the Suzuki–Miyaura reaction. 
 
 
Oxidative addition of aryl, 1-alkenyl, 1-alkynyl, allyl, and benzylic halides to a 
coordinatively unsaturated Pd
0
 complex, and subsequent cis-trans isomerisation, leads to 
the formation of a stable trans-palladium(II) complex. The reaction proceeds with 
complete retention of configuration for alkenyl halides and with inversion for allylic and 
benzylic halides. A variety of Pd
0 
complexes such as Pd
0
(PPh3)4 can be used as catalysts, 
as can mixtures of Pd2(dba)3 and ligands which form active Pd
0 
complexes in situ. Air 
stable Pd
II 
catalyst precursors such as PdCl2(PPh3)2 and Pd(OAc)2/phosphine systems are 
also highly effective, with in situ reduction via reaction with phosphines in the presence 
of water or organometallics generating the active Pd
0 
species.
125
 Alternatively, two 
transmetallations of the organoboronate to Pd
II
, followed by reductive elimination (i.e. 
homocoupling) of biaryl gives Pd
0
. 
 
1.2.5.1 Transmetallation in the Suzuki-Miyaura reaction 
 
Organoboronates are inert to transmetallation to palladium
II
 halides in neutral conditions 
due to the low nucleophilicity of the organic group on boron. Addition of NaOH or other 
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basic species have been shown to have a dramatic effect on the rate of the 
transmetallation of organoborons compounds to Au, Ag, Pt and Hg.
126,127,128
 The 
nucleophilicity of the substituent on boron is enhanced by quaternisation of boron by the 
coordination of the Lewis base (Scheme 1.8). The exact mechanism of the quaternisation 
of the organoboron species and its subsequent transmetallation to Pd
II
 halides is 
dependent on the nature of the organoboronate species and occurs via either a 
quaternerised boronate species or Pd
II
OR intermediates.  
PdIILn XR1
PdIILn OR2R1
MX
B(OH)2R3
BR3
MOR2
R3
PdIILn OR2
B
OH
OH
OH
OR2
OH
MX
M
R1
PdIILn R3R1
B(OH)2R2O
Path A
Path B
 
 
Scheme 1.8 Base assisted transmetallation of organoborons compounds to Pd
II
(Ln)(R)X. 
 
Evidence for the free boronate pathway in the transmetallation of boronic acids is 
provided by the observation that the rate of cross-coupling of aryl boronic acids is 
retarded at pH 7–8.5 relative to that at pH 9.5-11. The pKa of phenyl boronic acid is 8.8 
suggesting the formation of the hydroxyboronate anion R‟-B(OH)3
-
 at pH values in 
excess of 8.8, and its transmetallation to Pd
II
 halides.
129
 However, although the basicity of 
the hydroxypalladium species is unknown, the analogous platinum complex 
Pt
II
Ph(PPh3)2OH is more basic than hydroxide, further complicating the situation.
130
 
 
The choice of base has an important effect on the selectivity of the reaction for 
unsymmetrically substituted alkenyl boronic acids.
131
 Strong Lewis bases such as fluoride 
and hydroxide give a predominantly cross-coupled product. However, in the presence of 
weakly basic species such as NEt3, „head to tail‟ coupling is observed with the coupling 
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occurring  to the position of the boron atom. This results from a competing pathway in 
which oxidative addition to RX is followed by η2-coordination of the alkenyl boronate 
ester 15 and subsequent 1,2-insertion into to the Pd-C bond to give 16. The alkyl 
palladium species is capable of isomerising via -hydride/deuteride elimination and 1,2-
insertion to give 17 with base-assisted elimination of the haloboronic acid and Pd
0
 giving 
the product.
132 
The alternative 1,2-insertion product, in which palladium and the butyl 
group are on the same carbon, may also undergo boryl elimination, but the product is 
identical to that of the conventional cross-coupled product (Scheme 1.9). 
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Scheme 1.9 Mechanism of head to tail coupling in Suzuki-Miyaura reactions. 
 
1.2.5.2 Potassium organotrifluoroborates and their reactions 
 
Potassium organotrifluoroborates are monomeric, crystalline solids that are readily 
isolated, indefinitely stable in the air and highly resistant to moisture.
133
 These materials 
are readily synthesised via the addition of KHF2 to a variety of organoboron 
intermediates in aqueous methanol.
134
 Aryl, alkenyl and alkynyl potassium 
trifluoroborates have been shown to be efficient coupling partners in the Suzuki-Miyaura 
reaction
135
 with the active transmetallating species, formed by reaction of 
organotrifluoroborate with base under aqueous conditions, being tetracoordinate 
organoboronates bearing one or more hydroxyl groups.
134c,136 
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The Lewis acidity and sensitivity of trivalent organoboranes and organoboronates to 
nucleophiles, bases and oxidants renders selective functional group interconversions of 
orgonaboron compounds challenging. In contrast, potassium organotrifluoroborates have 
been shown to be resistant to a range of nucleophilic, basic and oxidative reaction 
conditions that destroy organoboronic acids and boronate esters. 
 
R1
R2
BF3K
R1
R2
BF3KO
OO
(1.2 equiv)
acetone, rt
C8H17 BF3KO
Ph
BF3KO
BF3KO
Cl BF3KO
85% 70% 71% 80%  
 
Equation 1.3 Epoxidation of potassium 1-alkenyl trifluoroborates with dimethyldioxirane. 
 
Molander and coworkers have shown that 1-alkenyl trifluoroborates could be oxidised 
with dimethyldioxirane to give their corresponding epoxides. In contrast, 1-alkenyl 
boronic acids and their corresponding pinacol esters yielded aldehydes, resulting from 
oxidative B-C cleavage (Equation 1.3).
137
 Similarly, aryl and alkyl trifluoroborates 
bearing alkene moieties underwent cis-dihydroxylation in the presence of catalytic OsO4 
and morpholine N-oxide without reaction of the trifluoroborate moiety.
138
  
 
I BF3K
1. Nucleophile (Nuc, 3 equiv)
2. aq. KHF2 (1.5 M)
Nuc BF3K
BF3KS
NC BF3K BF3K
O
EtO2C
S BF3K
Br
H
N BF3K
N3 BF3K
N BF3K
O
O BF3K N BF3K
CO2Me
 
Equation 1.4 Nucleophilic substitution of iodomethyl trifluoroborates. 
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Potassium organotrifluoroborates have been shown to undergo further functionalisation 
under basic conditions with retention of the trifluoroborate group. Potassium 
aryltrifluoroborates were functionalised using Wittig
139
 or Horner-Wadsworth-
Emmons
140
 reactions, with incorporation of potassium trifluoroborate into both the 
carbonyl and triphenylphosphonium chloride salt possible. In addition, potassium 
p-bromophenyltrifluoroborate may be functionalised by lithiation and trapping with a 
variety of electrophiles
141
 and potassium iodomethyltrifluoroborate can be reacted with a 
range of nucleophiles, to give a range of functionalised methyltrifluoroborate salts 
(Equation 1.4).
142
 
 
1.2.5.3 Suzuki-Miyaura cross-couplings of organoboron reagents with alkyl 
halides 
 
In 1992, Suzuki and coworkers showed that 9-alkyl-9-BBN derivatives possessing -
hydrogens as well as 9-aryl/alkenyl-9-BBN derivatives could be cross-coupled with 
primary alkyl iodides in the presence of catalytic Pd(PPh3)4 and excess K3PO4. 
143
 
 
More recently, work by Fu and coworkers has shown that trialkylphosphine ligands, 
especially PCy3, in conjunction with Pd catalyst precursors are effective for the couplings 
of 9-alkyl-9-BBN derivatives to primary alkyl bromides (Table 1.2).
144
 Couplings of 
9-alkyl-9-BBN derivatives to alkyl tosylates
145
 and chlorides
146
 were also reported by the 
same group.  
 
Although easily synthesised by alkene hydroboration, 9-alkyl-9-BBN derivatives are 
sensitive to air. In comparison, boronic acid derivatives possess high stability with 
respect to air and water, in addition to being commercially available. A catalyst derived 
from Pd(OAc)2/P(tBu)2Me was found to be highly effective for cross-couplings of 
arylboronic acids and primary alkyl bromides in the presence of base in t-amyl alcohol at 
room temperature
147
 and was shown to oxidatively add bromoalkanes at temperatures as 
low as 0 
o
C. Further work with Ni catalysts bearing 2-aminoalcohol ligands showed them 
to be highly effective for the cross-couplings of arylboronic acids with a variety of 
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unactivated primary and secondary alkyl halides (including the more challenging alkyl 
chlorides).
148 
 
Table 1.2 Cross-couplings of 9-alkyl-9-BBN derivatives with alkyl bromides by Fu 
and co-workers. 
B
n-Hex
Br
n-Dec
1.2 equiv.
4 mol % Pd(OAc)2
8 mol % PCy3
1.2 equiv. K3PO4 H2O
THF, rt
n-Dec
n-Hex
.
+
 
entry Ligand
a 
n-Dec
n-Hex n-Dec  
1 PCy3 85 <2 
2 PPh3 <2 <2 
3 P(2-furyl)3 <2 <2 
4 P(o-tol)3 <2 14 
5 P(2,4,6-methoxylphenyl)3 <2 31 
6 dppf <2 12 
7 Binap <2 <2 
8 P(OPh)3 <2 <2 
9 AsPh3 <2 <2 
10 P
t
Bu3 <2 21 
11 P
n
Bu3 9 27 
12 dcpe <2 21 
13 P
i
Pr3 68 6 
% yield after 16 h (by GC)  
a
 In the case of bidentate ligands 4% of the ligand was used 
 
1.2.5.4 Suzuki-Miyaura cross-couplings of organoboron reagents with aryl 
chlorides 
 
The use of unactivated aryl chlorides as coupling partners in the Suzuki-Miyaura reaction 
is highly desirable due to the low cost and facile synthesis of aryl chlorides. In the last 
decade, huge progress has been made in the use of these unreactive substrates in cross-
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couplings
149
 facilated by the use of bulky, highly electron rich ligands. In 1995, the 
Pd(OAc)2/P(o-tolyl)3 derived palladacycle 11 was shown to mediate the Suzuki-Miyaura 
reaction of 4-chloroacetophenone and phenylboronic acid with K2CO3 base at 130 
o
C 
with similar conditions yielding high TONs for the coupling of aryl bromides.
149d 
 
Nolan and coworkers have employed the NHC-ligated palladacycle 18 as a precatalyst 
for the Suzuki-Miyaura coupling of unactivated aryl chlorides bearing ortho substituents 
with boronic acids at room temperature in technical grade 
i
PrOH (Equation 1.5). 
 
N
Pd
Cl
N
N
R
R
Cl (HO)2B
2 mol % 18
NaOtBu 0.6 mmol
Isopropanol 1 mL
Room temperature, 75 min
+
0.5 mmol 0.7 mmol
87%
18 R =
 
 
Equation 1.5 Cross-couplings unactivated aryl chlorides with aryl boronic acids by Nolan and co-workers. 
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Scheme 1.10 Activation of palladacycle 18 in 2-propanol. 
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Couplings of aryl chlorides yielded the corresponding biaryl products in high yields with 
short reaction times with anyhydrous 
i
PrOH giving no improvement in activity or yields. 
It was proposed that the displacement of chloride by iso-propoxide in 18 gave a iso-
propoxy substituted palladacycle which may undergo β-hydride elimination with loss of 
acetone to give a palladium hydride. Reductive elimination of 2-dimethylaminobiphenyl 
may then give NHC-Pd
0
 as the active catalytic species (Equation 1.5 and Scheme 
1.10).
150
 
 
Dialkyl(biaryl)phosphines (Figure 1.27) have been shown to be highly active ligands for 
the cross-coupling of aryl boronic acids and aryl chlorides.
151,152
 A combination of the air 
stable 2-dimethylamino-2‟-dicyclohexylphosphinobiphenyl (davephos) and Pd(OAc)2 is 
highly effective for the room temperature couplings of aryl chlorides, even those 
possessing electron donating groups and ortho substituents.
150
 In comparison, 
Pd(PCy3)2Cl2  catalyses the  Suzuki-Miyaura reactions of activated aryl halides at 100-
120 
o
C in N-methylpyrrolidone with CsF as base. Electron donating substituents are not 
tolerated and the presence of ortho substituents is found to lower the yield.
151
 For the 
synthesis of biphenyls with more than one ortho substituent more active systems are 
required. The dicyclohexyl-(2-phenanthren-9-yl-phenyl)-phosphine ligand 19 gives an 
extremely active catalyst when used in conjunction with Pd2(dba)3. Biaryl products with 
4 ortho-substituents are produced in high yields from the couplings of aryl chlorides with 
aryl boronic acids.
152
  
 
The high activities of these ligands are attributed to their electron rich nature and large 
steric bulk which favours a PdL mediated oxidative addition pathway. nteractions 
between the  system of the diphenyl moieties and palladium may stabilise highly active 
monophosphine species and are believed to encourage reductive elimination.
151
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Figure 1.27 Dialkylbiarylphosphines for Suzuki-Miyaura reactions of aryl chlorides developed by 
Buchwald et al. 
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1.3 Transition metal-catalysed borylations of C-H bonds 
 
Organoboron compounds have received much attention, especially as intermediates in 
organic synthesis.
153,154
 The B-C bond may be cleaved with or without homologation and 
organoboranes can be utilised as substrates in a variety of catalytic reactions including 
Suzuki-Miyaura cross couplings,
82
 copper-catalysed Chan-Lam type couplings with N-, 
and O-nucleophiles,
155
 and rhodium-catalysed additions to a variety of unsaturated 
compounds.
156
  
 
1.3.1 Synthesis of organoborons 
 
The synthesis of organoboranes has traditionally involved the trapping of Grignard or 
organolithium reagents with trialkylborates
152
 or hydroboration of alkenes and alkynes,
152
 
as developed by H. C. Brown and coworkers, where the addition of the H-B bond 
proceeds with anti-Markovnikov regioselectivity. Diborylated products may be 
synthesised by the addition of diboron compounds to unsaturated systems. This was first 
demonstrated by Schlesinger and coworkers with the addition of B2Cl2 to ethene
157
 to 
form Cl2BC2H4BCl2, (Equation 1.6). 
 
 
 
 
Equation 1.6 Addition of B2Cl4 to ethene by Schlesinger and co-workers. 
 
However, due to the difficulty of preparation and instability of B2Cl4, this reaction has 
not found general application. However, the use of more stable diboron reagents such as 
B2(NMe2)4,
158
 B2pin2
159
 (pin = pinacolato = OCMe2CMe2O), B2neop2
160
 (neop = 
neopentaneglycolato = OCH2CMe2CH2O) and B2cat2
159, 161
 (cat = catecholato = 
1,2-O2C6H4) has allowed for the development of a variety of diborylation reactions, 
although transition metal catalysts are required to cleave the B-B bond.
162
 Figure 1.28. 
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Figure 1.28 Diboron compounds. 
 
Methods for the synthesis of aryl boron compounds have traditionally required 
preactivation of the aromatic ring or the presence of a directing group.
163
 Equation 1.7. 
 
X
H
DG
SiMe3
X
B(OR)2
B(OR)2
DG
BBr2
B(OR)2
B(OH)2
B(OH)2
DG
B(OH)2
H3O
+
H3O
+
H3O
+
1. R'M
2. B(OR)3
1. R'Li
2. B(OR)3
BBr3
HB(OR)2 or
B2(OR)4
Pd, base
X = Br, I
DG = directing group
X = halide, OTf  
 
Equation 1.7 Methods for the synthesis of arylboron compounds. 
 
1.3.2 Transition metal-catalysed C-H borylations 
 
The synthesis of aryl and benzylic boron compounds, which cannot be synthesised via 
hydroboration, by the direct functionalisation of C-H bonds is highly attractive as it 
eliminates the need for preliminary steps associated with the preactivation of arenes. The 
rest of this section will concentrate on the scope and limitations of methods for the 
synthesis of aryl-, benzyl-, and vinyl boronate esters via transition metal catalysed 
borylations of aromatic, benzylic and vinylic C-H bonds. 
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1.3.3 Transition metal-catalysed benzylic C-H borylation  
 
Marder and coworkers reported the use of [Rh(Cl)(N2)(P
i
Pr3)2] with HBpin to generate a 
catalyst for the benzylic borylation of methylarenes at 140 
o
C with Rh loadings between 1 
and 0.3 mol % (Equation 1.8). In addition, the same catalyst system was found to be 
effective for the aromatic C-H borylation of benzene. The borylation of mesitylene, 
p-xylene and toluene led predominantly to benzylic borylation products with only small 
amounts of products of arene C-H borylation observed. Toluene was borylated in 76% 
yield with 81% selectivity for benzylic borylation after 80 h at 140 
o
C. Reactions of 
p-xylene and mesitylene lead to lower yields (41 and 17% respectively) with 100% 
selectivity for benzylic functionalisation, which was attributed to increased steric 
hindrance around the aromatic C-H bonds. In the borylation of toluene, greater than 
statistical levels of bis-pinacolboryl-methylbenzene were observed, suggesting that the 
presence of a boryl group further activates adjacent benzylic C-H bonds.
164
 
 
Men
H
HBpin Men-1
Bpin
H2
RhCl(PiPr3)2(N2)
140 oC / 80 h
+ +
Bpin
Bpin
Bpin BpinBpin
69% 7%
+
41% 17%  
 
Equation 1.8 Benzylic borylation of methylarenes by Marder and co-workers.
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Subsequent computational studies
165
 into the reaction have suggested that oxidative 
addition of HBpin to the 14 electron species [Rh(Cl)(P
i
Pr3)2], 19, followed by elimination 
of ClBpin generated the active catalytic species [Rh(H)(P
i
Pr3)2]. Coordination of toluene 
gives a ζ C-H complex which undergoes oxidative addition of the bound C-H bond to 
give [Rh(P
i
Pr3)2(η
3
-benzyl)(H)2]. Stabilisation of the benzylic C-H activation product by 
η3 coordination accounts for the observed selectivity for benzylic over aromatic C-H 
borylation. Reductive elimination of H2 from [Rh(P
i
Pr3)2(η
3
-benzyl)(H)2] gives a  ζ-H2 
complex, from which H2  is displaced by HBPin to give a ζ-HBpin complex. Subsequent 
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oxidative addition yields [Rh(P
i
Pr3)2(η
3
-benzyl)(H)(Bpin)] which reductively eliminates 
the borylated product to regenerate the Rh(I) hydride catalyst (Scheme 1.11). 
 
[Rh] = Rh(PiPr3)2
[Rh](Cl)(H)(Bpin)
[Rh] -H
[Rh]
H2
CH
H
[Rh] -CH2Ph
H
Bpin
[Rh] -H
Bpin
Ph
Cl -Bpin
PhH2C- [Rh]
H
H
CH2[Rh]
PhCH3
HBpin
H2
PhCH2Bpin
Bpin
H
 
|Scheme 1.11 Catalytic cycle for the borylation of toluene with [Rh(Cl)(P
i
Pr3)2] and HBpin. 
 
Ishiyama et al. reported that the widely available palladium on carbon (10% Pd/C) 
catalysed the benzylic borylation of alkyl arenes with both HBpin and B2pin2 at 100 
o
C 
without aromatic C-H borylation (Table 1.3).
166
 Reactions of toluene, o-, m-, and p-
xylene and mesitylene led to exclusive formation of benzylic borylation products whereas 
in the reaction of ethylbenzene, a mixture of benzylic and terminal C-H activation was 
observed. The lower yields and slower reactions observed when HBpin is used instead of 
B2pin2 indicated that reactions involving diboron occur via a two step process involving a 
fast and quantitative reaction with diboron, followed by a slower reaction with the HBpin 
generated by the earlier process.  
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Table 1.3 Pd/C-catalysed benzylic borylations of alkyl arenes with B2pin2 and HBpin.
166 
Bpin
Bpin
Bpin
Bpin
Bpin
Bpin
Bpin
Bpin
Bpin
Bpin
Product     Yields / %    a               b Product     Yields / %    a               b
72          54
77
79
72          51
64          45
72          54
15           6
38          13
39          42
9            5
a with B2pin2, b with HBpin. Yields relative to boron  
 
Beller et al. have reported that combinations of 2‟2-bipyridine (bpy) and the rhodium 
complexes [RhCl(COD)]2, [Rh(acac)COD] and Rh2(OAc)4 at 1.5 mol % Rh loadings are 
effective for the benzylic borylation of ortho-xylene at 80 
o
C
 
with ratios of sp
3
:sp
2
 
borylation of up to 67:3.
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1.3.4 Transition metal-catalysed aromatic C-H borylation 
 
Direct functionalisation of aromatic C-H bonds is an attractive proposition, due to the 
elimination of synthetic steps usually associated with the preactivation of arenes. Of these 
reactions, the direct borylation of arene C-H bonds is of particular interest due to the wide 
range of transformations which utilize organoboranes. This field has recently been 
reviewed by Miyaura and Ishiyama.
168
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1.3.5 Stoichiometric group XII and XIII carbonyl mediated borylations 
 
One of the first examples of aromatic C-H borylation was reported by Hartwig and 
coworkers. Under photolytic conditions the stoichiometric borylation of benzene and 
toluene was achieved with [Mn(CO)5BCat], 20, [Re(CO)5BCat], 21 and 
[CpFe(CO)2BCat], 22. Reactions of toluene with Mn and Fe boryls 20 and 22 showed no 
formation of ortho substituted products and meta:para ratios of 1.6:1 and 1.1:1 
respectively.
169
 Later work by the same group reported the photolysis of 22 in benzene to 
give PhBcat in 99% yield.
170
 Photolysis of 22 in a range of monosubstituted arenes was 
studied, with the formation of only meta and para borylation products observed. Only 
photolysis reactions carried out in anisole yielded any ortho substituted products. This 
suggests that the regioselectivity is typically determined by steric effects, although the 
significant proportion of ortho-borylation observed for the reaction of 22 with anisole 
may result from the methoxy group acting as a directing group. The results are 
summarised in Table 1.4  
 
Table 1.4 Stoichiometric borylations of PhX with [CpFe(CO)2BCat], 22. 
 Product selectivities  
X o m p Yield / % 
Me - 1.1 1.0 70 
OMe 1.0 1.6 1.1 52 
Cl - 1.5 1.0 55 
CF3 - 1.5 1.0 33 
NMe2 - 1.0 8.0 30 
 
A pathway involving photochemical dissociation of CO to give a 16 electron intermediate 
followed by C-H bond oxidative addition or metathesis followed by reductive elimination 
of the B-C bond was proposed. 
 
 
75 
 
1.3.6 Rhodium-catalysed aromatic C-H borylation 
 
Hartwig and coworkers reported the use of [Cp
*Rh(η4-C6Me6)], 23, in the borylation of 
benzene with HBpin. Catalyst loadings of 5 and 0.5 mol % were employed and the 
reactions were carried out at 150 
o
C in mixtures of arene substrate and HBpin.
171
 Further 
work by Smith and coworkers detailed the borylation of a range of functionalised arenes 
with the same catalyst.
172
 Monosubstituted arenes gave statistical distributions of 
meta:para borylation products, the exception being that of diethylbenzamide, the 
borylation of which gave a ratio of o:m:p products of 4.17:1.98:1. The statistical ratio of 
meta and para isomers suggest that a chelation directed ortho metallation and non 
directed pathways are in direct competition. 1,3-disubstituted arenes and 2,6-lutidine 
were borylated selectively in the meta position (Equation 1.9). 
 
R1
Bpin
R1
[Cp*Rh(4-C6Me6)]
HBpin / 150 oC
Yields  65 - 92%                     
R1 = H, CF3, NMe2, OMe,
 Me, CO2Et
[Cp*Rh(4-C6Me6)]
HBpin / 150 oC
Yields  50%
o:m:p = 4.17:1.98:1
NEt2
O
NEt2
O
Bpin
BpinX
R1
R2
X
R1
R2
[Cp*Rh(4-C6Me6)]
HBpin / 150 oC
X = CH                
Yields  73 - 86% 
R1 = R2 = CF3,  Me
X = N
Yield 41%
 R1 = R2 = Me  
Equation 1.9 Rhodium-catalysed borylations of arenes by Hartwig and coworkers, and Smith and co-
workers. 
 
Smith and coworkers demonstrated the use of cyclohexane as an inert solvent in the 
borylation of arenes with HBpin and 23. This is highly desirable for the borylation of 
expensive or non volatile substrates, for which the use of the substrate as the solvent 
presents issues with cost and work up.
173
 Although 23 is able to catalyse the borylation of 
alkanes, secondary and tertiary C-H positions are not readily borylated. A range of 1,3-
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disubstituted arenes were borylated to give 1,3,5-substituted products, while veratrole 
(1,2-dimethoxybenzene) was borylated in the 4-position. N-protected 
1-triisopropylsilylpyrrole was selectively borylated in the least hindered 3-position 
(Equation 1.10). 
 
[Cp*Rh(4-C6Me6)]
HBpin / 150 oC
cyclohexane
R1
R2
R1
R2
Bpin
NTIPS NTIPS
Bpin[Cp*Rh(4-C6Me6)]
HBpin / 150 oC
cyclohexane
Yields  53 - 88%                     
R1 = CF3, NMe2, OMe, Me
R2 = CF3, NMe2, OMe, Me
Yield  81%
MeO
MeO
MeO
MeO
Bpin[Cp*Rh(4-C6Me6)]
HBpin / 150 oC
cyclohexane
Yield  82%
 
Equation 1.10 Regioselective aromatic borylations in cyclohexane by Smith and coworkers. 
 
Catalyst precursor [Rh(Cl)(N2)(P
i
Pr3)2], 19, previously discussed in relation to benzylic 
C-H borylation of methylarenes, is also effective for the aromatic C-H borylation of 
arenes (Equation 1.11).
163
 In the borylation of toluene, although benzylic C-H activation 
predominates, the ratio of sp
3
:sp
2
 products of 4:1 shows that the aromatic C-H borylation 
pathway is in competition with benzylic borylation and gives meta-MeC6H4Bpin as the 
main aromatic borylation product. Computational studies
164
 also show that the aromatic 
borylation pathway is similar in energetics to that for benzylic borylation. The borylation 
of benzene with HBpin in the presence of 1 mol % 19 gave 62% of PhBpin after 14 
hours, increasing to 86% after 58 hours.  
 
HBpin +
RhCl(PiPr3)2(N2)
140 oC
+
Bpin
H2
 
 
Equation 1.11 Borylation of benzene with [Rh(Cl)(N2)(P
i
Pr3)2] by Marder and co-workers. 
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1.3.7 Iridium-catalysed aromatic C-H borylation 
 
In 1993, during the preparation of Ir(η6-MeC6H5)(Bcat)3 from Ir(η
5
-C9H7)(COD), 24, and 
excess HBcat in toluene, Marder and coworkers observed substoichiometric borylation of 
the arene solvent. Reactions employing benzene and C6D6 gave similar results leading to 
the production of phenyl-Bcat and C6D5-Bcat as side products. When toluene was used as 
the solvent, 2 isomers of tolyl-Bcat were observed in a 2:1 ratio.
174
 
 
Later work by Smith and coworkers,
175
 in the light of earlier work by Bergman
176
 and 
Jones
177
 on alkyl C-H activation by group VII M(Cp
*
)PMe3 complexes,  detailed the 
thermal C-H activation of benzene using a Cp
*
(PMe3)Ir
I
 complex to give 
[Cp
*
Ir(PMe3)(H)(Ph)], 25. Reactions of 25 with HBpin and HBcat gave Ph-Bpin and Ph-
Bcat as the major products respectively (Equation 1.12). 
 
Cp*
Ir
H
Me3P
Ph
Cp*
Ir
Bcat
Me3P
Bcat
excess HBcat
C6D6, 150 
oC
PhBcat H2+ +
Cp*
Ir
H
Me3P
Ph
Cp*
Ir
H
Me3P
Bpin
HBpin
C6D6, 150 
oC
PhBpin H2+ +
 
 
Equation 1.12 Thermal reactions of [IrCp
*
PMe3(H)(Ph)] with HBcat and HBpin. 
 
The major product from the reaction of [Cp
*
Ir(PMe3)(H)(Ph)] with HBpin, 
[Cp
*
Ir(PMe3)(H)(Bpin)], 26, was found to be a precatalyst for the borylation of arenes 
with HBpin. The borylation of benzene was carried out with a catalyst loading of 17 mol 
%, at 150 
o
C for 120 hours, with three turnovers occurring in that time. Complex 26 was 
also employed as a catalyst in the borylation of a range of substituted arenes. Borylation 
was found to occur selectively in the meta and para positions, with many of the 
monosubstituted substrates giving statistical mixtures (in the range of 2:1) of meta and 
para isomers, Equation 1.13. 
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[Cp*Ir(PMe3)(H)(Bpin)]
HBpin, 150 oC
X
R1
R2
X
R1
R2
Bpin
R R
Bpin
Yields 55 - 99%
o:m:p - trace:2:1
R = H, Me, CF3, 
OMe, iPr
X = CH
Yields  60 - 86%
R1 = R2 =Me, CF3
X = N
Yield 41%
R1 = R2 = Me
[Cp*Ir(PMe3)(H)(Bpin)]
HBpin, 150 oC
 
 
Equation 1.13 [Cp
*
Ir(PMe3)(H)(Bpin)]-catalysed borylation of arenes. 
 
In 2002, building on the result of Marder,
173
 Smith and coworkers synthesised 
(η6-1,3,5-Me3C6H3)Ir(Bpin)3 by an analogous route from [Ir(η
5
-C9H7)(COD)], 24. This 
complex was used in conjunction with PMe3 to generate an active catalyst for the 
borylation of benzene with HBpin.
178
 The rate of borylation was found to decrease 
dramatically when the [P]:[Ir] ratio was 3:1 or higher, while [P]:[Ir] ratios of less than 3:1 
gave appreciable rates of borylation, suggesting that the active species possesses two 
dative ligands. In addition, catalysts were prepared in situ from a combination of 24, 
ligand and HBpin. Chelating phosphines such as 1,2-bis(diphenylphosphino)ethane 
(dppe) and 1,2-bis(dimethylphosphino)ethane (dmpe) led to substantial increases in 
activity and TONs, as demonstrated by dmpe, where the effective TON of 4500 
represents an improvement of 1500 fold over precatalyst (η6-1,3,5-Me3C6H3)Ir(Bpin)3. In 
addition, it was demonstrated that a combination of the commercially available 
[Ir(Cl)COD]2 dimer, 27, and dmpe led to an active catalyst for the borylation of benzene 
with HBpin.  
 
Catalyst precursor [Ir(η5-C9H7)(COD)], 24, in conjunction with dmpe and dppe, was 
utilised for the borylation of a range of mono-, and disubstituted arenes. As in borylations 
employing [Cp
*
Ir(PMe3)(H)(Bpin)], monosubstituted substrates gave statistical mixtures 
of meta and para isomers, while borylation of 1,3-disubstituted substrates occurred 
selectively at the mutually meta position. Borylation ortho to fluorine was demonstrated 
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for 1,4-difluorobenzene, demonstrating that the fluorine group has similar steric demands 
to that of a proton. In addition, 1,2-dimethoxybenzene was borylated at the 4-position. 
The results of these reactions are summarised in Equation 1.14. 
 
X
R1
R2
X
R1
R2
Bpin
MeO MeO
BpinMeO MeO
I I
Bpin
F
F
F
F
FF
Bpin
BpinF
F
F
F
HBpin
2 mol % Ir(Ind)COD
2 mol % dppe
100 oC
HBpin
2 mol % Ir(Ind)COD
2 mol % dmpe
150 oC
HBPin
2 mol % [(6-Mes)Ir(Bpin)3]
2 mol % dppe
100 oC
HBpin
2 mol % Ir(Ind)COD
2 mol % dmpe
150 oC
HBpin
2 mol % Ir(Ind)COD
2 mol % dppe
150 oC
X = CH                              X = N 
Yields  89 - 95%             Yield  69% 
R1 = Cl, Br                      R1 = R2 = Cl
R2 = Cl, Br, CO2Me
Yield  62%
Yield  77%
o:m:p - 0:21:79
ArH:HBPin - 4:1
1 h
Yield  63%
F
F
F
F
FF
Bpin
HBpin
2 mol % Ir(Ind)COD
2 mol % dmpe
150 oC
ArH:HBPin - 1:5
62 h
Yield  76%
Yield  81%
Bpin
Bpin
 
Equation 1.14 Iridium-catalysed arene C-H borylations by Smith and coworkers. 
 
Hartwig, Miyaura and coworkers demonstrated that a combination of [Ir(Cl)COD]2, 27, 
and 2,2‟-bipyridine (bpy) ligand was effective for the borylation of arenes with B2pin2 at 
80 
o
C in neat arene solvent.
179
 Both electron rich and electron poor arenes were borylated 
in high yields. Reactions were carried out over 16 hours using a 3 mol % Ir loading. 
Monosubstituted arenes gave statistical mixtures of meta and para borylation products, 
with steric effects preventing the formation of the ortho products for all substrates other 
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than anisole. Borylation of 1,2-disubstituted arenes, where R1 = R2, gave single products 
resulting from borylation in the para position, while 1,3-disubstituted arenes yielded 
1,3,5-substituted products resulting from borylation of the C-H bond meta to both 
substituents. Overall, the regioselectivity for the borylation of these arenes was 
characterized by the lack of borylation ortho to groups on the arene and statistical ratios 
of the meta and para borylation products, suggesting that it is the steric environment 
around the C-H bond, rather than electronic effects that determines the regioselectivity of 
Ir-catalysed borylations of substituted arenes. Borylations of benzene in the presence of 
either o-, m-, or p-borylanisole did not result in the formation of anisole, nor 
isomerisation of the boryl anisoles, showing that isomer ratios are kinetically rather than 
thermodynamically determined. The borylation of p-xylene, in which all aromatic C-H 
bonds are ortho to a methyl group, gives a single product although yields are lower than 
for o- and m-xylene due to steric hindrance (Table 1.5).   
 
Table 1.5 Iridium-catalysed direct borylations of arenes with B2pin2. 
Bpin
F3C
Bpin
MeO
Bpin
Bpin
Bpin
MeO
MeO
Bpin
Cl
Cl
Bpin
Bpin
Bpin
Bpin
MeO
Bpin
MeO
MeO
Product Yield / % (o:m:p) Product Yield / % (o:m:p)
95
95 (1:74:25)
82 (0:69:31)
82 (0:70:30)
83
86
83
58
86
72
73
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Competition reactions carried out in equimolar mixtures of trifluoromethylbenzene and 
toluene, trifluoromethylbenzene and anisole, and toluene and anisole gave product ratios 
of 90:10, 85:15 and 40:60, respectively, indicating that electron poor arenes are more 
reactive than electron rich ones. The higher reactivity of anisole, in comparison to 
toluene, suggests that coordination of substituent groups or inductive effects may also 
influence the reactivity of arenes. 
 
Later work by the same group sought to optimise this catalyst system via systematic 
studies into the effect of the nature of the 2,2‟-bipyridine ligand and the iridium source on 
the catalytic activity in room temperature reactions.
180
 Combinations of bpy and 
[IrX(COD)]2 complexes containing strongly basic and nucleophilic anions such as 
methoxide and hydroxide were found to be highly effective for the borylation of benzene 
with B2pin2 at room temperature in neat arene with 3 mol % Ir loadings, as was the use of 
[IrCl(COD)]2, 27, in conjunction with excess NaOH to generate [Ir(OH)COD]2 in situ. In 
contrast, the use of Ir(I)COD complexes of less basic and nucleophilic anions such as 
acetate, chloride and tetrafluoroborate as iridium sources showed little if any catalytic 
activity under identical conditions (Table 1.6). The high catalytic activity of (hydroxyl)-, 
and (alkoxy)-iridium complexes can be explained by faster formation of iridium 
monoboryl complexes. These species are formed by either; oxidative addition of B2pin2 
to (hydroxyl)-, or (alkoxy)-iridium species followed by reductive elimination of ROBpin 
or via transmetallation between B2pin2 and (hydroxyl)-, or (alkoxy)-iridium species 
(Scheme 1.12). In both cases the enhanced ability of hydroxyl and alkoxy ligands to 
interact with the vacant boron π-orbital and the formation of a strong B-O bond makes 
reactions more facile than for those of chloride, acetate and tetrafluoroborate complexes. 
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OMeIr
N
N BpinIr
N
N
OMeIr
N
N Ir
N
N Bpin
OMe
Bpin
BpinIr
N
N
+ B2pin2
+ B2pin2
+   MeO-Bpin
+   MeO-Bpin
Oxidative addtion / reduction elimination
Transmetallation N N
NN =
 
 
Scheme 1.12 Pathways for the formation of Ir
I 
monoboryl complexes from Ir(OMe) precursors. 
 
Table 1.6 Effects of differing iridium sources on the borylation of benzene with 
B2pin2 at room temperature. 
Entry Ir
I
 precursor Time / h Conversion / % Yield / % 
1 [IrCl(COD)]2 24 0 0 
2 [Ir(COD)2]BF4 24 3 0 
3 [Ir(OH)COD]2 4 100 88 
4 [Ir(OPh)COD]2 4 100 84 
5 [Ir(OMe)COD]2 4 100 90 
6 [{IrCl(COD)}2] / 4NaOH 4 100 73 
7 [Ir(OAc)COD]2 24 19 1 
 
To examine steric and electronic effects of substituents in 2,2‟-bipyridine ligands a range 
of substituted 2,2‟-bipyridines were used in conjunction with [Ir(OMe)COD]2, 28, (3 mol 
% Ir loading) for the room temperature of benzene with B2pin2 (Table 1.7). No large 
differences in activity was observed in catalysts featuring bpy (29a), 4,4‟- and 5,5‟-
dimethyl-2,2‟-bipyridine (29b and 29c, respectively) as ligands. The 3,3‟-dimethyl 
derivative 29d lead to reduced activity, suggesting that a planar ligand is desirable for 
high activity. The use 6,6‟-dimethyl substituted ligand 29e was ineffective due to steric 
crowding around the iridium centre. The use of ligands with electron donating 
substituents in the 4 and 4‟-positions (29f-29h) gave rise to higher activities than those 
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with no group or electron withdrawing groups in the 4 and 4‟-positions (29i and 29j, 
respectively).    
 
Table 1.7 Effects of ligands on the borylation of benzene with B2pin2 at room 
temperature. 
N N
R1 R1 R2
R3
R4R4
R3
R2
29a: R1, R2, R3, R4 = H
29b: R2 = Me, R1, R3, R4 = H
29c: R3 = Me, R1, R2, R4 = H
29d: R1 = Me, R2, R3, R4 = H
29e: R4 = Me, R1, R2, R3 = H
29f:  R2 = NMe2, R1, R3, R4 = H
29g: R2 = OMe, R1, R3, R4 = H
29h: R2 = 
tBu, R1, R3, R4 = H
29i:  R2 = , R1, R3, R4 = H
29j:  R2 = NO2, R1, R3, R4 = H  
Entry Ir
I 
precursor Ligand Time / h Conversion / % Yield / % 
1 [Ir(OMe)COD]2 29a 4 100 90 
2 [Ir(OMe)COD]2 29b 4 100 89 
3 [Ir(OMe)COD]2 29c 2 100 82 
4 [Ir(OMe)COD]2 29d 8 100 60 
5 [Ir(OMe)COD]2 29e 24 27 0 
6 [Ir(OMe)COD]2 29f 2 100 89 
7 [Ir(OMe)COD]2 29g 4 100 90 
8 [Ir(OMe)COD]2 29h 4 100 83 
9 [Ir(OMe)COD]2 29i 24 16 0 
10 [Ir(OMe)COD]2 29j 24 46 0 
 
 
1.3.7.1 Applications of the [Ir(X)COD]2/bpy catalyst system 
 
Since its initial publication, the use of [Ir(X)COD]2 (X = Cl, OMe) with 2,2‟-bipyridine 
ligands has become the predominant catalyst system for C-H borylation of arenes due to 
the stability of the catalyst precursors and its high activity under mild conditions in 
comparison to other reported systems. In the following pages the applications of this 
catalyst system will be reviewed. 
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1.3.7.1.1 Borylation of monosubstituted arenes  
 
Using a mixture of 27/bpy a range of monosubstituted arenes have been borylated with 
B2pin2 80 
o
C using neat substrate as the solvent.
178
 Borylation occurred in the meta and 
para positions giving a statistical ratio of products. Borylation ortho to the substituent is 
typically avoided due to steric factors (Equation 1.15). 
 
R R
Bpin0.5[IrCl(COD)]2/bpy (3 mol %)
80 oC, 16 h
Yields  80 - 95%
R = H, Me, CF3, OMe
B2pin2 +
 
 
Equation 1.15 Iridium-catalysed borylation of monosubstituted arenes with B2pin2 at 80 
o
C. 
 
1.3.7.1.2 Borylation of 1,2-disubstituted arenes 
 
Borylation of 1,2-disubstituted arenes has been demonstrated with both the 27/bpy and 
28/dtbpy catalyst systems.
178,179
 For symmetrical 1,2-disubstituted arenes, borylation 
para to the substituents yields a single regioisomer, with borylation of the C-H bonds 
ortho to substituents not observed (Equation 1.16). Borylation of unsymmetrical 1,2-
disubstituted arenes, which would yield two regioisomers, has, as yet, not been reported. 
 
B2pin2 +
0.5[IrCl(COD)]2/bpy (3 mol %)
80 oC, 16 h
R
R
R
R
Bpin
Yields  83 - 86%
R =  Me, Cl, OMe 
 
Equation 1.16 Iridium catalysed borylation of 1,2-disubstituted arenes with B2pin2 at 80 
o
C. 
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1.3.7.1.3 Borylation of 1,3-disubstituted arenes 
 
Borylation of 1,3-disubstituted arenes has been widely explored with both 27/bpy and 
28/dtbpy catalyst systems.
178,179,181
 For the latter, reactions may be carried out in a range 
of solvents at both ambient and elevated temperatures. Borylation typically occurs at the 
mutually meta position to yield 1,3,5-trisubstituted arenes with 100% regioselectivity. 
Due to the wide range of functional groups (Cl, Br, I, Me, OMe, CF3, CN, CO2Me, t-Bu) 
tolerated by Ir-catalysed borylation, this method offers an effective method for the 
functionalisation at the 5-position in 1,3-disustituted benzenes which is often difficult to 
access with ortho/para directing substituents. Borylations of 1,3-disubstituted arenes 
catalysed by the 28/dtbpy catalyst systems are summarised in Equation 1.17. 
 
0.5[Ir(OMe)COD]2/dtbpy
Yields  60 - 97%
R1 =  Cl, Br, I, Me, OMe, CF3 CN, CO2Me, 
tBu
R2 =  Cl, Br, I, Me, OMe, CF3 CN, CO2Me, 
tBu
R1
R2
R1
R2
BpinB2pin2 +
 
 
Equation 1.17 [Ir(OMe)COD]2/dtbpy-catalysed borylations of 1,3-disubstituted arenes. 
 
1.3.7.1.4 Borylation of 1,4-disubstituted arenes  
 
Although aromatic C-H bonds ortho to substituents are typically not borylated in the 
presence of less hindered aromatic C-H bonds, in substrates such as 1,4-disubstituted and 
1,3,5-trisubstituted benzenes borylation ortho to substituents can occur, albeit more 
slowly than with less hindered substrates. Borylation of p-xylene and 
1,4-dichlorobenzene was reported by Miyaura and coworkers using 27/bpy and 28/dtbpy 
respectively in 53–58% yields.178,179  
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Further work by Smith and coworkers detailed the borylation of a range of 4-substituted 
benzonitriles, for which borylation ortho to the two substituents may yield two isomeric 
products (Equation 1.18).
182
 Borylation ortho to the cyano group dominated when the 
4-substituent was larger than the cyano group, while for 4-fluorobenzonitrile, borylation 
ortho to the smaller fluoro group was favoured. The observed selectivity complements 
existing directed ortho metallation (DoM)
183
 and electrophillic aromatic substitution 
(EAS)
184
 chemistry allowing for selective functionalisation of 1,4-disubstituted arenes 
ortho to the cyano group in the presence of stronger ortho directing metallation groups 
(OMe, SMe, NMe2, CO2Me, NHAc) and ortho/para directors in the 4-position.  
 
CN
R
CN
R
Bpin CN
R Bpin
+
0.5[Ir(OMe)COD]2/dtbpy (3 mol %)
THF, 80 oC, 16 h
R = F, Cl, Br, I, Me, OMe, SMe
       NMe2, CO2Me, NHAc, CF3
Yields 55 - 70%                                            Ratio  
R = CF3, NHAc, CO2Me, NMe2, Br, I         99:1
R = Cl, SMe2, Me,                                        90:10
R = OMe                                                       67:33
R = F                                                             8:92
B2pin2 or HBpin +
 
 
Equation 1.18 Iridium-catalysed borylation of 4-substituted benzonitriles by Smith and coworkers. 
 
1.3.7.1.5 Borylation of polyaromatic substrates  
 
The high degree of regioselectivity displayed in Ir-catalysed arene borylations, and the 
steric basis of this selectivity allows for the functionalisation of a wide range of aromatic 
substrates with selectivity complementary to that of other methodologies. 
 
Sugihara and and coworkers. used a combination of 27 and bpy at 10 mol % Ir loading 
for the borylation of azulenes with B2pin2 in cyclohexane at reflux (Equation 1.19).
185
 
Borylation occurred predominantly at the 2-position with a minor isomer resulting from 
borylation of the more hindered 1-position adjacent to the ring junction. Interestingly, 
although the 7-membered ring possesses acidic and sterically unencumbered hydrogens, 
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borylation of these C-H bonds is not observed. The authors attributed this selectivity to 
the more favourable formation of π-coordinated precursors to C-H cleavage with the five 
membered ring. Borylation of both 4,6,8-trimethylazulene and 
1,4-dimethyl-7-isopropylazulene required longer reaction times and gave lower yields. In 
both cases, selective functionalisation of the 2-position was observed due to increased 
steric hindrance at the 1-, and 3-positions and blocking of the 2-position respectively. 
 
 
0.5[IrCl(COD)]2/bpy (10 mol %)
cyclohexane, reflux, 14 h
Bpin
Bpin
+
B2pin2
+ Yield 70%                           10%
 
 
Equation 1.19 Iridium-catalysed borylation of azulene with B2pin2 by Sugihara and coworkers. 
 
Marder and coworkers utilised 28/dtbpy for the borylation of a range of polycyclic 
aromatic hydrocarbons with B2pin2.
186
 Borylation of naphthalene with 1.1 equivalents of 
B2pin2 and 10 mol % Ir loading in cyclohexane at 80 
o
C led to the formation of 
monoborylated product along with 2 isomeric bisborylated products and unreacted 
starting material in a ratio of 29:49:10:12. The combined yield of the bisborylated 
products could be increased to 93% by the use of 2.2 molar equivalents of B2pin2. The 
borylation of pyrene under identical conditions with 1.1 equivalents of B2pin2 led to 
mono and bisborylated products in 68% and 6% yields respectively, with selective 
functionalisation at the 2-, and 7-positions. The use of 2.2 equivalents of B2pin2 yielded 
2,7-bisborylated pyrene as the sole product in 97% yield. Perylene was borylated with 4.4 
equivalents of B2pin2 to give a 2,5,8,11-tetraborylated product in 83% yield. The results 
are summarised in Equation 1.20. Hartwig and coworkers also reported the borylation of 
phenanthrene with B2pin2 and 1 mol % 28/dtbpy in cyclohexane to give 2 isomeric 
products.
187
 Although not fully analysed, by comparison with an authentic sample, it was 
shown that neither of the isomers were the 9-borylated product and were tentatively 
assigned as 2-, and 3-Bpin-phenanthrene.  
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In all cases, borylation occurred at the least hindered C-H bonds, while positions ortho to 
ring junctions were not borylated. For pyrene and perylene selective functionalisation of 
these positions is not possible by electrophillic aromatic substitution, which occurs at the 
1-, and 4-positions of pyrene and may occur at the 1-, 3-, 4-, 9-, and 10-positions of 
perylene. Thus selectivity of iridium-catalysed borylation for reaction of the less hindered 
C-H bonds complements that of electrophillic aromatic substititution which leads to 
reaction at the most electron rich positions. 
1.1 equiv B2pin2
0.5[Ir(OMe)COD]2/dtbpy (10 mol %)
cyclohexane, reflux, 16 h
1.1 equiv B2pin2
0.5[Ir(OMe)COD]2/dtbpy (10 mol %)
cyclohexane, reflux, 16 h
4.4 equiv B2pin2
0.5[Ir(OMe)COD]2/dtbpy (10 mol %)
cyclohexane, reflux, 16 h
Bpin
Bpin
Bpin
BpinBpin
Bpin
BpinBpin
BpinBpin
Bpin Bpin
+
+
+
 
 
Equation 1.20 Ir-catalysed borylation of polyaromatic hydrocarbons by Marder and coworkers. 
 
Plenio and coworkers reported the borylation of monosubstituted and 1,1‟-disubstituted 
ferrocenes (Equation 1.21), along with the half sandwich complexes CpMn(CO)3 and 
CpMo(CO)3Me in octane at 126 
o
C.
188
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R1
R2
Fe
R1
Fe
Bpin
R1
Bpin
Fe
Bpin
R1
R2
Fe
Bpin
+
0.5[Ir(OMe)COD]2/dtbpy
0.5 equiv B2pin2
octane
R2 = H
R1 = H, Br, Me, COCH3, CO2Me, CH2OCH3
R2 = H, Br, Me, COCH3, CO2Me, CH2OCH3
Yields  8 - 83%
 
 
Equation 1.21 Ir-catalysed borylation of ferrocenes with B2pin2 by Plenio and coworkers. 
 
Bae and coworkers reported the borylation of crystalline polystyrenes with 27/dtbpy in 
cyclooctane at 150 
o
C, with introduction of Bpin of up to 42% (Figure 58).
189
 Further 
work by the same group detailed the borylation of aromatic main-chain polymer to give 
borylated polysulfones (Equation 1.22).
190
 In both cases, subsequent transformations of 
the borylated polymer via Suzuki-Miyaura cross coupling or oxidation to give hydroxyl 
groups was demonstrated. 
 
B2pin2 or HBpin
3 mol % 0.5[IrCl(COD)]2/dtbpy
cyclooctane, 160 oC, 6 h
Bpin
O S
O
O
O
B2pin2 or HBpin
3 mol % 0.5[IrCl(COD)]2/dtbpy
THF, 80 oC, 12 h
O S
O
O
O
Bpin Bpin  
 
Equation 1.22 Ir-catalysed borylation of polymers by Bae and coworkers. 
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Osuka and coworkers have demonstrated that iridium-catalysed borylation is effective for 
the regioselective functionalisation of a range of porphyrins and aromatic substituents on 
porphyrins (Equation 1.23). Borylation of 1,15-disubstituted porphyrins, bearing groups 
which are unable to undergo borylation themselves, underwent borylation selectively at 
the β-position, with borylation of both free and metalloporphyrins being demonstrated.191 
Exhaustive borylation of 5,15-di(1,5-di-tert-butylphenyl)porphyrin with an excess of 
B2pin2 led to a tetraborylated product resulting from the reaction of all 4 β C-H bonds. 
For 1-aryl-10-phenyl-porphyrins bearing no β-substituents, no borylation occurs at the 
β-positions due to steric effects of the 1,10-substituents. Instead, when an excess of 
B2pin2 is employed, borylation occurs on the substituents phenyl group leading to the 
formation of products resulting from para borylation and diborylation of the meta isomer. 
In contrast to most borylations of monosubstituted arenes, borylation of 1-phenyl-β-
substituted porphyrins showed a high level of selectivity for the formation of the para 
product. This can be attributed to the extreme steric demands of the substituted porphyrin 
group which inhibits borylation of the meta C-H bonds on the phenyl ring.
192
  
 
N
N N
N
M
N
N N
N
M
Bpin
B2pin2 
3 mol % 0.5[Ir(OMe)COD]2/dtbpy
dioxane
M = H, H  43%
M = Ni      47%
M = Cu     44%  
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HNN
NNH
NN
NNH
NN
NN
M
C8H17O
C8H17O
C8H17O
C8H17O
Bpin
Bpin
NN
NNH
C8H17O
C8H17O
Bpin
M = H, H  74%
M = Zn     80%
6 equiv B2pin2 
3 mol % 0.5[Ir(OMe)COD]2/dtbpy
dioxane
Bpin
Bpin
NN
NN
M Bpin
NN
NN
M
M = H, H  13%
M = Zn     17%
6 equiv B2pin2 
3 mol % 0.5[Ir(OMe)COD]2/dtbpy
dioxane
Yield 12% Yield 82%
+
+
 
 
Equation 1.23 Regioselectivities of the Ir-catalysed borylation of substituted porphyrins with B2pin2. 
 
1.3.7.1.6 Borylation of 5-membered heterocycles 
 
Miyaura and coworkers have reported the iridium-catalysed borylation of a range of 
thiophenes, free and N-protected pyrroles and furans with B2pin2 using 27/dtbpy in 
octane at 80 
o
C, and with 28/dtbpy in hexane at room temperature.
193,194
 The borylation of 
thiophene, pyrrole and N-methylpyrrole was also reported by Beller et al. using the 
27/bpy catalyst system.
166
 For thiophenes, free pyrroles and furans, borylation was found 
to occur at the 2-position. However, for pyrroles bearing N-substituents, borylation at the 
2-position is less favourable due to steric hindrance. Borylation of N-methylpyrrole 
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yielded a mixture of 2-, and 3-borylated products in a 76:24: ratio, while borylation of 1-
triisopropylsilylpyrrole, previously reported by Smith
172
 using [Cp
*Rh(η4-C6Me6)], gave 
exclusive formation of the 3-borylated product. The results are summarised in Equation 
1.24. 
 
XR
XR Bpin
0.5[IrCl(COD)]2 or 0.5[Ir(OMe)COD]2/dtbpy
+   B2pin2
octane, 80 oC or hexane, rt
X = O,    R = H, Me, OMe, CO2Me
X = S,    R = H, Me, Br, CN
X = NH, R = H, Me, CO2Me
Yields  60 - 99%
N N Bpin
0.5[IrCl(COD)]2/dtbpy
octane, 80 oC
R R
N
R
+
Bpin
R = Me       76                :            24 
R = TiPS    0                  :            100
R = Me, TiPS
 
 
Equation 1.24 Ir-catalysed borylation of 5-membered heterocycles. 
 
Smith and coworkers have carried out an extensive study into the borylation of 2-, 3-, 
2,3- and 2,5-substituted thiophenes
195
 using 28/dtbpy (Equation 1.25). Borylation of 2-, 
and 2,3-substituted thiophenes gave single products resulting from selective borylation at 
the 5-position. In 3-substituted thiophenes borylation occurred in both the 2-, and 5-
positions with borylation at the 5-position favoured. The degree of selectivity was 
reported to be determined by the size of the 3-substituent, although how the relative size 
of the substituents were determined was not mentioned. For 2,5-substituted thiophenes 
borylation ortho to the smaller substituent was favoured, similar to the borylation of 
unsymmetrical 1,4-disubstituted benzenes. Borylations were carried out using 28/dtbpy 
with HBPin at room temperature in hexane, except for 2,5-dimethylthiophene, which 
required the use of 2 mol % [(Ind)Ir(COD)]/dmpe in neat HBpin at 150 
o
C.  
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SR1
S
R
SR1 R2
SR1
S
R
SR1 R2
HBpin
0.5[Ir(OMe)COD]2/dtbpy
hexane, rt
HBpin
0.5[Ir(OMe)COD]2/dtbpy
hexane, rt
HBpin
0.5[Ir(OMe)COD]2/dtbpy
hexane, rt
Bpin
Bpin S
R
SR1
Bpin
R2 R2
R1 = I, CO2Me, TMS, C(O)Me, R2 = H
R1 = Cl, R2 = Br
Yields  78 - 94%
R = CN, Cl, Br, Me, C(O)Me,
       CO2Me, TMS, p-tolyl
R1 = Cl, Br, Me
R2 = Cl, Br, I, TMS
+
+
Yields  54 - 95%
R      5-product : 2-product
CN                 1:1.13
Cl                   3.5:1
Br                   8.9:1
Me                  8.9:1
C(O)Me         >99:1
CO2Me          >99:1
TMS              >99:1
R2
R1   R2  3-borylation : 4-borylation
Cl    Cl            one product
Br    Br            one product
Cl    I                     5.7:1
Cl    Br                  2.0:1
Cl    Me                 2.3:1
Cl    TMS             >99:1
Bpin Bpin
Yields  56- 97%
 
 
Equation 1.25 Ir-catalysed borylation of substituted thiophenes by Smith and coworkers. 
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1.3.7.1.7 Borylation of benzofused 5-membered heterocycles 
 
Miyaura and coworkers have reported the borylation of benzofused heterocycles with 
27/dtbpy at 80 
o
C. Borylation was found to occur at the 2-position, due to activation of 
this position by the adjacent heteroatom. Borylation of N-protected substrates was also 
demonstrated, with N-methyl indole giving 2-, and 3-borylated products in an 89:11 ratio, 
while N-TiPS indole was selectively borylated at the 3-position.
192
 Boron:arene ratios of 
less than 1:1 were used in order to prevent the formation of diborylated products. Similar 
work was also reported by Beller et al.
166
 using 27/bpy at 80 
o
C, and by Miyaura using 
with 28/dtbpy at room temperature with B2pin2 or HBpin.
193
 Borylations of benzofused 
5-membered heterocycles are summarised in Equation 1.26. 
 
Bpin
XX
0.5[IrCl(COD)]2/dtbpy
octane, 80 oC, 16 h
+ B2pin2
X        
N
O
S
Yield
92%
91%
89%
Bpin
NN
0.5[IrCl(COD)]2/dtbpy
octane, 80 oC, 16 h
+ B2pin2
Yield 83%
TiPS TiPS
 
 
Equation 1.26 Iridium-catalysed borylations of benzofused heterocycles by Miyaura and coworkers. 
 
Smith and coworkers observed that the borylation of indole, with an excess of boron, led 
to the formation of small amounts of 2,7-diborylated indole as the sole bisborylated 
product. Further work on 2-substituted indoles showed that borylation occurred 
selectively at the 7-position, with coordination of the indole nitrogen to either iridium or 
boron directing the borylation (Equation 1.27).
196
 Similar results were reported by Beller 
and coworkers.
197
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0.5[Ir(OMe)COD]2/dtbpy
hexane, 60 oC, 1-6 h
+ HBpin
Yields  78 - 83%
N
H
R
N
H
R
Bpin
R = Me, CO2Me, CO2Et,
 CONEt2, TMS, Ph  
 
Equation 1.27 Selective borylation of the 7-position in 2-substituted indoles. 
 
1.3.7.1.8 Borylation of 6-membered N-heterocycles and benzofused 
analogues 
 
Since the initial report of the borylation of 2,6-lutidine with HBpin and 
[Cp
*
Ir(PMe3)(H)(Bpin)] by Smith and coworkers in 2000,
174
 Ir-catalysed borylation of a 
range of 6-membered heterocycles has been reported. Borylation of pyridine gave 
statistical mixtures of 3-, and 4-borylated products, with borylation at the 2-position not 
observed. However pyridine was found to be a poor substrate, giving a combined yield 
for the 2 isomers of 42% after 16 h at 100 
o
C. Similarly, borylations of 3-substituted 
pyridines by Hartwig and coworkers gave moderate conversions, with borylation 
occurring solely at the 5-position. This is in contrast to the borylations of 
2,6-dichloropyridine and 2,6-lutidine which are readily borylated.
193 
 
It was proposed by Marder and coworkers that the coordination of pyridines to iridium 
inhibits their borylation, with the strongly donating 4-tert-butylpyridine showing no 
borylation after heating at 80 
o
C for 2 days
 
with a 2.5 mol % loading of [IrCl(COE)2]2 
and dtbpy. Further work by the same group has shown that the incorporation of 
substituents at the 2-position prevents coordination of the pyridine substrate to the 
sterically hindered iridium centre and allows borylation to occur smoothly at the 4-, and 
5-positions.
198
 Similarly, quinoline, which may be considered a 2,3-disubstituted 
pyridine, borylates smoothly at the 3-position, with steric effects preventing borylation at 
the 4-position ortho to the ring junction.
193
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It has been suggested by Hartwig and Miyaura that coordination of pyridine to either 
iridium or boron sterically hinders the 2-position, thus preventing its borylation.
192
 
However, in light of the work Smith and coworkers on borylation of indoles,
195
 
coordination to iridium seems unlikely to be the origin of the observed regioselectivity. In 
addition, Marder and coworkers have reported that adducts of pyridines and B2pin2 do not 
form, even in highly concentrated solutions. Adducts of this type are known for the more 
Lewis acidic B2cat2 and readily identified by an upfield shift of the 
11
B NMR resonance 
for the 4 coordinate boron.
199
  
 
For 4,4‟-dimethoxy-2,2‟-bypyridine, effectively a 2,4 disubstituted pyridine, borylation 
occurred in the 5-, and 5‟-positions suggesting that borylation will occur at sites other 
than the 2/6-position even in the presence of a small ortho group. Borylation of the more 
bulky dtbpy lead to reaction at the 6/6‟-positions. The results for the borylations of 
pyridines and quinolines are summarised in Equation 1.28. 
 
NR NR
Bpin
0.5[IrCl(COD)]2 or 0.5[Ir(OMe)COD]2/dtbpy
B2pin2    +
octane, 100 oC or hexane, 100 oC
R = H, Ph, Me
0.5[IrCl(COD)]2/dtbpy
octane, 100 oCN N
B2pin2    +
Bpin
hexane, 80 oC
B2pin2    +
N N
R R
N N
MeO OMe
R = MeO, tBu
0.5[Ir(OMe)COD]2/dtbpy
Bpin Bpin
N N
Bpin Bpin
or
 
 
Equation 1.28 Ir-catalysed borylation of pyridines and related substrates. 
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1.3.7.2 Tandem reactions  
 
Iridium-catalysed borylation of arenes has been shown to be compatible with a large 
range of transformations of boronic acids and boronate esters, and a variety of one-pot 
tandem reactions have been reported which feature aromatic C-H borylation as their 
initial step. The majority of the one-pot reactions have concentrated on the use of 
1,3-disubstituted substrates as their borylation results in a single product. The current 
scope of transformations of the Bpin group that have been utilised in tandem reactions is 
shown in Scheme 1.13. 
 
R1
R2
R1
R2
BF3K
R1
R2
B(OH)2
R1
R2
Cl
R1
R2
OH
R1
R2
Ar
R1
R2
NH3
R3
Cl
Bpin
R1
R2
Br
R1
R2
FR1
R2
OR
R1
R2
NR2
 
 
Scheme 1.13 Current scope of one-pot C-H borylation / transformation of the Bpin group. 
 
Hartwig and coworkers have reported one-pot synthesises of aryl and heteroaryl boronic 
acids and potassium trifluorborates from the corresponding 1,3-disubstituted arenes and 
benzofused heterocycles.
200
 Borylations were carried out in THF at 80 
o
C and the 
boronate esters were transformed into either boronic acids, via oxidative hydrolysis with 
NaIO4 in THF/H2O, or potassium trifluoroborate salts via displacement of pinacol with 
KHF2 in THF/H2O. 
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Smith and coworkers have shown that iridium-catalysed C-H borylation/oxidation is an 
effective, one-pot route for the synthesis of meta substituted phenols from 
1,3-disubstituted arenes.
201
 Synthesis of these products is notoriously difficult when the 
1,3-substituents are ortho/para directing groups. Borylations were carried out in 
substrate/HBpin mixtures using (Ind)Ir(COD)/dmpe as the catalyst, and the subsequent 
oxidations were performed using aqueous Oxone
®
 in acetone at 25 
o
C giving the products 
in high yields. 
 
Hartwig and coworkers have demonstrated one-pot meta chlorination and bromination of 
1,3-disubstituted arenes and 3-substituted pyridines via C-H borylations and oxidative 
halogenation with CuCl2 and CuBr2 respectively. Borylations were carried out in THF 
using 0.2 mol % Ir loadings of 28/dtbpy, while the subsequent halogenations were carried 
out in MeOH giving the products in 46–81% yields.202 Although conversions of aryl-, 
and vinyl-boronic acids and trifluoroborates to the corresponding iodides have been 
reported by Kabalka,
203
 as yet, no one-pot C-H borylation/iodination protocol has been 
reported. 
 
In addition to simple transformations of the pinacolboronate ester group, Ir-catalysed C-H 
borylation has been shown to be compatible with transition metal-catalysed couplings of 
arylboronate esters with a range of electrophiles and nucleophiles.  
 
One-pot C-H borylation/Suzuki-Miyaura cross couplings have been widely reported as 
demonstrations of the synthetic utility of C-H borylations. Miyaura and coworkers have 
reported a one-pot C-H borylation/Suzuki-Miyaura reaction synthesis of unsymmetrical 
biaryls. Borylations were carried out using HBpin in hexane with 28/dtbpy at 25 
o
C, 
while addition of Pd(dppf)Cl2, K3PO4·nH2O, arylbromide and DMF gave the biaryl 
products.
180
 This method is an improvement on previous reports in which the solvent 
used for borylation was evaporated, prior to carrying out the cross coupling in a 
secondary solvent. In a further improvement, Marder and coworkers demonstrated a one-
pot C-H borylation/Suzuki-Miyaura cross coupling sequence in a single solvent. Both 
C-H borylation and Suzuki-Miyaura cross couplings were found to proceed smoothly and 
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with high yields in methyl-tert-butyl ether (MTBE). Other polar solvents typically used 
for Suzuki-Miyaura reactions, such as DMF and DMSO, have been previously shown to 
be poor solvents for Ir-catalysed borylations.
204
 Hartwig and coworkers have reported the 
combination of C-H borylations and Chan-Lam couplings as a one-pot route to anilines 
and aryl ethers from arene starting materials (Equation 1.29).
205
 Alkylamines could be 
coupled directly with the boronate ester products, while the use of phenols and anilines as 
coupling partners required the boronate ester to be oxidised to the more reactive boronic 
acid.  
 
R1
R2
R1
R2
Bpin
R1
R2
N
H
R3
R1
R2
B(OH)2
R1
R2
N
H
Ar
R1
R2
N
H
Ar
[Ir(OMe)COD]2/dtbpy
cyclohexane, 80 oC
2 equiv H2NR3, 1 equiv KF
10 mol % Cu(OAc)2
.H2O
4 A MS, CH3CN, O2, 80
oC
3 equiv NaIO4
0.6 equiv HCl
H2O/THF, rt H2NAr, 2 equiv lutidine
10 mol % Cu(OAc)2
.H2O
20 mol % decanoic acid
toluene, air, rt
1 equiv Cu(OAc)2
.H2O
5 equiv NEt3
HOAr, CHCl2, 4 A MS, rt
R1 = OMe, CH3, CF3, 
CO2Me, Cl, H
R2 = OMe, CH3, Cl, H
Yields  31 - 67%
Yields  70 - 95%
Yields  39 - 94% 
 
Equation 1.29 Cu-catalysed couplings of boronic acids and boronate esters with N-, and O-nucleophiles. 
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In addition to transformations of the Bpin groups, the tolerance of halogens exhibited by 
Ir-catalysed C-H borylation allows for functionalisation of these reactive groups 
following C-H borylation. Smith and coworkers have demonstrated sequential 
borylation/Buchwald-Hartwig aminations of 3-substituted aryl chlorides and bromides to 
give arylamine boronate ester products in one-pot reactions (Equation 1.30).
206
  
 
R1
X
Bpin
R1
R3R2N
R1
Br
OH
R1
R2N
R3
O
R1 = Me, CO2Me, CF3, 
        OMe, NMe2
X = Cl, Br
Yields  49 - 83%
NR2R3 = NHPh, NPhMe, 
                NBu2, NC4H8O
1. 2 equiv HBpin
   (Ind)Ir(COD)/dmpe, 150 o C
2. Pd2dba3/P(t-Bu)3, K3PO4
    amine, DME, 100 oC
1. 2 equiv HBpin
   (Ind)Ir(COD)/dmpe, 150 o C
2. Pd2dba3/Xantphos, Cs3CO3
    amide, dioxane or DME, 100 oC
3. Filtration through SiO2 then
    Oxone, acetone, rt
4. 10 equiv NaIO4, acetone, rt
R1 = Me, CO2Me, CF3, 
        Cl, CN
Yields  33 - 82%
HR2COR3, AcNH2, BocNH2,
Bn2NCONH2, acrylamide, tiglic amide,
-valerolactam  
 
Equation 1.30 Sequential C-H borylation/Buchwald–Hartwig reactions by Smith and coworkers. 
 
Synthesis of 5-substituted 3-amidophenols from 3-substituted haloarenes via sequential 
C-H borylation/Pd-catalysed amidation/oxidation was also reported by the same group 
(Equation 1.30).
207
 Although C-H borylation/amidation could be carried out in a one-pot 
fashion, subsequent oxidation with Oxone
®
 failed without prior filtration of the 
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amidoarylboronate ester solution. In both cases the use of anhydrous conditions was 
found to be essential for preventing unwanted side reactions of the boronate ester group. 
 
Rhodium-catalysed additions of organoboronates to a range of electrophiles are widely 
known.
155
 Hartwig and Boebel have reported that arenes may be converted to chiral -
diarylmethylsufinylamines via a sequence of C-H borylation and Rh-catalysed addition of 
aryl boronate esters to chiral sulfinimines.
208
 Both stepwise and one-pot syntheses were 
demonstrated, Equation 1.31. 
 
1. 0.5 mol % [IrCl(COD)]2/1 mol % dtbpy
    1.7 equiv. B2pin2, 10 mol % HBpin
    THF, 80 oC
2. 5 mol % [Rh(COD)(CH3CN)2]BF4
    2 equiv NEt3
    1:1 H2O / dioxane2 equiv.
1 equiv.
75%
87% de
Me
Me
Me
Me
HN
S
O
CF3
F3C
HN
S
O
H
 
 
Equation 1.31 One-pot synthesis of chiral -diarylmethylsufinylamines by Hartwig and Boebel. 
 
1.3.7.3 Iridium-catalysed borylations of silicon containing substrates 
 
Hartwig and Boebel have utilised the ability of iridium complexes to cleave and 
functionalise Si-H bonds in two studies into the borylation of silane substrates.  
Borylation of benzyldimethylsilane led to ortho-substituted products with no reaction at 
the meta or para positions observed. Phenols and anilines were silylated via 
[IrCl(COD)]2 catalysed coupling with SiMe2H2 to give functionalised dimethylsilanes, 
followed by silane directed C-H borylation with 27/dtbpy and B2pin2. The reversal of 
selectivity observed in the borylation to silane functionalised arenes was attributed to 
oxidative addition of the Si-H bond to the Ir centre followed by elimination of HBpin to 
give a new iridium complex in which the arene is coordinated via the silane moiety. The 
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reaction may then occur at the ortho C-H bonds of the bound arene, followed by Si-H 
reductive elimination from Ir(III)
 
which releases the ortho borylated product.
209
 
 
Later work by the same authors reported the catalytic borylation of a range of 
trialkylsilanes at 80 
o
C
 
with B2pin2 and 28/dtbpy as the catalyst to give borylsilane 
products in moderate to high yields.
210
  The borylsilane products were then employed as 
boron sources in the 28/dtbpy catalysed borylation of a range of methylarenes. Notably 
only borylation occurred with no silylation products observed. In contrast to typical 
28/dtbpy catalysed borylation of methylarenes both sp
2
 and sp
3
 borylation products were 
observed, with hindered substrates such as mesitylene borylated selectively at the 
benzylic positions.  
 
1.3.7.4 Novel iridium catalysts for aromatic C-H borylations 
 
Although the catalyst systems developed by Miyaura and Hartwig, and Smith have been 
the most widely studied and applied, other groups have reported the use of other ligands 
for iridium alternative catalyst systems (Figure 1.29). 
 
Masuda and coworkers have shown that Ir(Tp)COD or combinations of 27 and 
trispyrazolylborate (Tp) salts are effective catalysts for aromatic C-H borylations. 
Borylations of mono-, and 1,2-, 1,3- and 1,4-disubstituted arenes showed the same 
selectivities as for the use of [Ir(X)COD]2/dtbpy.
211
 Nishida and coworkers have shown 
that combinations of 27 and 2,6-diisopropyl-N-(pyridylmethylene)-aniline, 29, and 
related ligands are effective for the borylation of arenes and heteroarenes at 80 
o
C.
212
 
Borylations of 1,3-disubstituted benzenes and 2,6-disubstituted pyridines reacted 
selectively at the least hindered C-H bond, while benzofuran, benzothiophene and indole 
underwent selective borylation at the 2-position. 
 
Maguire and coworkers have shown that Ir(I)-salicylaldiminato(COD) complexes such as 
30 are effective for the borylation of arenes when used in conjunction with the ionic 
liquid tributyltetradecylphosphonium dodecylbenzenesulfonate (TBPB), CH2Cl2 and 
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tetra-2-pyridinylpyrazine, giving a catalyst system that can be reused up to 3 times 
without loss of activity.
213
 Borylations of monosubstituted benzenes (R = CF3, OMe and 
Me) led to the formation of meta and para substituted products in of 1.3:1, 1.1:1 and 
1.5:1 for trifluoromethylbenzene, anisole and toluene, respectively.   
 
Hermann and coworkers synthesised a range of iridium complexes of mono-, and 
bidentate NHC ligands (31 and 32) which were evaluated as catalysts for the borylation 
of arenes with HBpin at 40–45 oC. Mono-, 1,2-,  and 1,3-disubstituted arenes were all 
effectively borylated although the regioselectivity of the reactions was not confirmed.
214
 
 
Maguire and coworkers have demonstrated that Ir(0) nanoparticles, prepared by the 
reduction of hydridoiridiumcarborane (PPh3)Ir(H)(7,8-nido-C2B9H11), are active catalysts 
for the borylation of benzene with HBpin in mixtures of CH2Cl2 and ionic liquids when 
used in conjunction with tetra-2-pyridinylpyrazine and microwave heating. The catalyst 
systems could be recycled up to 6 times with less than 0.5% loss in activity.
215
 
 
N N
N
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N
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N
Ir
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N
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TfO-+
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Figure 1.29 Novel ligands and Ir complexes employed in Ir-catalysed C-H borylations. 
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1.3.7.5 Proposed mechanism for the Ir(OMe)COD/L2-catalysed borylation 
of arenes 
 
Miyaura and coworkers have proposed that [Ir(dtbpy)(Bpin)3], 33, is the resting catalyst 
state in the [IrCl(COD)]2/dtbpy. Analysis of catalytic reactions containing high catalyst 
loadings by 
1
H NMR spectroscopy showed the main species to be a dtbpy-ligated Ir 
complex. This species was shown to be [Ir(dtbpy)(Bpin)3] by comparison to be the fac-
Ir
III
 trisboryl complex [Ir(dtbpy)(Bpin)3(COE)], 34, which was independently synthesised 
from [IrCl(COE)2]2, 2 equivalents of dtbpy and 10 equivalents of B2pin2 in mesitylene at 
50 
o
C (Figure 1.30). Dissolution of 34 in C6D6 rapidly generated 3 equivalents of 
C6D5Bpin at room temperature, showing that the complex is chemically and kinetically 
competent to be an intermediate in the catalytic cycle.
178
  
 
The proposed mechanism starts with the coordinatively unsaturated 33 which cleaves and 
functionalises the arene C-H bonds by either oxidative addition of the arene C-H bond to 
give the Ir(V) complex [Ir(dtbpy)(Bpin)3(Ar)(H)], 35, and subsequent reductive 
elimination of Ar-Bpin to give [Ir(dtbpy)(Bpin)2(H)], 36, or via a concerted ζ-bond 
metathesis pathway to give the same products. Reaction of B2pin2 with 36 is proposed to 
give [Ir(dtbpy)(Bpin)4(H)], 37, which may reductively eliminate HBpin to reform 33, 
completing the catalytic cycle. The HBpin byproduct is utilised in a second catalytic 
cycle in which HBpin reacts with 36 to give [Ir(dtbpy)(Bpin)3(H)2], 38, which eliminates 
H2 to give 33. This complex then reacts with arene substrate to give Ar-Bpin and to 
reform 36. The proposed catalytic cycle featuring an oxidative addition/reductive 
elimination pathway for C-H borylation is detailed in Scheme 1.14. 
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[Ir(dtbpy)(Bpin)3]  33
[Ir(dtbpy)(Bpin)3(H)(Ar)]  35
[Ir(dtbpy)(Bpin)2(H)]  36
[Ir(dtbpy)(Bpin)4(H)]  37[Ir(dtbpy)(Bpin)3(H)2]  38
B2pin2
HBpin
H2 Ar-H
Ar-Bpin
[Ir(dtbpy)(X)]
B2pin2
XBpin
a
 
 
Scheme 1.14 Proposed catalytic cycle of [Ir(X)COD]2 / dtbpy catalysed borylation of arenes with B2pin2. 
 
Catalytic borylations carried out with [Ir(X)COD]2/dtbpy catalyst precursors were found 
to show an induction period, in which COD is reduced or hydroborated to give COE or 
related species. Reactions carried out with [Ir(X)(COE)2]2/dtbpy or 
[Ir(dtbpy)(Bpin)3(COE)] showed no such induction period. In addition, the species 
formed in the stoichiometric reaction of [Ir(TfO)(COD)] , dtbpy and B2pin2, namely 
[Ir(dtbpy)(Bpin)2(COD)]TfO, 39, (Figure 1.30) did not borylate C6D6 in the absence of 
added B2pin2.
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Figure 1.30 Iridium tris-, and bis-boryl complexes ligated by dtbpy. 
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Sakaki and coworkers have reported a theoretical study of the borylation of benzene 
using B2eg2 (eg = ethylene glycolato) as a model for B2pin2 and 
ethane-1,2-diylidenediamine (diim) or bpy as models of the dtbpy ligand.
216
 The results 
suggest that [Ir(bpy)(Bpin)3] is the active species for C-H bond activation, with oxidative 
addition of Ph-H to [Ir(bpy)(Bpin)3] to give to [Ir(bpy)(Bpin)3(H)(Ph)] occuring, rather 
than the reaction with [Ir(bpy)(Bpin)]. Reductive elimination of Ph-Bpin was proposed to 
occur from [Ir(bpy)(Bpin)3(H)(Ph)] to give [Ir(bpy)(Bpin)2(H)]. Oxidative addition of 
both B2pin2 and HBpin to [Ir(bpy)(Bpin)2(H)], giving [Ir(bpy)(Bpin)4(H)] and 
[Ir(bpy)(Bpin)3(H)2] respectively, are feasible, with the reaction of B2pin2 more 
favourable than that of HBpin. This supports the suggestion of Smith et al. that the 
catalytic borylation of benzene with B2pin2 at 80 
o
C is a two step process, with rapid 
reaction with B2pin2, followed by a slower reaction with HBpin once B2pin2 has been 
consumed. Sakaki and coworkers suggested that the formation of the unusual iridium(V) 
intermediates is made more favourable by the strongly electron donating Bpin and bpy 
ligands which stabilise the high oxidation state of iridium. In addition, the use of planar 
bpy ligands makes the formation of seven coordinate iridium(V) complexes more 
favourable by reducing steric hindrance in this highly congested intermediate. 
 
Hartwig and coworkers reported experimental mechanistic studies on the 
[Ir(X)COD]/dtbpy catalysed borylation of arenes with B2pin2, with the conclusions in 
consensus with those of Sakaki et al. COE was found to dissociate reversibly from 34 to 
give the active species 33. As suggested by Sakaki et al., C-H activation via 
[Ir(dtbpy)(Bpin)], although energetically feasible, does not occur as the equilibrium for 
the reversible oxidative addition of B2pin2 to [Ir(dtbpy)(Bpin)] lies far towards the 
iridium(III) trisboryl species 33.
186 
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1.3.8 Dehydrogenative borylation of olefins 
 
Vinyl boronate esters (VBEs) are useful intermediates in organic chemistry. They have 
been employed as precursors to aldehydes and vinyl halides, and can undergo a range of 
metal-catalysed reactions. Vinyl boron reagents can be synthesised by a variety of 
methods including hydroboration of alkynes,
217
 palladium-catalysed borylation of vinyl 
halides,
218
 lithiation of vinyl halides and subsequent trapping with trialkylborates,
219
 
hydrogenation of 1-borylalkynes,
220
 hydrozirconation of 1-borylalkynes,
221
 cross-
metathesis of terminal olefins with pinacolvinylboronate,
222
 transmetallation of vinyl 
metal reagents,
223
 and transition metal-catalysed diboration of alkynes with diboron 
reagents.
224
 However, the majority of these methods involve the preactivation of the vinyl 
group or are unsuitable for the synthesis of β,β-disubstituted vinylboronates. Thus, the 
dehydrogenative borylation of olefins, in which a vinylic C-H bond is replaced with a C-
B bond, is an attractive alternative to these methods. It does not require the preactivation 
of the olefin substrates, and it can be used to form VBEs from β,β-disubstituted olefins. 
 
1.3.8.1 Dehydrogenative borylation of olefins using borane clusters 
 
Sneddon and coworkers reported the first dehydrogenative borylations of olefins. The 
borylation of ethene, but-1-ene and propene was reported to occur with pentaborane in 
the presence of PdBr2 as a catalyst (Equation 1.31).
225
 However, the borylation of 
propene led to the formation of 3 isomeric vinylboranes, along with 2 hydroboration 
products. In addition, 50% of the olefin was hydrogenated using the hydrogen which is 
formed in the dehydrogenative borylation process. 
B5H9
+ B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
BPdBr2
0 oC
+ + + +
 
 
Equation 1.31 PdBr2-catalysed dehydrogenative borylation of propene with pentaborane by Sneddon and 
coworkers. Terminal and bridging hydrogens on the boron cluster are omitted for clarity. 
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1.3.8.2 Dehydrogenative borylation of olefins with concomitant 
hydrogenation and/or hydroboration 
 
In 1992, Brown et al. reported the dehydrogenative borylation of 4-vinylanisole with 
oxazaborolidene 40 in the presence of [Rh(μ-Cl)(η2-CH2=CHAr)2]2, 41, (Ar = 
4-MeOC6H4) as catalyst.
226
 Reactions were conducted in toluene at room temperature 
giving a 1:1 mixture of VBE and hydrogenation products. In a subsequent publication by 
the same group, borylations of 4-vinylanisole, 4-vinylchlorobenzene and vinylferrocene 
with oxazaborolidene 40 and 0.2 mol % 41 gave a 1:1 ratio of VBE and hydrogenation 
products.
227
 No products from hydroboration were observed (Equation 1.33).  
 
Ar
Ar = 4-C6H4OMe
        4-C6H4Cl
        ferrocenyl
N
B OH
Ph
Me
+ 0.2 mol % [Rh(-Cl)(
2-CH2=CHAr)2]2 (41)
toluene, 25 oC Ar
N
B O
Ph
Me
Ar
Ar                    Yield / %
4-C6H4OMe    
4-C6H4Cl         
ferrocenyl
+
98
99
38
(40)
 
 
Equation 1.33 Rhodium-catalysed dehydrogenative borylations of vinylarenes by Brown et al. 
 
The proposed mechanism of Brown‟s rhodium-catalysed dehydrogenative borylation of 
vinylarenes is detailed in Scheme 1.15. Initial reaction of the borane species with [Rh(μ-
Cl)(η2-CH2=CHAr)2]2, 41, is proposed to lead to the formation of 42, which acts as a 
source of the active monomeric rhodium hydride 43 Reversible 1,2-insertion of one of the 
bound olefin ligands into the Rh-H bond then gives the 12 electron species 44 which 
oxidatively adds the oxazaborolidene B-H bond to give 45. Reductive elimination of 
alkane and coordination of additional olefin would then give rhodium boryl complex 46 
which may insert one of the olefin ligands into the Rh-B bond to give the rhodium 
β-borylalkyl species 47. Subsequent β-hydride elimination gives the rhodium hydride 
complex 48 from which the bound VBE product is displaced by unreacted olefin to 
regenerate 43 and complete the catalytic cycle. 
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Scheme 1.15 Rhodium-catalysed dehydrogenative borylations of vinylarenes by Brown et al. 
 
Masuda and coworkers have reported the dehydrogenative borylation of olefins with 
HBpin catalysed by [RhCl(COD)]2 at room temperature in toluene (Scheme 1.34).
228
 This 
reaction is clearly reminiscent of the [Rh(μ-Cl)(η2-olefin)2]2-catalysed reaction reported 
by Brown and Lloyd-Jones. VBE products were obtained in high yields with respect to 
HBpin and with selectivities as high as 96%; however, in all cases, the formation of an 
equal quantity of the ethylarene byproduct resulting from the sacrificial hydrogenation of 
the substrate was observed. In addition, the synthesis of an unsymmetrical stilbene by a 
one-pot sequence of dehydrogenative borylation, followed by Suzuki-Miyaura cross-
coupling, was reported.  
110 
 
RhCl(COD)]2
Toluene, rt, 4 h
HBpin+
Bpin Bpin
Bpin
+ +
49 50 51
Boron containing product ratio     49 : 50 : 51
96 :   3 :   1
Ratio of 49:EtPh = 1:1   
 
Equation 1.34 Rhodium-catalysed dehydrogenative borylation of olefins by Masuda and coworkers. 
 
In addition to their work on rhodium-catalysed dehydrogenative olefin borylations, 
Masuda and coworkers reported dehydrogenative borylations of vinylarenes catalysed by 
1:4 mixtures of [Ru(COD)(COT)] (COD = 1,5-cyclooctadiene and COT = 1,3,5-
cyclooctatriene) and monodentate phosphines to give (E)-vinylboronate products 
(Equation 1.35).
229 
However, these catalysts were less active than those based on 
rhodium. Reactions catalysed by complexes containing phosphine ligands possessing 
electron-deficient aryl groups occurred with higher selectivities for dehydrogenative 
borylation over hydroboration, while those catalysed by complexes of PCy3 gave 
products resulting almost exclusively from hydroboration. In all cases, dehydrogenative 
borylation was accompanied by hydrogenation of the olefin. The proposed catalytic cycle 
involves the addition of two molecules of vinylarene to the ruthenium center, 
dehydrogenative borylation of one of the two vinylarenes and hydrogenation of the 
second.  
 Ru(COD)(COT)/4 PR3
Toluene, rt, 4 h
HBpin+
Bpin Bpin
Bpin
+ +
49 50 51
                                 Yields / %
PR3                         49 : 50 : 51
               
P(4-CF3C6H4)3         
P(3,4,5-F3C6H2)3     
PPh3                           
P(4-MeOC6H4)3
PCy3
+
78 : 15 :   7
76 : 15 :   5
62 : 18 : 19
50 : 22 :   9
3 : 52 :   0  
 Equation 1.35 Ruthenium-catalysed dehydrogenative borylation of olefins by Masuda and coworkers. 
111 
 
Sabo-Etienne and coworkers have demonstrated that [Ru(H)2(H2)2(PCy3)2] and 
[RuH{(μ-H)2Bpin}(ζ-HBpin)(PCy3)2] are catalyst precursors for the dehydrogenative 
borylation of linear and cyclic olefins with HBpin.
230
 The reaction of HBpin with 
[Ru(H)2(H2)2(PCy3)2] formed H2 and [RuH{(μ-H)2Bpin}(ζ-HBpin)(PCy3)2]. The reaction 
of this complex with ethene formed [RuH(Bpin)(C2H4)(PCy3)2], and this complex was 
proposed to be the catalyst resting state. A range of linear and cyclic olefins underwent 
dehydrogenative borylation at room temperature leading to mixtures of VBEs, 
hydroboration products, and alkanes from sacrificial hydrogenation of the substrates. 
 
n
n = 1-3
Bpin
n
Ar
B2pin2, DBU
2 mol % [IrCl(COD)]2
B2pin2
2 mol % [IrCl(COD)]2
Ar = Ph, 2-C6H4-Cl, 4-C6H4-Cl
Yields  72-99%
R = Ph, 4-C6H4Br, 4-C6H4NO2
CH=CHPh
Yields  53-61%
RHO
H
n
Bpin
ArI, base
5 mol % Pd(PPh3)4
neat substrate, 70 oC
neat substrate, 70-100 oC
RCHO
20-40 oC
dioxane/H2O
60-70 oC
 
 
Equation 1.36 Iridium-catalysed borylations of cyclic olefins by Szabó and coworkers. 
 
Szabó and coworkers reported the dehydrogenative borylation of cyclic olefins using 
B2pin2 catalysed by [IrCl(COD)]2 (Equation 1.36).
231
 For cyclohexene, a 1:1 ratio of 
allylic and vinylic borylation products was obtained after 3 h at 70 
o
C, while only the 
vinylic borylation product was observed after 16 h. Addition of 0.5 equivalents of 
1,8-diazabicyclo[5.4.0]undecane (DBU) led to an increase in the ratio of allylic to vinylic 
products (5:1 after 3 h at 70 
o
C), although the proportion of the vinylic product increased 
with prolonged heating. At 90-100 
o
C, the borylation reactions gave equimolar amounts 
of vinylboronate esters and their saturated counterparts, the latter resulting from 
sacrificial hydroboration of the substrate. The vinylboronate products were coupled in 
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situ with aryl iodides to give cyclic trisubstituted olefins, whereas the allylic boronates 
were allowed to react with aldehydes in situ to give stereo-defined homoallyl alcohols. 
 
Szabó also reported the dehydrogenative borylation of certain linear, terminal olefins 
with [IrCl(COD)]2 and B2pin2 at 80 
o
C to give vinylboronate esters which were then 
coupled with a range of aryl and vinyl halides in a one-pot process (Equation 1.37).
232
 
Allylsilanes and carbonyl, acetal and ether substituted olefins underwent dehydrogenative 
borylation to give 1:1 ratios of vinyl-, and alkylboronate ester products, the latter 
resulting from hydroboration by the HBpin generated by the dehydrogenative borylation 
with B2pin2. Of particular interest was the selective formation of VBEs over 
allylboronates from the reaction of B2pin2 with allyltrimethylsilane. This selectivity was 
attributed to a greater thermodynamic stability of the VBE product and a more favorable 
β-hydride elimination step. 
 
Me3Si
R2
1. B2pin2
    2 mol % [IrCl(COD)]2 
    neat substrate, 80 oC
2. R1X, Cs2CO3, 5 mol % Pd(PPh3)4
   dioxane/H2O, 50-60 
oC
R2 = CH(OMe)2, CO2Me
       C(O)Me, OBu
1. B2pin2, [IrCl(COD)]2 
    neat substrate, 80 oC
2. trans-BrCH=CHSiMe3
    Cs2CO3, Pd source
    dioxane/H2O, 40-50 
oC
R2
SiMe3
Me3Si R1
Yields  56-75%
R1 = substituted aryl or vinyl
Yields  54-87%
 
 
Equation 1.37 Iridium-catalysed dehydrogenative borylation of olefins and subsequent cross-coupling by 
Szabó and coworkers. 
 
Smith and coworkers reported the reactions of ethene with monoboranes catalysed by 3 
mol % [Cp
*
2Ti(η
2
-CH2=CH2)], 52.
233,234
 The catalytic reaction using HBop (op = benzo-
1,2,3-diazaborolene) gave VBE (58% yield) plus ethane. In contrast catalytic reactions 
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using HBcat gave the hydroboration product, ethylBcat, instead. Stoichiometric addition 
of HBcat or HBop to 52 led to the formation of boryl-substituted titanacycles, which 
underwent ligand exchange with additional ethene to regenerate 52 and give the VBE 
products. Borylation of 52 with HBop to give 53 was much slower than that with HBcat; 
however, subsequent displacement of the VBE by ethene was much faster for the Bop 
analog 14 than for the Bcat compound 54 (Equation 1.38). 
 
Ti
Cp*
Cp*
Ti
Cp*
Cp*
Bcat
Ti
Cp*
Cp*
Bop
HBcat
< 5 min at -80 oC
HBop
30 min at 25 oC
C2H4
40% conversion 
72 h at 25 oC
C2H4
> 90% conversion 
< 5 min at -80 oC
Ti
Cp*
Cp* Bcat
+
Ti
Cp*
Cp*
Bop+
52
52
52
54
53   
 
Equation 1.38 Stoichiometric reactions of [Cp
*
2Ti(η
2
-CH2=CH2)] with boranes and ethene by Smith and 
coworkers. 
 
1.3.8.3 Photochemically induced stoichiometric dehydrogenative olefin 
borylation  
 
During the course of initial studies on stoichiometric C-H activation reactions, Hartwig 
and coworkers reported the photolysis of [CpFe(CO)2(Bcat)], 22, and [Re(CO)5(Bcat)], 
21, in the presence of terminal and internal olefins (Equation 1.39).
169,170
 The reaction of 
22 with hex-1-ene led to the formation of the terminal hexenylboronate ester in 90% 
yield, along with 10% of hexyl-Bcat. The reaction of rhenium boryl 21 with hex-1-ene 
gave 55% of the terminal, trans-VBE product by NMR spectroscopy, with the majority 
of the remaining material (20–25%) consisting of the alkylboronate, presumably formed 
by metal-catalysed hydroboration. Reactions of 21 with internal olefins were less 
selective; the reaction of 4-octene gave the VBE product, along with at least 3 isomeric 
vinylboronates and octyl-Bcat from hydroboration. Photolysis of 21 in the presence of 
norbornene gave a single VBE product, along with two isomeric hydroboration products, 
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whereas the reaction with cyclohexene formed products other than vinylboronate esters. 
The formation of the VBE products was proposed to occur via photochemically induced 
dissociation of CO, followed by coordination of the olefin and either direct C-H bond 
cleavage or migratory insertion of the olefin into the M-B bond, followed by β-hydride 
elimination. 
Fe(Cp)(CO)2Bcat Bu+ Bu Bcat
Bu
Bcat
+h
90% 10%
alkane
22
Re(CO)5Bcat Bu+ Bu Bcat
Bu
Bcat
+h
55% 20-25%
neat hex-1-ene
21
 
 
Equation 1.39 Photochemically induced dehydrogenative borylation of olefins by Hartwig and coworkers. 
 
1.3.8.4 Dehydrogenative borylation of olefins under hydroboration 
conditions 
 
Marder, Baker and coworkers observed the formation of vinylboranes in the 
stoichiometric reactions of [Ru(η2-C2H4)(PMe3)4], 55, with 9-borabicyclo[3.3.1]- nonane 
(9-BBN).
235
 Addition of the boryl group to the bound olefin formed the cyclic species 56 
which is in equilibrium with the ruthenium β-borylalkyl complex 57, from which 
β-hydride elimination and hydride transfer gave the vinylborane product and 
[Ru(H)2(PMe3)4], 58 (Scheme 1.16).  
 
The same group observed the formation of VBE products in their study of the 
stoichiometric insertion of olefins into Rh-B bonds.
236
 Analysis of the reaction of 
[RhCl(Bcat)2(PPh3)2] with 2 equivalents of 4-vinylanisole in CD2Cl2 by 
1
H NMR 
spectroscopy showed the formation of VBE, 1,2-bis(boronate ester) (1,2-BBE) and 
internal hydroboration products in a 2:3:2 ratio, and trace amounts of the terminal 
hydroboration product. 
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VBEs were observed as side products in the catalytic diborations of olefins with B2cat2 
and 1 mol % of [RhCl(PPh3)3] as catalyst precursor at room temperature
237
 and in the 
catalytic hydroborations of certain allyl silyl ethers with HBcat in the presence of 
[RhCl(PPh3)3] as catalyst.
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Scheme 1.16 Stoichiometric Ru-mediated formation of vinylboranes reported by Marder, Baker and 
coworkers. 
 
Marder, Baker and coworkers reported the first example of catalytic dehydrogenative 
olefin borylation without significant hydrogenation of the substrate.
239
 In addition, they 
reported the dehydrogenative borylation of 1,1-disubstituted olefins. The reaction of 
α-methylstyrene with 1.1 equivalents of HBcat in the presence of 2 mol % of 
[RhCl(PPh3)3] as a catalyst precursor in THF at room temperature gave VBE and 
1,1-BBE (derived from the hydroboration of the VBE product) with a combined 
selectivity of 80% (53% for VBE and 27% for 1,1-BBE), along with 17% hydroboration 
and 3% hydrogenation. The pathways are summarised in Equation 1.40.  
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Ph Ph
Bcat
Ph
Bcat
Bcat
Ph
Ph
Bcat
Ph
Bcat
+
HBcat
1.1 equiv. HBcat
2 mol % RhCl(PPh3)3
25 oC, THF
Hydroboration
Dehydrogenative
borylation
Hydrogenation
VBE 1,1-BBE
 
 
Equation 1.40 Borylation of α-methylstyrene with HBcat catalysed by [RhCl(PPh3)3] (Wilkinson‟s 
catalyst). 
 
Westcott and coworkers reported several systems for the dehydrogenative borylation of 
olefins. They showed that the dehydrogenative borylation of aminopropyl vinyl ethers in 
the presence of [RhCl(PPh3)3] as a catalyst precursor formed exclusively VBE as the sole 
boron containing product,
240
 although the issue of whether sacrificial hydrogenation of 
the substrate occurred was not explicitly addressed.  
 
1.3.8.5 Dehydrogenative borylation of olefins without sacrificial 
hydrogenation and/or hydroboration 
 
In 2003, Marder and coworkers reported the dehydrogenative borylation of olefins with 
B2pin2 or B2neop2 (neop = neopentaneglycolate = OCH2CMe2CH2O) in the presence of 3 
mol % of the catalyst precursor trans-[RhCl(CO)(PPh3)2], 59, at 80 
o
C
 
without sacrificial 
hydrogenation of an equivalent of the substrate.
241
 Vinylarenes, such as 4-vinylanisole, 
along with 1,1-disubstituted olefins, such as α-methylstyrene, diphenylethylene, 
methylenecyclopentane and methylenecyclohexane, underwent dehydrogenative 
borylation in the presence of 59 as the catalyst precursor. The selectivity depended on the 
solvent. Reactions conducted in THF, toluene and 1,4-dioxane yielded complex mixtures 
of VBEs, hydroboration products, hydrogenation, vinyl-bis(boronate) esters (VBBEs) 
and saturated bis-boronate esters (BBEs) with 4-vinylanisole as substrate. In contrast, 
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reactions conducted in neat CH3CN selectively formed VBEs, but these reactions were 
slow. Reactions performed in a 3:1 mixture of toluene to CH3CN selectively formed 
VBEs with acceptable rates. Reactions conducted with substoichiometric amounts of 
B2pin2 (0.67 equivalents) occurred in up to 100% conversion, showing that both boron 
moieties of B2pin2 can be incorporated into the VBE products with some substrates.  
 
In subsequent work, Marder and coworkers extended the scope of the dehydrogenative 
borylations catalysed by 59 (Equation 1.41).
242
 In addition to the diboron reagents B2pin2 
and B2neop2, they found that HBpin was an effective borylating agent; however, 
reactions with HBpin are slower than reactions conducted with B2pin2 or B2neop2. 
R1
R2
R
R1
R2
R
B(OR')2
B(OR')2
Bpin
R = Ph, 4-MeOC6H4
R1 = Ph, Me
R2 = Ph
n n
Bpin
n = 1, 2
B2pin2 or B2neop2                                
5 mol % [RhCl(CO)(PPh3)2] (59)
PhMe/MeCN (3:1), 80 oC
B2pin2 or B2neop2                        
3 mol % [RhCl(CO)(PPh3)2] (59)
PhMe / MeCN (3:1), 80 oC
B2pin2                                          
3 mol % [RhCl(CO)(PPh3)2] (59)
PhMe/MeCN (3:1), 80 oC
PhMe/MeCN (3:1), 6 d, 80 oC
Conversions  100%
Conversions  100%
Conversions  81-96%
Conversion  19%
B2pin2                                          
3 mol % [RhCl(CO)(PPh3)2] (59)
2 equiv. B2pin2                                                 
5 mol % [RhCl(CO)(PPh3)2] (59)
PhMe/MeCN (3:1), 80 oC
MeO
MeO
Bpin
Bpin
Conversion 93%
1,1-VBBE
 
 
Equation 1.41 Rhodium-catalysed dehydrogenative borylations of olefins by Marder and coworkers. 
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The relative reactivity of B2neop2 vs. B2pin2 was found to vary somewhat with substrate, 
but it appears that 1 equivalent of the former diboron compound is required to effect 
complete conversions as only one of the two boron moieties can be readily incorporated. 
This is presumably due to the instability of HBneop formed under the reaction conditions. 
Using 2 equivalents of B2pin2, and increasing the catalyst loading from 3 to 5 mol % with 
4-vinylanisole as substrate, led to the formation of the 1,1-vinyl bis(boronate ester) (1,1-
VBBE), i.e., the replacement of both geminal hydrogen atoms on the =CH2 group with 
boronate moieties in a single catalytic reaction (up to 93% selectivity for VBBE 
formation). The range of substrates was expanded from the vinyl arenes and 
1,1-disubstituted olefins previously studied to include 1-octene and indene. The reaction 
of 1-octene was rapid, but led to mixtures of the VBBE and VBE in a 2:1 ratio with the 
VBBE product consisting of several isomers, presumably resulting from double bond 
isomerization. Of the VBBEs formed, the major component is the 1,1-VBBE isomer 
(66%), indicating that both geminal olefin hydrogens were replaced. In contrast, the 
borylation of indene with B2pin2 led to selective formation of the VBE, with borylation 
occurring at the 2-position, but was slow giving only 19% conversion after 6 days at 80 
oC. The slow reaction of indene was attributed to an unfavorable β-hydride elimination 
step due to the difficulty of achieving coplanarity of the Rh and β-hydride moieties, 
although it is possible that this substrate is borylated via a different mechanism from 
other olefins. No reaction was observed with 2-methyl-2-butene or 3,4,4-trimethyl-2-
pentene, suggesting that the system is not effective for dehydrogenative borylation of 
1,1,2-trisubstituted olefins. 
 
The reactions could also be conducted at 150 
o
C in sealed tubes in a microwave reactor 
giving, in general, fairly similar product distributions to those obtained by conventional 
heating at 80 
o
C, but with much shorter reaction periods (minutes vs. days). For 1,1-
disubstituted styrenes, conversions were improved when the amount of B2pin2 was 
increased from 0.67 equivalents to 1.0 or 2.0 equivalents. In general, the rate 
enhancements observed in the microwave reactions were consistent with that expected 
from the higher temperature employed, and thus do not appear to reflect any special 
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microwave enhancement, although catalyst lifetimes were somewhat reduced at the 
higher temperatures. 
 
The origin of the selectivity for VBE formation over diboration/hydroboration and the 
origins of the beneficial role of MeCN solvent in achieving the highest selectivities 
remain unclear. Certainly, the system promotes rapid -hydride elimination following 
olefin insertion into a Rh-B bond, which must be faster than competing processes that 
would result in saturated products.  
 
The observed selectivity for the formation of (E)-vinyl boronate products was proposed 
to result from diastereoselective β-hydride elimination from a rhodium β-borylalkyl 
intermediate. For -methylstyrene, highly selective borylation of the C-H bond cis to the 
Me group gives rise to a 1,1-disubstituted product that cannot be prepared by alkyne 
hydroboration. Following a syn addition of Rh and boryl groups to the olefin, either of 
the 2 diastereotopic β-hydrogens may be transferred to Rh. As β-hydride elimination 
requires a syn disposition of rhodium and hydride moieties, rotation around the C-C bond 
is required. Elimination from the least hindered rotamer (as illustrated for the 
α-methylstyrene case in Figure 1.31) would therefore lead to the observed (E)-product. 
The direction of the insertion of the styrenic substrates into the Rh-B bond generates the 
more hindered insertion product, placing the large groups  to the metal center. This is 
presumably a direct consequence of the nucleophilicity of the boryl ligands,
243
 which 
prefer to attack the terminal carbon of the styrenes during the olefin insertion step. 
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Rh Me
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insertion
(E)-productleast hindered
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Figure 1.31 Conformation leading to the formation of (E)-VBE product. 
 
Westcott and coworkers reported dehydrogenative borylations of a range of vinylarenes 
in the presence of bulky rhodium diimine complexes as catalysts.
244
 The reactions of 
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HBcat, B2cat2 and HBpin with vinylarenes catalysed by 60, 61 and 62 (Figure 85) gave 
complex mixtures of products, but reactions with B2pin2 gave predominantly trans-VBE 
products. The borylation of 4-fluorostyrene with B2pin2 and an unspecified catalytic 
amount of 61 in toluene at 80 
o
C gave a 98% yield of the VBE product along with trace 
hydrogenation products. 
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Figure 1.32 Bulky rhodium diimine catalysts for dehydrogenative borylation of olefins by Westcott and 
coworkers 
  
Miyaura and coworkers reported the borylation of vinyl C-H bonds in cyclic vinyl ethers 
by B2pin2 catalysed by [Ir(OMe)COD]2 and dtbpy (Table 1.8).
245
 This catalyst has been 
used widely for the borylation of aromatic C-H bonds, vide supra. Borylation of 1,4-
dioxene with 0.5 equivalents of B2pin2 at room temperature in hexane gave the VBE 
product in 81% yield. Borylations of dihydropyran and dihydrofuran gave regioisomeric 
mixtures of α-, and β-borylated products in ratios of 75:25 and 49:51, respectively. The 
introduction of substituents at the γ-position in dihydropyrans increased the 
regioselectivity, with borylation occurring solely at the α-position. Borylation of 
dihydrofurans was less selective; even γ,γ-disubstituted substrates gave products resulting 
from both α-, and β-borylation. In addition, the borylation of 1H-isochromene occurred 
solely α to oxygen, even in the presence of unhindered aromatic C-H bonds.  
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Table 1.8 Iridium-catalysed dehydrogenative borylation of cyclic vinyl ethers. 
Bpin
O
Bpin
O
Bpin
O
Bpin
O
Bpin
O
Bpin
O
p -C6H4Cl
p -C6H4Cl
Bu
Bu
Bpin
O
Bpin
O
Bpin
O
Bpin
O
Bpin
O
+ +
+
+
Product GC yield / % Product GC yield / %
64 (75:25)
61
65
81
75 (49:51)
71 (86:14)
73 (95:5)
All reactions were carried out at 80 oC for 8 h using B2pin2 (1.0 mmol), substrate (3.0 mmol), [Ir(OMe)COD]2
(0.015 mmol), dtbpy (0.03 mmol) in octane in a sealed tube. GC yields based on boron moieties in B2pin2.
O
R2
R1
O
R1R2
R3
O
R2
R1
O
R1R2
R3
Bpin
Bpin
B2pin2
1.5 mol % [Ir(OMe)COD]2
3 mol % dtbpy
octane, 80 oC
B2pin2
1.5 mol % [Ir(OMe)COD]2
3 mol % dtbpy
octane, 80 oC
 
Suginome and coworkers have reported a platinum-catalysed dehydrogenative borylation 
of 1,2-disubstituted olefins tethered to silylboronate groups to give (E)-VBEs, in which 
Si-B and olefinic C-H bonds are transformed into Si-H and C-B bonds, respectively 
(Equation 1.42).
246
 Silylboronates were synthesised from their corresponding alcohols
247
 
by reaction with ClPh2SiBpin, and were stirred in toluene at 80–100 
o
C in the presence of 
5 mol % Pt(dba)3 and 11 mol % PAr3, to give the VBE products in moderate to high 
yields, with no products arising from intramolecular alkene silylboration
248
 observed. A 
mechanism was proposed in which oxidative addition of the Si-B bond to the Pt
0 
center 
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would give a Pt
II 
(boryl)(silyl) species. Subsequent intramolecular 1,2-insertion of the 
olefin into the Pt-B bond, followed by β-hydride elimination would give the VBE product 
and a platinum hydride which could reductively eliminate Si-H to regenerate the Pt
0 
species. 
 
O R3
Si
R1
R2
Ph
Ph Bpin
n
O R3
Si
R1
R2
Ph
Ph H
n
Bpin
5 mol % Pt(dba)2
11 mol % PAr3
toluene
80-110 oC
n = 1,2 PAr3 = PPh3, P(4-C6H4CF3)3 
 
Equation 1.42 Dehydrogenative borylation of 1,2-disubstituted alkenes by Suginome and coworkers. 
 
1.3.8.6 Boryl transfer reactions and β-boryl elimination  
 
Pietraszuk and coworkers reported a boryl transfer reaction between two olefins using 
[Ru(H)(Cl)(PCy3)2(CO)], 63, as the catalyst and vinyl-ethyleneglycolato-boronate, 
(vinyl-Beg) or vinyl-trimethyleneglycolato-boronate, as sources of a boryl group.
249
 A 
range of styrenic and vinyl ether substrates were borylated in moderate to high yields, 
with reactions performed at 80 
o
C in benzene using a 5:1 ratio of olefin to vinylboronate 
to limit background reactions. A mechanism was proposed (Scheme 1.17) in which 63 
dissociates PCy3 to give the active species [Ru(H)(Cl)(PCy3)(CO)], 64. Migratory 
insertion of vinylboronate into the Ru-H bond of 64, would give the β-borylalkyl species 
65 which may undergo β-boryl elimination to give [Ru{B(OR)2}(Cl)(PCy3)(CO)], 66. 
Insertion of olefin into the Ru-B bond would give 67 which, followed by β-hydride 
elimination, would yield the VBE product and regenerate 64. The insertion of vinyl-Bcat 
into the Ru-H bond of 63 and subsequent extrusion of ethene to give 
[Ru(Bcat)(Cl)(PCy3)2(CO)] was demonstrated in stoichiometric experiments, as was the 
reaction of  [Ru(Bcat)(Cl)(PCy3)2(CO)] and styrene to give VBE and 63. The possibility 
of an olefin cross-metathesis pathway was eliminated via deuterium labeling studies. 
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Scheme 1.17 Ruthenium-catalysed transfer borylation of vinylarenes by Pietraszuk and coworkers. 
 
The mechanism of the above process was also examined via DFT calculations.
250
 
The energetics of the reversibility of the boryl ligand migration (olefin insertion into a 
metal-boryl bond) was explored, and the -boryl elimination process was calculated to 
have a low barrier. It was concluded that the “empty” p orbital on boron of the boryl 
ligand was not important in either the boryl migration or -boryl elimination processes, 
but that the high nucleophilicity of the Ru-boryl -bond promotes the boryl migration. 
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Synthesis of retinoids via sequential catalytic C-H 
borylations and Suzuki-Miyaura cross-couplings 
 
2.1 Introduction 
 
 
Retinoids are a group of more than 4000 natural and synthetic molecules that are 
structurally and/or functionally analogous to all-trans-retinoic acid (ATRA, 1) (Figure 
2.1), the major active metabolite of vitamin A. Endogenous retinoids regulate a range of 
essential processes during chordate embryogenesis and adult homeostasis, including 
embryonic development,
251 
vision,
252
 and cellular differentiation, proliferation and 
apoptosis.
253
 
 
 
CO2H CO2H
CO2H
CO2H
9cRA (2)
3-Me-TTNPB (4)
ATRA (1)
TTNPB (3)  
 
Figure 2.1 Natural and synthetic retinoids. 
 
Retinoids are successfully used to treat dermatological conditions
254 
and have the 
potential to act as chemopreventative and chemotherapeutic agents.
255,256 
However, for 
many retinoids, administration at efficacious concentrations is associated with side 
effects ranging from skin irritation to toxicity and teratogenicity.
257
 The pleiotropic 
(multiple) effects of retinoids are mediated via the retinoid nuclear receptors (RARs and 
RXRs).
258,259
 ATRA binds strongly with all three isotypes of RAR (,  and ) but has no 
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affinity for the RXRs, whereas 9-cis-retinoic acid (9cRA, 2), another physiological 
retinoid, binds and transactivates both the RARs and RXRs.
260
 
 
A common approach to designing new retinoids is to modify the structure of ATRA, for 
example, by replacing the tetraene chain with one or more aromatic rings in order to 
constrain the geometric conformation. These compounds are often referred to as 
arotinoids. One of the first retinoids of this type to be prepared was 4-(E)-[2-(5,6,7,8-
tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]-benzoic acid (TTNPB, 3) 
(Scheme 2.1),
261,262
 a highly teratogenic pan-RAR agonist which is cytotoxic and a strong 
inducer of apoptosis, with a potency 500 times greater than that of ATRA. TTNPB 3 was 
initially prepared from 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-ethan-1-
one, via a reduction-bromination-phosphorylation-Wittig sequence to derive the methyl-
diphenyl tri-substituted alkene. The Wittig reaction gave a mixture of Z-, and E-isomers, 
the E-isomer being separated by crystallization, and subsequent hydrolysis of the ethyl 
ester gave 3. 
 
CO2Et
O
OH Br
PPh3Br
HCO
CO2Et
LiAlH4
Et2O
PBr3, pyridine
hexane
TTNPB (3)
NaOEt, DMF
PPh3
xylene
 
Scheme 2.1 Synthesis of TTNPB by Loeliger and coworkers. 
 
The replacement of a proton in the 3-position in 3 by a methyl group generates 
4-(E)-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propenyl]-benzoic 
acid, (3-Me-TTNPB, 4),
262
 (Figure 2.1). RAR- and RAR- isotypes are activated by 4, 
as is RXR-. The RAR binding affinity of 4, and consequently its toxicity, is decreased 
by 100-fold compared to 3. The differences in the observed receptor selectivities between 
3 and 4 result from unfavorable steric interactions between the C-3 methyl substituent 
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and the vinylic proton in 4, which are not present in 3. This causes a conformational 
change that alters the dihedral angle about the arene-olefin bond, giving 4 a twisted 
conformation that interacts more favorably with the RXRs and less favorably with the 
RARs. 
 
Heteroarotinoid analogues of TTNPB 3 and 3-Me TTNPB 4 are also known with 
5-oxo,
263
 5-thia
263,264
 and 5,8-disila-TTNPB
265 
(accessed by a [2+2+2]-cobalt-mediated 
phenyl ring construction, Scheme 2.2)
266 
previously synthesised as well as analogues 
bearing heterocycles such as thiophene,
267
 thiazole,
268
 imidazole,
268
 isoxazole
269 
and 
pyridine
267
 in place of the phenyl ring in the benzoic acid polar terminus. 
 
R = H, Me
1. DMSO, Cl(O)CC(O)Cl
2. NEt3
CO2Et
Si
Si
O
Si
Si
disila-TTNPBs
R
P
CO2EtO
EtO
EtO
1. NaH, DMSO
2. NaOEt (R = H)
R
Si
Si
OH
Si
Si
OTMS
+
CpCo(CO)2, m -xylene
1. CpCo(CO)2, m-xylene
2. MeOH (AcOH)
Si
Si
O
+
R = H, Me  
 
Scheme 2.2  Synthesis of disila-TTNPBs by Tacke and coworkers. 
 
A rapid synthesis of TTNPB 3 and its analogues from simple hydrocarbon starting 
materials via a sequence of C-H borylations and subsequent Suzuki-Miyaura 
cross-couplings was envisaged (Scheme 2.3). Iridium-catalysed aromatic C-H borylation 
of tetrahydronapthalenes would give arylboronate esters which would be cross coupled 
with 2-bromopropene to give the desired α-methylstyrenes. Rhodium-catalysed 
dehydrogenative alkene borylation would yield (E)-vinylboronate esters that could 
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undergo Suzuki-Miyaura cross-coupling with iodobenzoic acids to give the desired 
products. 
R
CO2H
1. Aromatic C-H borylation
2. Suzuki-Miyaura cross-coupling
3. Vinylic C-H borylation
4. Suzuki-Miyaura cross-coupling
R
H
Br
H
CO2H
I
+ +
 
 
Scheme 2.3 Retrosynthetic analysis for the synthesis of TTNPBs via a combination of C-H borylations and 
Suzuki-Miyaura cross-couplings. 
 
Iridium-catalysed aromatic C-H borylation has attracted much attention since its original 
development due to the atom efficiency that results from the direct functionalisation of 
C-H bonds and the high levels of largely sterically induced selectivity observed, which 
complement traditional methods such as EAS (electrophilic aromatic substitution)
270
 and 
DoM (directed ortho metalation)
271
 chemistry. However, despite its inherent advantages 
and the large amount of methodological work published, its application in synthesis is 
extremely limited, with examples being the works of Hartwig,
272
 Moore,
273
 Gaunt,
274
  and 
Odom.
275
  
 
2.2 Results and discussion 
 
Borylation of 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 5 was performed in 
hexane with 1 equivalent of B2pin2 and [Ir(OMe)COD]2/dtbpy (3 mol % Ir) as catalyst 
precursors. The reaction was monitored by in situ GC-MS analysis, with heating for 18 
hours at 80 
o
C required to give full conversion to 6,
276
 (95% isolated yield) with 100% 
regioselectivity for borylation of the least hindered aromatic C-H bonds (Equation 2.1).  
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B
O
O
6
H
1 equiv. B2pin2
0.5[Ir(OMe)COD]2/dtbpy (3 mol %)
hexane, 80 oC, 18 h, 95%
5  
 
Equation 2.1 Synthesis of 6 by Ir-catalysed aromatic C-H borylation of 5. 
 
4 .0 0 6 .0 0 8 .0 0 1 0 .0 0 1 2 .0 0 1 4 . 0 0 1 6 .0 0 1 8 . 0 0 2 0 . 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 0 0 0 0 0 0
   1 e + 0 7
 1 .1 e + 0 7
 1 .2 e + 0 7
 1 .3 e + 0 7
 1 .4 e + 0 7
 1 .5 e + 0 7
 1 .6 e + 0 7
 1 .7 e + 0 7
T im e -->
A b u n d a n c e
T IC :  jh b 3 8 1 b . D
 
Figure 2.2 GC (TIC) of the synthesis of 6 after 4 h. 
4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
4 0 0 0 0 0
4 5 0 0 0 0
5 0 0 0 0 0
5 5 0 0 0 0
6 0 0 0 0 0
m / z -->
A b u n d a n c e
S c a n  9 4 8  (7 . 9 9 7  m in ):  jh b 3 8 1 b . D
2 9 9
1 5 7 3 1 4
1 0 1 1 9 9
1 2 95 7 8 3 1 7 11 4 3 2 1 51 8 5
1 1 5 2 4 1 2 5 72 7 1 3 5 92 8 5
 
Figure 2.3 MS of 6. 
 
 
The Suzuki-Miyaura coupling of 6 with 2-bromopropene was carried out with 3 mol % 
Pd(dppf)Cl2 and 2 equivalents of Ba(OH)2·8H2O base to give the α-methylstyrene 
product 7 in high yields.
277
 Reactions were heated thermally at 80 
o
C in a 5:1 mixture of 
DMF/H2O. In addition, 7 could be synthesised from 1,1,4,4-tetramethyl-1,2,3,4-
tetrahydronaphthalene in a one-pot C-H , single solvent
278
 borylation/Suzuki-Miyaura 
B2pin2
BpinOBpin
B
O
O
6
5
B
O
O
6
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reaction process in which both reactions were performed in MTBE, with thermal heating 
at 80 
o
C (Equation 2.2). 
 
a 1 eq B2pin2, 0.5[Ir(OMe)COD]2/dtbpy (3%), MTBE, 80 
oC, 18 h  
b 2-bromopropene, 3% Pd(dppf)Cl2, Ba(OH)2
.8H2O, H2O, 80 
oC, 2 h
B
O
O
6 7  93%
H a b
B
O
O
6 7 91%
2-bromopropene
3 mol % Pd(dppf)Cl2, Ba(OH)2
.8H2O
DMF/H2O, 80 
oC, 2 h
5
 
 
Equation 2.2 Synthesis of 7. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 0 0 0 0 0 0
   1 e + 0 7
 1 . 1 e + 0 7
 1 . 2 e + 0 7
 1 . 3 e + 0 7
 1 . 4 e + 0 7
 1 . 5 e + 0 7
 1 . 6 e + 0 7
 1 . 7 e + 0 7
 1 . 8 e + 0 7
T im e -->
A b u n d a n c e
T I C :  jh b 3 8 6 b 2 . D
 
Figure 2.4 GC (TIC) of the reaction of 6 and 2 bromopropene after 2 h. 
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4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0 3 8 0 4 0 0
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
2 2 0 0 0 0
2 4 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  6 1 4  ( 6 . 0 8 9  m i n ) :  j h b 3 8 6 b 2 . D
2 1 3
2 2 8
1 7 1
1 4 3
1 2 8
5 7
9 17 3
1 9 8 2 8 11 0 6 2 4 4 4 0 2
 
Figure 2.5 MS of 7. 
 
Synthesis of pentamethylated tetrahydronaphthalene 9
262c
 was achieved via 
AlCl3-catalysed Friedel-Crafts dialkylation of toluene with 2,3-dichloro-2,3-dimethyl-
butane, 8,
279
 which was synthesised from 2,3-dimethyl-butane-2,3-diol via chlorination in 
neat HCl (Equation 2.3). The use of high purity toluene was found to be necessary as 
reactions carried out with GPR (general purpose reagent) grade toluene led to a 
competing reaction between toluene and traces of ortho-xylene which were clearly 
present. Clearly the activating effect of the additional methyl group in ortho-xylene is 
significant, with even small quantities of xylene reacting preferentially over toluene. 
Similarly, attempts to synthesise 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene via 
AlCl3 catalysed Friedel-Crafts dialkylation of benzene with 2,3-dichloro-2,3-dimethyl-
butane resulted in the formation of the doubly reacted product even when reactions were 
carried out in neat benzene. 
 
OH
OH
Cl
Clconc. HCl
rt, 18 h, 87%
1.3 mol % AlCl3
2 equiv. PhMe
DCM, rt, 30 min then
65 oC, 15 min, 87%
8 9  
 
Equation 2.3 Synthesis of pentamethylated tetrahydronaphthalene 9. 
 
Borylations of 1,4-disubstituted benzenes typically give low conversions due to steric 
hindrance, with the exceptions being fluoro-, or cyano-substituted substrates.
280
 
7
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Borylation of 9, in which all aromatic C-H bonds are adjacent to methyl or bulky 
CMe2CH2R substituents, proceeded slowly with 10% iridium loadings and prolonged 
reaction times giving only 45% conversion. In contrast to the reaction of 1,1,4,4-
tetramethyl-1,2,3,4-tetrahydronaphthalene, two isomeric borylation products were 
observed by GC-MS in an 85:15 ratio, resulting from competing borylation of the two 
least hindered C-H bonds (Equation 2.4).  
 
9
H
H
Borylation ortho to C(CH3)2R - disfavoured
Borylation ortho to CH3 - favoured
B
H
O
O
H
B
OO
1 equiv B2pin2
0.5[Ir(OMe)COD]2/dtbpy (10 mol %)
hexane, 80 oC +
10a 10b
 
Equation 2.4 Attempted Ir-catalysed aromatic C-H borylation of 9. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
T im e -->
A b u n d a n c e
T I C :  jh b 9 4 h . D
 
Figure 2.6 GC (TIC) of the attempted synthesis of 10a by aromatic C-H borylation of 9 with B2pin2. 
 
B O
O
B2pin2
10b
9
10a
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4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
2 2 0 0 0 0
2 4 0 0 0 0
2 6 0 0 0 0
2 8 0 0 0 0
3 0 0 0 0 0
T im e - - >
A b u n d a n c e
I o n  3 2 8 . 0 0  ( 3 2 7 . 7 0  t o  3 2 8 . 7 0 ) :  jh b 9 4 h . D
 
Figure 2.7 Ion chromatogram (m/z = 328) of the attempted synthesis of 10a by aromatic C-H borylation of 
9 with B2pin2. 
 
6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
8 0 0 0 0 0
1 0 0 0 0 0 0
1 2 0 0 0 0 0
1 4 0 0 0 0 0
1 6 0 0 0 0 0
1 8 0 0 0 0 0
2 0 0 0 0 0 0
2 2 0 0 0 0 0
m / z -->
A b u n d a n c e
S c a n  1 0 1 3  (8 .3 6 9  m in ):  jh b 9 4 h .D
3 1 3
3 2 8
1 7 1
2 1 31 0 1 1 8 51 4 3 1 5 78 3 1 2 8 2 2 95 7 1 1 5 1 9 9 2 5 5 2 7 16 9 2 9 72 4 1 2 8 4
 
Figure 2.8 MS of 10a. 
 
In light of the poor selectivity and low reactivity exhibited in the Ir-catalysed C-H 
borylation of 9, alternative routes to the methylated analogue of 2 were sought. 
Friedel-Crafts acylation of 9 with acetylchoride and AlCl3 gave ketone 11
281
 The 
combination of 3 ortho/para directing groups on benzene in a 1,2,5 substitution pattern 
favoured acetylation para to the strongest activating group C(Me)2R and ortho to the 
methyl substituent with a regioselectivity of >99% observed by GC-MS. Ketone 11 was 
purified by Kugelrohr distillation to give pure product in high yields. Wittig 
methylenation of 11 with PPh3CH3I and potassium tert-butoxide in THF gave olefin 12 
which was purified by Kugelrohr distillation. 
B O
O
10b
10a
B O
O
10a
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9 11
O
12
1 equiv. AcCl 
2 equiv. AlCl3
DCM, 60 oC, 18 h, 86%
1.5 equiv. [PPh3CH3]I
1.5 equiv. KOt-Bu
THF, rt,  3 d, 84%
 
 
Equation 2.5 Synthesis of 12 via Friedel-Crafts acetylation and Wittig methylenation. 
 
3 . 0 0 4 . 0 0 5 . 0 0 6 . 0 0 7 . 0 0 8 . 0 0 9 . 0 0 1 0 . 0 0 1 1 . 0 0 1 2 . 0 0 1 3 . 0 0 1 4 . 0 0 1 5 . 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 0 0 0 0 0 0
   1 e + 0 7
T im e - ->
A b u n d a n c e
T I C :  jh b  p m n  k e t  2 0 0 9  2 . D
 
Figure 2.9 GC (TIC) of the acetylation of 9 with acetyl chloride to give 11 after 18 h. 
5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
m / z -->
A b u n d a n c e
S c a n  8 6 6  (7 .5 2 9  m in ):  jh b  p m n  k e t  2 0 0 9  2 .D
2 2 9
1 8 71 4 5
1 1 5
9 15 7 4 5 93 6 7 5 1 02 8 2 3 9 13 0 8 4 2 9 5 3 33 4 42 6 0 4 8 7
 
Figure 2.10 MS of 11. 
 
Monoclinic single crystals (P21/c) of compound 11 grew from liquid 11 upon standing. 
The C(O)Me group is inclined by 24.6° to the arene plane. The C(15) and O atoms are 
tilted out of this plane by 0.14 Å and 0.63 Å, while the methyl atom C(17) is displaced to 
the opposite side by −0.02 Å (Figure 2.11).  
O
11
O
11
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Figure 2.11 The molecular structure of ketone 11. Thermal ellipsoids are drawn at 50% probability. 
 
4 .0 0 6 .0 0 8 .0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
T im e -->
A b u n d a n c e
T I C :  jh b 1 5 6 a . D
 
Figure 2.12 GC (TIC) of the reaction of 11 with PPh3CH3I to give 12 after 48 h 
5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0 2 1 0 2 2 0 2 3 0 2 4 0 2 5 0
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
8 0 0 0 0 0
1 0 0 0 0 0 0
1 2 0 0 0 0 0
1 4 0 0 0 0 0
1 6 0 0 0 0 0
m / z - ->
A b u n d a n c e
S c a n  6 2 1  (6 . 1 2 9  m in ) :  jh b 1 5 6 a . D
2 2 7
2 4 2
1 7 11 5 7 1 8 5
1 4 3
1 2 8
1 1 55 7 9 1 1 9 81 0 57 7 2 1 16 7
 
Figure 2.13 MS of 12. 
OPPh3
12
O
11
12
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Monoclinic single crystals (P21/c) of olefin 12 were obtained by the slow evaporation of 
a diethyl ether/hexafluorobenzene solution. In 12 the olefinic moiety forms a dihedral 
angle of 80° with the benzene ring, due to steric interactions with the C(18) ortho-methyl 
group on the arene ring (Figure 2.14).  
 
Figure 2.14 The molecular structure of olefin 12. Thermal ellipsoids are drawn at 50% probability. 
 
Alternatively, olefin 12 could be synthesised via a borylation/Suzuki-Miyaura cross-
coupling route, analogous to the synthesis of 7. Due to the poor results obtained in the 
direct borylation of 9 alternative routes to the ortho-methylated boronate ester 10a were 
sought. Iodination of 9 with I2/HIO4 in AcOH/H2O/H2SO4 gave iodide 13. Although 
substoichiometric amounts of I2 were employed, in situ GC-MS analysis showed that full 
consumption of 9 occurred, with 13 being the sole species observed (Equation 2.6).  
 
I
0.2 equiv.  HIO4, 0.4 equiv. I2
1 equiv. H2SO4, AcOH, H2O
18 h, 70 oC, 64%
9 13  
 
Equation 2.6 Iodination of 9 with HIO4/I2 to give 13. 
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2 . 0 0 4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0 2 2 . 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 0 0 0 0 0 0
   1 e + 0 7
T im e -->
A b u n d a n c e
T I C :  J H B 1 6 0 B . D
 
Figure 2.15 GC (TIC) for the iodination of 9 with I2/HIO4 to give 13 after 18 h. 
 
2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
8 0 0 0 0 0
1 0 0 0 0 0 0
1 2 0 0 0 0 0
1 4 0 0 0 0 0
1 6 0 0 0 0 0
1 8 0 0 0 0 0
2 0 0 0 0 0 0
2 2 0 0 0 0 0
2 4 0 0 0 0 0
2 6 0 0 0 0 0
2 8 0 0 0 0 0
3 0 0 0 0 0 0
3 2 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 7 5 8  ( 1 1 . 8 7 6  m i n ) :  J H B 1 6 0 B . D
3 1 3
3 2 8
1 7 1
1 4 4
1 8 6
1 2 8
2 7 1
5 7
7 7
4 1 1 0 5 2 9 72 3 12 0 1 2 5 51 5 3 6 2
 
Figure 2.16 MS of 13. 
 
Miyaura borylation
282
 of 13 with B2pin2 and KOAc in the presence of 5 mol % 
Pd(dppf)Cl2 required heating at 80 
o
C for a full week in DMF for the reaction to be 
complete. The use of DMSO as solvent reduced the reaction time to 4 days under the 
same conditions. Gratifyingly, exchanging B2neop2 for B2pin2 gave a marked 
improvement, with reactions in both DMF and DMSO giving full conversion after 18 
hours of heating (Equation 2.7). Similar results have been reported in the literature, with 
Wang and coworkers suggesting that the lesser steric demand of B2neop2, compared to 
B2pin2, led to the increase in reactivity, although a detailed explanation was not given.
283, 
284
 Although a variety of approaches have been taken to the Pd-catalysed borylation of 
reluctant substrates,
285 
the use of B2neop2 as a more active borylating agent has not been 
widely explored.  
I
13
I
13
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I
a  0.2 equiv. HIO4, 0.4 equiv. I2, 1 equiv. H2SO4, AcOH, H2O, 70 
oC, 18 h, 64%
b  1 equiv. B2pin2, 5 mol % Pd(dppf)Cl2, 2 equiv. KOAc, DMSO, 80 
oC, 4 d, 60%
c  1 equiv. B2neop2, 5 mol % Pd(dppf)Cl2, 2 equiv. KOAc, DMSO, 80 
oC, 18 h, 67%
B
O
O
B
O
O
10a
14
a
b
c139
 
 
Equation 2.7 Palladium-catalysed borylations of 13 with B2pin2 and B2neop2. 
 
3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00
2000000
4000000
6000000
8000000
   1e+07
 1.2e+07
 1.4e+07
 1.6e+07
 1.8e+07
   2e+07
 2.2e+07
 2.4e+07
 2.6e+07
 2.8e+07
T ime-->
Abundanc e
T IC: jhb162d.D
 
Figure 2.17 GC (TIC) of the borylation of 13 with B2pin2 to give 10a after 96 h. 
 
5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 4 0 0 4 5 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 0 3 0  ( 8 . 4 6 6  m in ) :  jh b 1 6 2 d . D
3 1 3
1 7 1 2 1 3
1 0 1 1 4 3
2 5 55 7 7 7 2 8 4 4 2 11 2 1 1 9 4 3 7 92 3 5 3 5 93 3 2 4 0 1 4 8 4
 
Figure 2.18 MS of 10a. 
I
13
B O
O
10a
B O
O
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4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
9 0 0 0 0 0 0
9 5 0 0 0 0 0
T im e - ->
A b u n d a n c e
T I C :  jh b 1 9 5  2 a . D
 
Figure 2.19 GC (TIC) of the borylation of 13 with B2neop2  to give 14 after 18 h. 
 
6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
2 2 0 0 0 0
2 4 0 0 0 0
2 6 0 0 0 0
2 8 0 0 0 0
3 0 0 0 0 0
3 2 0 0 0 0
3 4 0 0 0 0
3 6 0 0 0 0
3 8 0 0 0 0
4 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 2 1 7  ( 9 . 5 3 5  m i n ) :  j h b 1 9 5  2 a . D
2 9 9
3 1 4
1 7 1 2 5 71 4 3 1 5 7 1 8 5
6 9 1 2 8
2 1 3 2 4 35 7 1 1 5 1 9 9 2 2 9 2 8 32 6 99 1 1 0 3
 
Figure 2.20 MS of 14. 
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Monoclinic single crystals (Pc) of 10a were grown from a MeOH / DCM solution at -20 
o
C (Figure 2.21). 
 
Figure 2.21 The molecular structure of 10a showing the non-disordered molecule of 10a in the asymmetric 
unit. The disordered molecule of 10a is not shown for clarity. Thermal ellipsoids are drawn at 50% 
probability. 
 
For 10a, the asymmetric unit comprises of two molecules, one of which has the alkyl ring 
and its methyl substituents disordered between two conformations with occupancies 
0.626(4) and 0.374(4) (Figure 2.22). The methyl C(21) and the B atom deviate slightly 
from the arene plane in opposite directions, by 0.03 and −0.03 Å in the disordered 
molecule, and by 0.05 and −0.01 Å in the ordered molecule. The angles between the 
arene and C(6)BO2 planes are 2.5° and 6.7°, respectively. (Figure 2.22).  
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Figure 2.22 (a) The molecular structure of 10a with two independent molecules in the asymmetric unit, 
showing the disorder of one of the two molecules of 10a, (b) disorder in alkyl ring of one of the molecules 
of 10a. All hydrogen atoms, the C(21) methyl group and the Bpin group are removed for clarity. Thermal 
ellipsoids are drawn at 50% probability. 
 
Figure 2.23 The molecular structure of 14. Thermal ellipsoids are drawn at 50% probability. 
ba
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Tetragonal crystals (I41/a) of compound 14 (the neopentaneglycolate analogue of 10a) 
were grown from a MeOH solution at -20 
o
C (Figure 2.23).  
  
In comparison to 10a,  the molecular structure is more strained for 14, where the arene 
ring undergoes a small but significant twist of 4.7° between the C(6)−C(7) and 
C(9)−C(10) bonds. The boron and methyl C(20) atoms are displaced from the mean plane 
of the ring in opposite directions, by 0.13 and −0.14 Å, i.e. substantially more than in 
10a. Even so, the intramolecular non-bonding contact O(1)...C(20) of 2.863(2) Å in 10 is 
shorter than the corresponding contacts in 10a, O(1)...C(21) 2.923(2) and O(1')...C(21') 
2.942(2) Å. The angle between the arene and C(6)BO2 planes is 8.6°, and the 6-
membered boryl ring adopts an envelope conformation with the C(16) atom out-of-plane 
by 0.67 Å (Figure 2.13). Thermal ellipsoids are drawn at 50% probability. 
 
Due to its more rapid synthesis, in comparison to compound 10a, compound 14 was 
utilized as the coupling partner in the Suzuki-Miyaura cross coupling to give 12. The 
reaction with 2-bromopropene, in the presence of 5 mol % Pd(dppf)Cl2 catalyst and 2 
equivalents of Ba(OH)2·8H2O base was carried out in a 5:1 mixture of DMF/H2O at 80 
o
C 
to give 12  in a high yield (Equation 2.8). 
 
B
O
O
14
DMF/H2O, 80 
oC, 18 h, 81%
12
2-bromopropene
5 mol % Pd(dppf)Cl2
2 equiv. Ba(OH)2
.8H2O
 
 
Equation 2.8 Synthesis of 12 via Suzuki-Miyaura cross-coupling of 14 with 2-bromopropene. 
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4 .0 0 6 .0 0 8 .0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
5 0 0 0 0 0 0
   1 e + 0 7
 1 . 5 e + 0 7
   2 e + 0 7
 2 . 5 e + 0 7
   3 e + 0 7
 3 . 5 e + 0 7
   4 e + 0 7
 4 . 5 e + 0 7
   5 e + 0 7
 5 . 5 e + 0 7
   6 e + 0 7
 6 . 5 e + 0 7
T im e -->
A b u n d a n c e
T I C :  jh b 2 4 9 b . D
 
Figure 2.24 GC (TIC) of the reaction of 14 with 2-bromopropene to give 12 after 18 h. 
 
Although compound 6 could be synthesised via Pd-catalysed borylation,
26
 direct C-H 
borylation is a more efficient route. However, for reasons not yet understood, Ir-catalysed 
aromatic C-H borylation is currently not effective with B2neop2, making this attractive 
route to the Bneop analogue of 6 unavailable. Iodination of 5 with I2/HIO4, under the 
same conditions utilized for the synthesis of 13, gave iodide 15.
286
 Although 
substoichiometric amounts of I2 were employed, in situ GC-MS analysis showed that full 
consumption of 5 had occurred after 4 hours, with 15 being the sole species. The 
borylation of iodide 15 with B2neop2 was performed with 1 mol % Pd(dppf)Cl2 catalyst 
and 2 equivalents of KOAc base in anhydrous DMSO and resulted in the full conversion, 
after 18 hours at 80 
o
C, of iodide 15 to the boronate ester 16 (Equation 2.8). 
 
B
O
O
16
DMSO, 80 oC, 18 h, 75%
15
I B2neop2, 1 mol % Pd(dppf)Cl2
2 equiv. KOAc
I
0.2 equiv. HIO4, 0.4 equiv. I2
1 equiv. H2SO4, AcOH, H2O
4 h, 70 oC, 71%
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Equation 2.9 Synthesis of 16 via iodination of 5 and subsequent Miyaura borylation with B2neop2. 
 
9
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3 . 0 0 4 . 0 0 5 . 0 0 6 . 0 0 7 . 0 0 8 . 0 0 9 . 0 0 1 0 . 0 0 1 1 . 0 0 1 2 . 0 0 1 3 . 0 0 1 4 . 0 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
T im e - ->
A b u n d a n c e
T I C :  jh b  T M N I  2 0 0 9  3 b . D
 
Figure 2.25 GC (TIC) of the iodination of 5 with I2/HIO4 to give 15 after 4 h 
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Figure 2.26 MS of 15. 
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Figure 2.27 GC (TIC) of the borylation of 15 with B2neop2 to give 16 after 18 h. 
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Figure 2.28 MS of 16. 
 
Orthorhombic single crystals (Pbca) of 16 were grown form a concentrated MeOH 
solution at -20 
o
C (Figure 2.29).  
 
 
Figure 2.29 The molecular structure of 16. Thermal ellipsoids are drawn at 50% probability. 
 
The six-membered boryl ring adopts an envelope conformation with the dimethylated 
atom C(16) is tilted by 0.68 Å from the mean plane of the remaining five atoms, which is 
inclined to the benzene ring plane by only 2.2° (Figure 2.29). Interestingly, the 
differences in relative rates of formation of 10a and 14 were not observed in their 
subsequent Suzuki-Miyaura cross-couplings with 2-bromopropene to give the product 12. 
Thus, reactions of 10a and 14 at both 80 and 40 
o
C
 
gave similar results, as did analogous 
16
B
O
O
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reactions of the non-ortho-methylated aryl boronate esters 6 and 16. In an attempt to 
ascertain whether the nature of the base affected the relative activities of Ar-Bpin and Ar-
Bneop substrates in Suzuki-Miyaura cross-couplings, aryl boronates 6 and 16 were 
coupled to 2-bromopropene in the presence of 2 mol % Pd(dppf)Cl2 with a range of bases 
at room temperature in a 5:1 mixture of DMF/H2O to give the product 7 (Table 2.1). The 
reactions were examined by in situ GC-MS after 1 hour (i.e. at partial conversion).  
 
Table 2.1 Effects of base on Suzuki-Miyaura cross-couplings of 6 and 16 with 
2-bromopropene to give 7 
B(OR)2
6 / 16 7
2-bromopropene
2 mol % Pd(dppf)Cl2, 2 equiv. base
DMF/H2O, rt, 1 h
 
Base With 6 (Bpin) 
Protodeborylation / 6 / 7 
With 16 (Bneop) 
Protodeborylation / 16 / 7 
Ba(OH)2 3 / 48 / 49 6 / 63 / 31 
K3PO4 9 / 39 / 52 8 / 51 / 41 
K2CO3 20 / 58 / 19 20 / 54 / 26 
KOAc 47 / 52 / 1 31 / 67 / 2 
Results for the Suzuki-Miyaura cross-coupling of aryl boronates 6 and 16 with 2-bromopropene in the 
presence of 2 mol % Pd(dppf)Cl2 after 1 h at 20 
o
C. Product ratios were determined by GC-MS. 
  
 
It is proposed that under the mild conditions required to prevent unwanted 
Suzuki-Miyaura cross-coupling in the borylation of 13 with B2pin2 or B2neop2, the use of 
the more Lewis acidic B2neop2 leads to more favorable coordination of the weakly basic 
Pd(II)(dppf)Ar(OAc) intermediate and thus more facile transmetallation. Under the 
Suzuki-Miyaura conditions used for the biaryl coupling, with strong bases such as 
hydroxide and phosphate, transmetallation is rapid, leading to the negligible differences 
observed in the reactivities of the aryl and vinyl boronates. It was also noted that for the 
strong bases KOH and K3PO4, the Suzuki-Miyaura reaction of 6 is marginally faster than 
that of 16, whereas for K2CO3 the reverse is observed. Thus, it may be suggested that, 
under mild conditions, B2neop2 and neopentaneglycolate boronate esters may be more 
effective coupling partners than B2pin2 and pinacolboronate esters, though this effect is 
nullified by the use of more forcing conditions. In addition, it must be noted that although 
in Suzuki-Miyaura cross-couplings with 2-bromopropene, the Bneop aryl boronate ester 
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16 is a marginally poorer coupling partner, full conversion of 16 to 7 (and of Bneop ester 
14 to 12) can be achieved after heating at 80 
o
C for 1 h in the presence of 2 mol % 
Pd(dppf)Cl2 and 2 equivalents of Ba(OH)2·8H2O. This, in conjunction with the more 
rapid synthesis of the Bneop ester 14 from 13, makes the use of Bneop aryl boronate 
esters attractive intermediates for Pd-catalysed borylation/Suzuki-Miyaura reaction 
sequences. 
 
As noted above, dehydrogenative borylation of 1,1-disubstituted alkenes, using 
trans-[Rh(PPh3)2(CO)Cl] as catalyst precursor, offers an attractive method for the 
synthesis of 1,1-disubstituted vinylboronate esters (VBEs) which cannot be accessed via 
alkyne hydroboration, and yields air and moisture stable products (in contrast to Zr-
catalysed carboalumination of alkynes
287
) which may be coupled with organic halides to 
give trisubstituted alkenes in high yields and stereoselectivities.
288
 In contrast, Heck-
Mizoroki reactions of α-methylstyrenes are characterised by low conversions and poor 
selectivities arising from β-hydride elimination pathways giving vinylic and allylic 
products.
289
 
 
Alkenes 7 and 12 underwent dehydrogenative borylation with either B2pin2 or B2neop2 in 
the presence of trans-[Rh(PPh3)(Cl)CO] at 80 
o
C , with a 3:1 mixture of toluene and 
MeCN being the optimal solvent system. E-vinyl boronate products were obtained with 
high stereoselectivities, with no sacrificial hydrogenation of the substrate alkene observed 
(Equation 2.10). Borylations of 12 were noticeably slower than those of 7 and did not 
proceed past 70% conversion, although the precise origin of this effect is not known. It is 
possible that either increased steric hindrance or partial loss of conjugation between the 
alkene and arene π-systems, vide infra, are responsible. In addition, no improvement in 
reaction rate was observed for borylations carried out with B2neop2.  
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B
O
O
a  1 equiv B2neop2, 5 mol % [Rh(PPh3)2(CO)Cl], 3:1 PhMe/MeCN, 80 
oC
b  1 equiv B2pin2, 5 mol % [Rh(PPh3)2(CO)Cl], 3:1 PhMe/MeCN, 80 
oC
B
R
RR
O
O
7     R = H
12   R = Me
a b
19, R = H, 3 d, 57%
20, R = Me, 7 d, 49%
17, R = H, 3 d, 50% 
18, R = Me, 7 d, 63%
H
 
 
Equation 2.10 Dehydrogenative borylations of 7 and 12 to give 17, 18, 19 and 20. 
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1 5 0 0 0 0 0
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2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
T im e - - >
A b u n d a n c e
T I C :  jh b 9 0 b . D
 
Figure 2.30 GC (TIC) of the dehydrogenative borylation of 7 with B2pin2 to give 17 after 48 h. 
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Figure 2.31 MS of 17. 
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3 . 0 0 4 . 0 0 5 . 0 0 6 . 0 0 7 . 0 0 8 . 0 0 9 . 0 0 1 0 . 0 0 1 1 . 0 0 1 2 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
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T i m e - - >
A b u n d a n c e
T I C :  j h b 1 5 7  5 b 2 . D
 
Figure 2.32 GC (TIC) of the dehydrogenative borylation of 12 with B2pin2 to give 18 after 72 h. 
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Figure 2.33 MS of 18. 
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Figure 2.34 GC (TIC) of the dehydrogenative borylation of 7 with B2neop2 to give 19 after 48 h. 
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Figure 2.35 MS of 19. 
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Figure 2.36 GC (TIC) of the dehydrogenative borylation of 12 with B2neop2 to give 20 after 72 h. 
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Figure 2.37 MS of 20. 
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The Suzuki-Miyaura cross-coupling of vinyl boronate ester 17 directly with 
4-iodobenzoic acid led to TTNPB 3. However, analysis of the reaction mixture and 
subsequent purification of the product was extremely troublesome, making this route 
inefficient. Despite these drawbacks, monoclinic single crystals (P21/c) of TTNPB (the 
acid form of 21) were grown via slow evaporation of a CDCl3 solution of TTNPB 
derived from the coupling described above. TTNPB crystallised as doubly hydrogen 
bonded dimers with its inversion equivalent. The carboxylic C-O bond distances C(24)-
O(1) 1.278(4) and C(24)-O(2) 1.257(4) Å are nearly symmetrical, suggesting a double-
minimum hydrogen bond O(1)...O(2'), in agreement with the electron density distribution 
along this vector. Two hydrogen atom positions, H(01) and H(02), were included in the 
final refinement with occupancies of 0.6 and 0.4, respectively. The planes of the arene 
ring (i), olefinic moiety (ii), the benzene ring (iii) and the carboxylic group (iv) were 
found to form dihedral angles: i/ii 41.2, ii/iii 31.9, i/iii 73.3 and iii/iv 3.9° (Figure 2.38). 
 
Figure 2.38 Molecular structure of TTNPB. Shown as one half of its doubly hydrogen bonded dimer. 
Thermal ellipsoids are drawn at 50% probability. 
 
In contrast to the cross-couplings with iodobenzoic acids, the use of 3-, and 
4-iodobenzoic acid methyl esters as coupling partners, allowed for easy analysis and 
purification of products 21, 22, 23 and 24 in high yields (Equation 2.11). 
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O
O
21, R = H, Ar = 4-C6H4CO2Me, 84%; 22, R = H, Ar = 3-C6H4CO2Me, 75%;
23, R = Me, Ar = 4-C6H4CO2Me, 86%; 24, R = Me, Ar = 3-C6H4CO2Me, 86%
R
B
R
O
O ArI, 5 mol % Pd(dppf)Cl2
2 equiv. K3PO4
5:1 DMF/H2O, 80 
oC, 2 d
 
 
Equation 2.11 Suzuki-Miyaura reactions of 17 and 18 with aryl iodides to give 21, 22, 23 and 24. 
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Figure 2.39 GC (TIC) of the Suzuki-Miyaura reaction of 17 and 4-C6H4-CO2Me to give 21 after 48 h. 
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Figure 2.40 MS of 21. 
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Figure 2.41 GC (TIC) of the Suzuki-Miyaura reaction of 17 and 3-C6H4-CO2Me to give 22 after 48 h. 
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Figure 2.42 MS of 22. 
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Figure 2.43 GC (TIC) of the Suzuki-Miyaura reaction of 18 and 4-C6H4-CO2Me to give 23 after 48 h. 
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Figure 2.44 MS of 23. 
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Figure 2.45 GC (TIC) of the Suzuki-Miyaura reaction of 18 and 3-C6H4-CO2Me to give 25 after 48 h. 
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Figure 2.46 MS of 24. 
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Monoclinic single crystals (P21/c) of TTNPB methyl esters 22 were grown via slow 
evaporation from a hexane solution.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.47 Molecular structures of compound 22 in conformations A and B (a and b, respectively). 
Superimposition of both conformations of compound 22 (c). Thermal ellipsoids are drawn at 50% 
probability for all figures. 
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For 22, the crystal is disordered with equal probability between two conformations (A and 
B) with the exceptions being the C(4), C(8), C(9), C(10), C(11), C(12) atoms (with their 
attached hydrogens) and the benzoate methyl ester moiety which are ordered. The 
dihedral angles between the planes of the arene ring (i), olefinic moiety (ii), the benzene 
ring (iii) and the carboxylate group (iv) were found to be i/ii 41.4, ii/iii 51.4, and i/iii 
88.2° for conformation A and 42.0, 42.2 and 83.8° for conformation B, respectively. The 
iii/iv angle equals 14.9° in both A and B.  
 
Monoclinic single crystals (P21/c) of compound 23 were grown via the slow evaporation 
of a MeOH solution.  
  
Figure 2.48 Molecular structure of compound 23. Thermal ellipsoids are drawn at 50% probability. 
 
For 23, the dihedral angles between the planes of the arene ring (i), olefinic moiety (ii), 
the benzene ring (iii) and the carboxylic group (iv) were found to be i/ii 56.1
o
, ii/iii 11.1, 
i/iii 45.0
o
 and iii/iv 5.5
o
.  
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2.2.2 Discussion of the relative solid and solution state structures of TTNPB 
esters and their vinylic precursors 
 
The effects of addition of a methyl group (or larger substituents) to the ortho position of 
TTNPB on the biological activity have been widely documented and may result from 
steric interactions between the 3-substituent and the vinylic proton which induces an 
increase in the dihedral angle between the aryl ring of the hydrophobic terminus and the 
alkene moiety, giving a bent a conformation similar to that of 9cRA.
 
 
Comparison of the molecular structures of 12, 17 and 23 with those of 18, 1 and 22 
shows that for ortho methylated species, the presence of the 3-substituent makes planar 
conformations unfavourable. In alkene 12, the olefinic moiety forms a dihedral angle of 
80° with the benzene ring, however crystallographic comparison with 7 was not possible 
as 7 is a liquid at both room temperature and -20 
o
C.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.49 Comparison of the molecular structures of 17 and 18, showing the increase in the dihedral 
angle between the arene and olefin planes caused by the ortho-methyl group in 18 over 17. Disorder of the 
Bpin group is removed for clarity in 17. Disorder of the C(15)C(16)C(17)C(18) alkyl group is removed for 
clarity in 18. Thermal ellipsoids are drawn at 50% probability. 
 
In vinylboronate ester 17, the olefinic fragment C(9)C(8)C(7)B(1) is planar within 
experimental error, and is inclined by 6.2° to the arene  plane. In the ortho-methylated 
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vinylboronate ester 18 the conformation is altered drastically. Due to steric crowding, the 
olefinic moiety is twisted by 3.4° around the double bond, while its mean plane is 
inclined by 60.3° to the arene plane (Figures 2.49)  
 
For TTNPB the dihedral angle between the planes of the benzene ring of the hydrophobic 
unit and the olefinic moiety is 41.2
o
. For 23, the ester of the ortho-methylated analogue 
3-Me TTNPB, steric interactions between the ortho-methyl group and the olefinic moiety 
lead to an increased dihedral angle of 56.1
o
 (Figure 2.50). In the case of 22 direct 
crystallographic comparison with its ortho-methylated analogue 24 was not achieved, but 
the dihedral angle between the planes of the benzene ring of the hydrophobic unit i and 
the olefinic moiety ii was found to be either 41.4 or 42.0
o
 (for the two conformations of 
22 present in the unit cell), values similar to that of TTNPB.   
 
Figure 2.50 Comparison of TTNPB and 3-Me TTNPB methyl ester 23, showing the increase in the i/ii 
dihedral angle caused by the ortho-methyl group in 23. Thermal ellipsoids are drawn at 50% probability. 
 
Although comparisons of solid state structures are useful, information about the relative 
solution conformations of the methylated and non-methylated compounds detailed above 
is necessary as the solid state structures might be influenced by intermolecular 
interactions (i.e. packing effects). In this case, the use of UV-vis spectrometry is highly 
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beneficial. Comparisons of λmax values give information on the relative degrees of 
conjugation, and therefore twist, in compounds which differ only by the presence of an 
ortho-methyl group (Table 2.2). This is especially useful for pairs of compounds for 
which suitable single crystals could not be obtained for one or both members (i.e. 7 and 
12, where 7 is a liquid at room temperature and at -20 
o
C). 
 
Table 2.2 UV-vis spectrometry data of TTNPB esters and vinylic precursors 
Compound                λmax (nm) / CHCl3 ε (L mol-1 cm-1) / CHCl3 
7 246 10900 
 12 252 4540 
 17 270 18600 
 18 253 9500 
 19 268 10500 
 20 255 9100 
 21 309 29500 
 22 284 22800 
 23 288 17500 
 24 241, 268 24800, 16200 
 
Comparison of λmax values showed that for related pairs of vinylboronate esters and 
TTNPB methyl esters, the incorporation of an ortho-methyl group led to a blue shift in 
λmax of between 21 and 13 nm. For Bpin and Bneop vinylboronates 17, 18, and 19, 20, 
respectively, the nature of the boronate ester moiety did not greatly affect λmax. In 21, 22, 
23, and 24 conjugation extends throughout the stilbene moiety to the electron 
withdrawing ester group, with λmax values for para-retinoid esters 21 and 23 being red 
shifted by 25 and 20 nm compared with their meta-substituted analogues, 22 and 24, 
respectively. The addition of ortho-methyl groups led to blue shifts in the λmax values of 
21 and 16 nm for the para-, and meta-TTNPB esters, respectively. 
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2.3 Conclusions 
 
In conclusion, concise and stereoselective syntheses of the methyl esters of the highly 
active TTNPB series of synthetic retinoids has been achieved. The approach, based upon 
combinations of Ir-, and Rh-catalysed C-H borylations  of unactivated arenes and alkenes 
to give aryl-, and vinyl-boronate esters, and subsequent Suzuki-Miyaura cross-couplings 
gave the products in good yields, with excellent regio-, and stereoselectivities, 
exemplifying the synthetic utility of these transformations.  The effect of adding an 
ortho-methyl group, well documented in biological studies, has been studied both 
crystallographically and spectroscopically, and shown to induce an increase in dihedral 
angle between the arene and olefin planes, giving twisted conformations which may be 
proposed to be more like those adopted by the endogenous retinoid 9cRA than for 
ATRA, hence resulting in the increase in RXR selectivity often shown for ortho-
methylated retinoids.  
 
2.4 Experimental 
 
General Experimental  
 
All reactions were carried out under a dry nitrogen atmosphere using standard Schlenk 
techniques or in an Innovative Technology Inc. System 1 double-length glove box. 
Glassware was oven dried before transfer into the glove box. Hexane and THF were dried 
over sodium / benzophenone and acetonitrile was dried over CaH2 and all were distilled 
under nitrogen. The solvents 1,4-dioxane, DMF, MTBE, THF and DMSO and H2O were 
degassed by 3 freeze-pump-thaw-cycles. Toluene was dried and deoxygenated by 
passage through columns of activated alumina and BASF-R311 catalyst under Ar 
pressure using a locally modified version of the Innovative Technology Inc. SPS-400 
solvent purification system. The compound 1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-
naphthalene, 5, was purchased from Avocado Chemical Company or from Maybridge 
and was dried over CaH2 and distilled. [Ir(μ-Cl)(COE)2]2,
290 
[Ir(μ-OMe)COD]2,
291
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trans-[Rh(PPh3)2(CO)Cl]
292,293
 and the Wittig reagent [Ph3PMe]I
294
 were synthesised by 
literature procedures. B2pin2 was supplied as a gift by Frontier Scientific Inc., NetChem 
Inc. and AllyChem Co. Ltd. Hydrochloric acid was obtained from Fisher Scientific and 
all other compounds were obtained from Aldrich Chemical Company, tested for purity by 
GC-MS and used without further purification. NMR spectra were recorded at ambient 
temperature on Varian Inova 500 (
1
H, 
13
C{
1
H}, HSQC), Varian C500 (
1
H, 
13
C{
1
H}, 
HSQC, HMBC Bruker 400 Ultrashield (
1
H, 
13
C{
1
H},
11
B and 
11
B{
1
H}), Varian Unity 300 
(
11
B and 
11
B{
1
H}) and Bruker AC200 (
13
C{
1
H}) instruments. Proton and carbon spectra 
were referenced to external SiMe4 via residual protons in the deuterated solvents or 
solvent resonance respectively. 
11
B NMR spectra were referenced to external BF3∙OEt3. 
UV-vis and fluorescence measurements were recorded in CHCl3. UV-vis absorption 
spectra and extinction coefficients were obtained on a Hewlett-Packard 8453 diode array 
spectrophotometer using standard 1 cm quartz cells. Fluorescence spectra were recorded 
on a Horiba Jobin-Yvon Fluoromax-3 spectrophotometer. The spectra of dilute solutions 
with absorbance maxima of less than 0.1 were recorded using conventional 90 degree 
geometry. The emission spectra were fully corrected using the manufacturer‟s correction 
curves for the spectral response of emission optical components. Elemental analyses were 
conducted in the Department of Chemistry at Durham University using an Exeter 
Analytical Inc. CE-440 Elemental Analyser. GC-MS analyses were performed on a 
Hewlett-Packard 5890 Series II gas chromatograph equipped with a 5971 mass selective 
detector and a 7673 autosampler or on an Agilent 6890 Plus GC equipped with a 5973N 
MSD and an Anatune Focus robotic liquid handling system / autosampler. A fused silica 
capillary column (10 m or 12 m, cross-linked 5% phenylmethylsilicone) was used, and 
the oven temperature was ramped from 50 
o
C to 280 
o
C at a rate of 20 
o
C/min. UHP 
grade helium was used as the carrier gas. The screw-cap autosampler vials used were 
supplied by Thermoquest Inc. and were fitted with Teflon / silicone / Teflon septa and 0.2 
mL micro inserts. HRMS spectra were recorded in the Department of Chemistry at 
Durham University using a Thermo Finnigan LTQ FT Ultra Hybrid mass spectrometer. 
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B
O
O
6 
 
4,4,5,5-Tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
[1,3,2] -dioxaborolane (6).
276
 In a dry, N2 filled glove box, a solution of [Ir(OMe)COD]2 
(0.16 g, 0.24 mmol) and 4,4‟-di-tert-butyl-2,2‟-bipyridine (0.13 g, 0.48 mmol) in hexane 
(3 mL) was shaken vigorously and added to a solution of 1,1,4,4-tetramethyl-1,2,3,4-
tetrahydronaphthalene, 5, (3.0 g, 15.9 mmol) and B2pin2 (4.45 g, 17.5 mmol) in hexane 
(12 mL) in a thick walled glass tube fitted with a Young‟s tap. The mixture was heated at 
80 
o
C until GC-MS analysis showed the reaction to be complete (18 h). The reaction 
mixture was passed through a short silica gel column (hexane as eluent). The hexane was 
evaporated and the residue was recrystallised from MeOH giving 6 as a white powder 
(4.71 g, 95%); mp 115-117 
o
C; IR (KBr disc, cm
-1
) 2966, 2857, 1607, 1553, 1466, 1408, 
1358, 1314, 1294, 1267, 1210, 1144, 1117, 1099; UV-vis (CHCl3) λmax (ε) 243 nm (2730 
L mol
-1 
cm
-1
); λem (CHCl3) 298 nm; m/z (EI-MS) 314 (15%, M
+
), 299 (100%, M
+
 - Me); 
1
H NMR
 
(400.13 MHz, C6D6)  8.23 (1H, s), 8.01 (1H, d, J = 8.0 Hz), 7.26 (1H, d,  J = 
8.0 Hz), 1.52 (4H, s), 1.19 (6H, s), 1.15 (6H, s) 1.06 (12H, s); 
13
C{
1
H} NMR (100.13 
MHz, C6D6)  148.35, 144.22, 133.97, 132.70, 126.39, 88.55, 35.55, 35.40, 34.54, 34.40, 
31.94, 31.82, 24.95, the resonance of the carbon attached to boron was not observed; 
11
B{
1
H} NMR (128.37 MHz, C6D6)  31.30; elemental analysis calcd. (%) for 
C20H31BO2: C 76.44, H 9.94; found: C 76.15, H 9.93. 
 
 
7 
 
6-Isopropenyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (7).
277
 In a dry, N2 
filled glovebox, Pd(dppf)Cl2 (64 mg, 0.08 mmol), compound 6 (0.80 g, 2.6 mmol), 2-
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bromopropene (0.73 g, 3.3 mmol), and Ba(OH)2·8H2O (1.77 g, 5.2 mmol) were added to 
a thick walled glass tube fitted with a Young‟s tap along with degassed DMF (10 mL) 
and degassed H2O (2 mL). The mixture was heated at 80 
o
C until GC-MS analysis 
showed the reaction to be complete (2 h). Dilute HCl(aq.) (2 mL) was added and the 
mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with dilute 
HCl(aq.) (3 x 10 mL) then H2O (3 x 10 mL), dried over MgSO4 and concentrated in vacuo. 
Purification by silica gel chromatography, eluting with 40:60 DCM/hexane gave 7 as a 
clear oil (0.53 g, 91%); IR (KBr disc, cm
-1
) 2966, 2857, 1607, 1553, 1466, 1408, 1358, 
1314, 1294, 1267, 1210, 1144, 1117, 1099; UV-vis (CHCl3) λmax (ε) 246 nm (10900 L 
mol
-1 
cm
-1
); λem (CHCl3) 315 nm;  m/z (EI-MS) 228 (20%, M
+
), 213 (100%, M
+
 - Me); 
1
H NMR (400.13 MHz, CDCl3)   7.44 (1H, s), 7.27 (2H, s), 5.35 (1H, s), 5.04 (1H, s), 
2.16 (3H, s), 1.70 (4H, s), 1.32 (6H, s) 1.30 (6H, s); 
13
C{
1
H} NMR (100.61 MHz, CDCl3) 
 144.76, 144.44, 143.63, 138.57, 126.58, 123.74, 123.10, 111.69, 35.46, 35.32, 34.43, 
34.32, 32.11, 32.04, 22.27.  
 
One-pot synthesis of 7. In a dry, N2 filled glove box, a solution of [Ir(OMe)COD]2 (26 
mg, 0.04 mmol) and 4,4‟-di-tert-butyl-2,2‟-bipyridine (21 mg, 0.08 mmol) in MTBE (2 
mL) was shaken vigorously and added to a solution of 5 (0.50 g, 2.65 mmol) and B2pin2 
(0.675 g, 2.65 mmol) in MTBE (8 mL) in a thick walled glass tube fitted with a Young‟s 
tap. The mixture was heated at 80 
o
C until GC-MS analysis showed the reaction to be 
complete (18 h). After transfer of the reaction vessel to a glove box, degassed H2O (2 
mL) was added and the mixture was stirred for 5 minutes. Pd(dppf)Cl2 (64 mg, 0.079 
mmol), Ba(OH)2·8H2O (1.67 g, 5.30 mmol) and 2-bromopropene (0.42 g, 3.44 mmol) 
were added and the reaction mixture was heated at 80 
o
C until GC-MS analysis showed 
the reaction to be complete (2 h). Dilute HCl(aq.) (2 mL) was added and the mixture was 
extracted with DCM (3 x 10 mL). The organic phase was washed with dilute HCl(aq.) (3 x 
10 mL) then H2O (3 x 10 mL), dried over MgSO4 and concentrated in vacuo. Purification 
via silica gel chromatography, eluting with 40:60 DCM/hexane and removal of the 
solvent in vacuo gave 7 as a clear oil (0.56 g, 93%). All other analytical data are identical 
to those obtained when using the above methods.   
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Cl
Cl
  8 
 
2,5-Dichloro-2,5-dimethyl-hexane (8).
262c,279
 2,5-Dimethyl-hexane-2,5-diol (20.0 g, 137 
mmol) was added to a 1 L conical flask and 250 mL HCl conc. (37% v/v, d = 1.18) was 
added. The solution was stirred overnight, filtered and the filtrate was washed with H2O 
(2 x 100 mL) and then dissolved in Et2O (200 mL). The organic layer was dried over 
MgSO4, filtered and the solvent removed in vacuo to give a crude product. Purification 
via a short silica gel column (eluting with hexane) and removal of solvent in vacuo gave 
8 as white needles (21.8 g, 87%), mp 67-68 
o
C (lit.
262c
 mp 63-65 
o
C), m/z (EI-MS) 133 
(100% M
+
 - MeCl); 
1
H NMR (400.13 MHz, CDCl3) 1.95 (4H, s), 1.59 (12H, s), 
13
C{
1
H} NMR (100.61 MHz, CDCl3)  70.57, 41.45, 32.79; elemental analysis calcd. 
(%) for C8H16Cl2: C 52.47, H 8.81; found: C 52.55, H 8.97.  
 
 
  9 
 
1,1,4,4,6-Pentamethyl-1,2,3,4-tetrahydronaphthalene (9).
262c
 This compound was 
synthesised as previously described.
12c 
To a stirred solution of toluene (10.0 g, 110 mmol) 
and compound 8 (10.0 g, 54.5 mmol) in DCM (75 mL) under N2 was added anhydrous 
AlCl3 (0.10 g, 0.75 mmol). The mixture was stirred for 30 min then refluxed for 15 min 
and then quenched with 10 mL of 10% HCl(aq.). The mixture was extracted with hexane (2 
x 60 mL). The organic layers were combined, washed with H2O (2 x 100 mL), dried over 
MgSO4 and the solvent was removed in vacuo to give a brown/orange oil. Kugelrohr 
distillation (131 
o
C, 3.3 x 10
-2 
mbar) gave 9 as white crystals (9.43 g, 85%); mp 30-32 
o
C 
(lit.
262c
 31-32 
o
C); IR (KBr disc, cm
-1
) 2956, 2917, 2868, 1614, 1499, 1456, 1385, 1362, 
1274, 1188, 1106, 1068, 1047; UV-vis (CHCl3) λmax (ε) 289 nm (405 L mol
-1 
cm
-1); λem 
(CHCl3) 357 nm; m/z (EI-MS) 202 (10% M
+
), 187 (100% M
+
 - Me); 
1
H NMR (400.13 
182 
 
MHz, CDCl3)  7.25 (1H, d, J = 8.0 Hz), 7.14 (1H, s), 6.99 (1H, d, J
 
= 8.0 Hz), 2.33 (3H, 
s), 1.70 (4H, s), 1.30 (6H, s), 1.29 (6H, s); 
13
C{
1
H} NMR (100.61 MHz, CDCl3)  
144.88, 142.05, 134.95, 127.22, 126.76, 126.64, 35.48, 35.42, 34.35, 34.12, 32.15, 32.09, 
21.34; elemental analysis calcd. (%) for C15H22: C 89.04, H 10.96; found: C 89.02, H 
11.13. 
 
 
O
  11 
 
1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-ethanone (11).
280
 To a 
solution of acetyl chloride (0.7 mL, 9.9 mmol) and compound 9 (2.0 g, 9.9 mmol) in 
DCM (40 mL) was added anhydrous AlCl3 (2.63 g, 19.8 mmol) in 0.5 g aliquots. The 
mixture was refluxed under N2 for 15 min then stirred overnight at room temperature. 
20% HCl(aq.) (5 mL) was added and the mixture was extracted with hexane (2 x 30 mL). 
The organic layers were combined, washed with H2O (2 x 30 mL), dried over MgSO4 and 
the solvent was removed in vacuo to give a crude product. Purification by Kugelrohr 
distillation (170 
o
C, 9 x 10
-3
 mbar) yielded 11 as white crystals (1.94 g, 86%); mp 31-32 
o
C; IR (KBr disc, cm
-1
) 2958, 2923, 1673 (C=O), 1609, 1545, 1499, 1460, 1362, 1254, 
1117, 1086, 1037; UV-vis (CHCl3) λmax (ε) 296 nm (1570 L mol
-1 
cm
-1
); λem (CHCl3) 349 
nm; m/z (EI-MS) 244 (35%, M
+
), 229 (100%, M
+
 - Me); 
1
H NMR
 
(400.13 MHz, C6D6)  
7.58 (1H, s), 7.08 (1H, s), 2.61 (3H, s), 2.22 (3H, s), 1.55 (4H, s), 1.19 (6H, s), 1.17 (6H, 
s); 
13
C{
1
H} NMR (100.13 MHz, C6D6)  199.70, 148.53, 142.18, 136.02, 135.75, 130.28, 
127.13, 35.26, 35.24, 34.32, 33.93, 31.86, 31.58, 28.88, 21.68; elemental analysis calcd. 
(%) for C17H24O: C 83.55, H 9.90; found: C 83.73, H 10.03. 
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 12 
 
6-Isopropenyl-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene (12).
277
 To a 
flask containing a solution of compound 11 (4.0 g, 16.4 mmol) and [CH3PPh3]I (9.90 g, 
24.6 mmol) in THF (100 mL), under N2, was added KO(t-Bu) (2.75 g, 24.6 mmol). A 
rapid color change from white to dark orange was observed. The mixture was stirred until 
GC-MS analysis showed the reaction to be complete (3 d). The solution was filtered 
though celite with hexane as the eluent and the solvent was removed in vacuo. 
Purification by Kugelrohr distillation (100 
o
C, 1.5 x 10
-1
 mbar) yielded 12 as white 
crystals (3.30 g, 84%); mp 46-47 
o
C; IR (KBr disc, cm
-1
) 2956, 2912, 2857, 1637, 1497, 
1454, 1387, 1362, 1264, 1189, 1115, 1045; UV-vis (CHCl3) λmax (ε) 252 nm (4540 L 
mol
-1 
cm
-1
); λem (CHCl3) 328 nm; m/z (EI-MS) 242 (35%, M
+
), 227 (100%, M
+
 - Me); 
1
H 
NMR (400.13 MHz, C6D6)  7.37 (1H, s), 7.27 (1H, s), 5.25 (1H, d, J = 2.5 Hz), 5.04 
(1H, d, J = 2.5 Hz), 2.38 (3H, s), 2.06 (3H, s), 1.71 (4H, s), 1.38 (6H, s), 1.37 (6H, s); 
13
C{
1
H} NMR (100.13 MHz, C6D6)  146.67, 143.42, 142.17, 141.64, 131.66, 127.34 
126.08, 114.54, 35.63, 35.61, 34.01, 33.98, 32.05, 32.01, 24.56, 19.71; elemental analysis 
calcd. (%) for C18H26: C 89.19, H 10.81; found: C 89.30, H 10.86. 
 
Alternative synthesis of 12 by Suzuki-Miyaura cross-coupling.  
In a dry, N2 filled glovebox, Pd(dppf)Cl2 (0.15 g, 0.18 mmol), compound 14 (1.0 g, 3.7 
mmol), Ba(OH)2·8H2O (2.33 g, 7.4 mmol) and 2-bromopropene (0.49 mL, 5.5 mmol) 
were placed in a thick walled glass tube fitted with a Young‟s tap along with DMF (10 
mL) and H2O (2 mL). The mixture was heated at 80 
o
C for 18 h at which time GC-MS 
analysis showed the reaction to be complete. Dilute HCl(aq.) (2 mL) was added and the 
mixture was extracted with Et2O (3 x 10 mL); the organic phase was washed with dilute 
HCl(aq.) (3 x 10 mL), dried over MgSO4 and concentrated in vacuo. The mixture was 
passed through a short silica gel column (eluting with hexane) and the solvent was 
removed in vacuo to give a clear oil which solidified upon standing to give 12 as a white 
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solid (0.73 g, 81%). All other analytical data are identical to those obtained when using 
the above method.   
 
I
  13 
 
6-Iodo-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene (13). A solution of 
compound 9 (10.1 g, 50 mmol), iodine (5.1 g, 20 mmol) and HIO4 (2.30 g, 10 mmol) in 
glacial acetic acid (50 mL), H2O (10 mL) and 98% H2SO4 (1.5 mL) was heated at 70 
o
C 
for 24 h. The mixture was extracted into Et2O (200 mL), washed with H2O (200 mL) and 
aqueous Na2S2O3 solution (200 mL). The organic layer was dried over MgSO4 and the 
solvent was removed in vacuo. The crude product was passed through a short silica gel 
column (eluting with hexane) and the solvent was removed in vacuo to give a solid which 
was recrystallised from hot MeOH to give 13 as white crystals (10.45 g, 64%); mp 65-67 
o
C; IR (KBr disc, cm
-1
) 2956, 2917, 2868, 1478, 1385, 1361, 1298, 1264, 1190, 1111, 
1071; UV-vis (CHCl3) λmax (ε) 241 nm (6620 L mol
-1 
cm
-1
); λem (CHCl3) does not 
fluoresce; m/z (EI-MS) 328 (40%, M
+
), 315 (100%, M
+
 - Me); 
1
H NMR (499.80 MHz, 
CDCl3) δ 7.69 (1H, s), 7.15 (1H, s), 2.37 (3H, s), 1.65 (4H, s), 1.25 (12H, s); 
13
C{
1
H} 
NMR 125.67 MHz, CDCl3) δ 145.57, 145.17, 138.50, 137.34, 128.28, 98.56, 35.25 (two 
peaks), 34.38, 34.20, 32.11, 32.01, 27.99; elemental analysis calcd. for C15H21I: C 54.89, 
H 6.45, found: C 54.82, H 6.31.  
 
B
O
O
10a 
 
4,4,5,5-Tetramethyl-2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
[1,3,2]dioxaborolane (10a). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (0.124 g, 0.15 
mmol), compound 13 (1.0 g, 3.05 mmol), B2pin2 (0.77 g, 3.05 mmol) and KOAc (0.59 g, 
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6.1 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along with 
dry, degassed DMSO (8 mL). The mixture was heated at 80 
o
C until GC-MS analysis 
showed the reaction to be complete (4 d). The mixture was extracted with DCM (30 mL) 
and washed with dilute HCl(aq.) (30 mL) and H2O (30 mL). The organic layer was dried 
over MgSO4, filtered and the solvent removed in vacuo. The crude product was passed 
through a short silica gel column, eluting with hexane, and then 50:50 DCM/hexane. 
Removal of the solvent in vacuo gave a white powder which was recrystallised from hot 
MeOH to give pure 10a (0.60 g, 60%); mp 131-133 
o
C; IR (KBr disc, cm
-1
) 2963, 2917, 
2862, 1606, 1541, 1492, 1409, 1393, 1295, 1266, 1215, 1143, 1112, 1095; UV-vis 
(CHCl3) λmax (ε) 241 nm (8240 L mol
-1 
cm
-1
); λem (CHCl3) 304 nm;  m/z (EI-MS) 328 
(20%, M
+
), 313 (100%, M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ 7.73 (1H, s), 7.01 
(1H, s), 2.49 (3H, s) 1.67 (4H, s), 1.31 (6H, s), 1.30 (6H, s), 1.27 (12H, s); 
13
C{
1
H} NMR 
125.67 MHz, CDCl3) δ 147.91, 141.90, 141.27, 134.69, 128.09, 83.31, 35.48, 35.30, 
34.46, 33.99, 32.08, 31.88, 25.09, 22.25; the resonance for the carbon attached to boron 
was not observed; 
11
B{
1
H} NMR (128.37 MHz, C6D6)  31.28; elemental analysis calcd. 
for C21H33BO2; C 76.83, H 10.13, found: C 76.75, H 10.18. 
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5,5-Dimethyl-2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
[1,3,2]dioxaborinane (14). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (0.124 g, 0.15 
mmol), compound 13 (1.0 g, 3.05 mmol), B2neop2 (0.69 g, 3.05 mmol) and KOAc (0.59 
g, 6.1 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along 
with dry, degassed DMSO (8 mL). The mixture was heated at 80 
o
C for 18 h, at which 
time analysis by GC-MS showed the reaction to be complete. The mixture was extracted 
with DCM (30 mL) and washed with dilute HCl (30 mL) and H2O (30 mL). The organic 
layer was dried over MgSO4, filtered and the solvent was removed in vacuo. The crude 
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product was filtered through a SiO2 plug eluting with hexane and then 50:50 
DCM/hexane. Removal of the solvent in vacuo gave a white powder which was 
recrystallised from hot MeOH to give pure 14 (0.64 g, 67%); mp 115-117 
o
C; IR (KBr 
disc, cm
-1
) 2958, 2923, 2865, 1604, 1477, 1417, 1377, 1339, 1308, 1267, 1248, 1124; 
UV-vis (CHCl3) λmax (ε) 242 nm (9450 L mol
-1 
cm
-1
); λem (CHCl3) 305 nm;  m/z (EI-MS) 
314 (20%, M
+
), 299 (100%, M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ 7.71 (1H, s), 
7.07 (1H, s), 3.75 (4H, s) 2.47 (3H, s), 1.66 (4H, s) 1.29 (6H, s), 1.27 (6H, s), 1.02 (6H, 
s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 147.14, 141.22, 141.14, 133.76, 128.34, 72.51, 
35.65, 35.50, 34.47, 34.09, 32.23, 32.02, 31.96, 22.53, 22.27; the resonance for the 
carbon attached to boron was not observed; 
11
B{
1
H} NMR (128.37 MHz, C6D6) ; 
elemental analysis calcd. for C20H30BO2: C 76.44, H 10.18; found: C 76.17, H 10.00. 
 
 
I
15 
 
6-Iodo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (15).
286
 To a mixture of 
compound 5 (3.76 g, 20 mmol), iodine (2.04 g, 8.0 mmol) and HIO4 (0.92 g, 4.0 mmol) 
was added glacial acetic acid (20 mL), H2O  (4 mL) and concentrated H2SO4
 
(98%, 1 
mL). The reaction mixture was heated to 70 
o
C for 4 h. A precipitate formed upon 
cooling, which was collected by filtration, dissolved in hexane and passed through a short 
silica gel column (eluting with hexane). The hexane was evaporated and the residue was 
recrystallised from EtOH to give 15 as a white crystalline solid (4.45 g, 71%); mp 69-70 
o
C; IR (KBr disc, cm
-1
) 2961, 2924, 2856, 1577, 1478, 1457, 1384l 1363, 1295, 1264, 
1191, 1107, 1066, 1039; UV-vis (CHCl3) λmax (ε) 241 nm (4800 L mol
-1 
cm
-1
); the 
compound did not fluoresce; m/z (EI-MS) 314 (25%, M
+
), 299 (100%, M
+
 - Me);  
1
H 
NMR (200 MHz, CDCl3) 
(1H, d, J = 8.0 Hz), 1.66 (4H, s), 1.28 (6H, s), 1.26 (6H, s); 
13
C{
1
H} NMR (100 MHz, 
CDCl3) 
elemental analysis calcd for C14H19I: C, 53.52; H, 6.10. Found: C, 53.66; H, 6.13.  
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5,5-Dimethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
[1,3,2]dioxaborinane (16). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (26 mg, 0.032 
mmol), compound 15 (1.0 g, 3.18 mmol), B2neop2 (790 mg, 3.18 mmol) and KOAc (0.64 
g, 6.36 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along 
with dry, degassed DMSO (10 mL). The mixture was heated at 80 
o
C overnight, at which 
time analysis by GC-MS showed the reaction to be complete. The mixture was extracted 
with Et2O (30 mL) and washed with H2O (30 mL). The organic layer was dried over 
MgSO4, filtered and the solvent was removed in vacuo. The crude product was filtered 
through a SiO2 plug eluting with hexane, and then 50:50 DCM/hexane. Removal of the 
solvent in vacuo gave white powder which was recrystallised from hot MeOH to give 
pure 16 (0.71 g, 75%); mp 116-119 
o
C; IR (KBr disc, cm
-1
) 2961, 2932, 2888, 1605, 
1473, 1417, 1345, 1323, 1296, 1268, 1246, 1135, 1069; UV-vis (CHCl3) λmax (ε) 241 nm 
(8700 L mol
-1 
cm
-1
); λem (CHCl3) 297 nm; m/z (EI-MS) 300 (15%, M
+
), 285 (100%, M
+
 - 
Me); 
1
H NMR
 
(400.13 MHz, C6D6)  7.78 (1H, s), 7.57 (1H, dd, J = 8.0, 1.0 Hz), 7.31 
(1H, d, J = 8.0 Hz), 3.76 (4H, s), 1.69 (4H, s), 1.32 (6H, s), 1.30 (6H, s), 1.03 (6H, s); 
13
C{
1
H} NMR (100.13 MHz, C6D6) δ 147.69, 143.41, 132.41, 131.13, 125.93, 72.42, 
35.44, 35.25, 34.56, 34.30, 32.03, 32.02, 31.92, 22.09, the resonance of the carbon 
attached to boron was not observed; 
11
B{
1
H} NMR (128.37 MHz, C6D6)  26.67; 
elemental analysis calcd. (%) for C19H28BO2: C 76.01, H 9.74; found: C 75.88, H 9.51. 
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4,4,5,5-Tetramethyl-2-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
propenyl]-[1,3,2]-dioxaborolane (17). In a dry, N2 filled, glovebox, B2pin2 (0.33 g, 1.3 
mmol), compound 7 (0.30 g, 1.3 mmol), and trans-[Rh(PPh3)2(CO)Cl] (45 mg, 0.07 
mmol) were dissolved in 6 mL of 3:1 toluene/MeCN and added to a thick walled glass 
tube fitted with a Young‟s tap. The reaction was heated at 80 oC until GC-MS analysis 
showed the reaction to be complete (3 d). H2O (5 mL) was added, and the aqueous layer 
was washed with ethyl acetate (3 x 5 mL). The combined organic phases were dried over 
MgSO4 and concentrated in vacuo to give a dark green oil. Recrystallization from hot 
MeOH gave 17 as a white, fluffy powder (0.23 g, 50%); mp 125-127 
o
C; IR (KBr disc, 
cm
-1
) 2958, 2857, 1618, 1555, 1497, 1453, 1410, 1345, 1263, 1209, 1144, 1108, 1078; 
UV-vis (CHCl3) λmax (ε) 270 nm (18600 L mol
-1 
cm
-1
); λem (CHCl3) 344 nm; m/z (EI-MS) 
354 (30%, M
+
), 339 (100%, M
+
 - Me); 
1
H NMR (400.13 MHz, C6D6) 7.64 (1H, d, J = 
2.0 Hz), 7.31 (1H, dd, J = 8.5, 2.0 Hz), 7.10 (1H, d, J = 8.0 Hz), 6.28 (1H, s), 2.68 (3H, 
s), 1.55 (4H, s), 1.19 (6H, s), 1.17 (6H, s), 1.14 (12H, s); 
13
C{
1
H} NMR (100.13 MHz, 
C6D6) 159.03, 144.85, 144.63, 141.89, 126.72, 124.36, 123.83, 115.43, 82.77, 35.55, 
35.41, 34.39, 34.21, 31.92, 31.89, 24.99, 20.48; 
11
B{
1
H} NMR (128.37 MHz, C6D6) 
29.58; elemental analysis calcd. (%) for C23H35BO2: C 77.96, H 9.96; found: C 78.18, 
H 10.18. 
 
Alternative synthesis and purification of 17. In a dry, N2 filled, glove box, B2pin2 (89 
mg, 0.35
 
mmol), compound 7 (80 mg, 0.35
 
mmol) and trans-[Rh(PPh3)2(CO)Cl] (12 mg, 
17 x 10
-3 
mmol) were dissolved in 4 mL of 3:1 toluene/MeCN in a thick walled glass tube 
fitted with a Young‟s tap and then heated to 80 C. The reaction was monitored by GC-
MS. After 3 d, the solvent was removed in vacuo and the crude solid redissolved in a 
mixture of hexane/DCM (60:40), and then purified via silica gel chromatography 
(hexane/DCM, 60:40) to yield 17 as an analytically pure white powder (98 mg, 80%); 
elemental analysis calcd. for C23H35BO2: C 77.96, H 9.96; found: C 77.84, H 9.77. All 
other analytical data are identical to those obtained when using the above synthesis and 
purification. 
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4,4,5,5-Tetramethyl-2-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
propenyl]-[1,3,2]-dioxaborolane (18). In a dry, N2 filled glovebox, B2pin2 (0.31 g, 1.2 
mmol), compound 12 (0.30 g, 1.2 mmol), and trans-[Rh(PPh3)2(CO)Cl] (43 mg, 0.07 
mmol) were dissolved in 6 mL of 3:1 toluene/MeCN and added to a thick walled glass 
tube fitted with a Young‟s tap. The reaction was heated at 80 oC until GC-MS analysis 
showed no further progress (7 d). H2O (5 mL) was added, and the aqueous layer was 
washed with ethyl acetate (3 x 5 mL). The combined organic phases were dried over 
MgSO4 and concentrated in vacuo to give a dark green oil. Purification by silica gel 
chromatography, eluting with 1:1 DCM/hexane, and recrystallization from hot MeOH 
gave 18 as white needles (0.29 g, 63%); mp 69-71 
o
C; IR (KBr disc, cm
-1
) 2954, 2857, 
1633, 1498, 1435, 1389, 1318, 1287, 1273, 1226, 1213, 1189, 1163, 1146, 1111, 1077; 
UV-vis (CHCl3) λmax (ε) 253 nm (9500 L mol
-1 
cm
-1
); λem (CHCl3) 324 nm; m/z (EI-MS)  
368 (35%, M
+
), 353 (100%, M
+
 - Me); 
1
H NMR 399.96 MHz, CDCl3)  7.05 (1H, s), 
7.02 (1H, s), 5.26 (1H, s), 2.27 (3H, s), 2.24 (3H, s), 1.66 (4H, s), 1.32 (12H, s), 1.27 (6H, 
s), 1.24 (6H, s); 
13
C{
1
H} NMR 100.57 MHz, CDCl3)  161.71, 144.19, 143.44, 142.10, 
130.80, 128.17, 125.47, 83.04, 35.41, 35.39, 34.09, 34.08, 32.08, 32.06, 25.13, 23.31, 
20.01; the resonance for the carbon attached to boron was not observed; 
11
B{
1
H} NMR 
(128.37 MHz, C6D6)  29.70; elemental analysis calcd. (%) for C24H37BO2: C 78.25, H 
10.12; found: C 77.97, H 10.14. 
 
Alternative synthesis and purification of 18. In a dry, N2 filled glovebox, B2pin2 (201 
mg, 0.79 mmol), compound 12 (200 mg, 0.83
 
mmol) and trans-[Rh(PPh3)2(CO)Cl] (28.5 
mg, 41.3 x 10
-3 
mmol) were dissolved in 4 mL of 3:1 toluene/MeCN in a thick walled 
glass tube fitted with a Young‟s tap. The reaction was heated to 80 C and monitored by 
in situ GC-MS. After 3 d, the solvent was removed in vacuo and the resulting solid was 
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redissolved in 40:60 DCM/hexane and then purified via silica gel chromatography, 
eluting with 40:60 DCM/hexane, to yield 18 as an analytically pure white solid (151 mg, 
50%); elemental analysis calcd. (%) for C24H37BO2: C 78.25, H 10.12; found: C 78.12, H 
9.98. All other analytical data are identical to those obtained when using the above 
synthesis and purification. 
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5-Dimethyl-2-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-
[1,3,2]dioxaborinane (19). In a dry, N2 filled, glovebox, B2neop2 (0.50 g, 2.20 mmol), 
compound 7 (0.50 g, 2.20 mmol), and trans-[Rh(PPh3)2(CO)Cl] (70 mg, 0.1 mmol) were 
dissolved in 4 mL of 3:1 toluene/MeCN and added to a thick walled glass tube fitted with 
a Young‟s tap. The reaction was heated at 80 oC until GC-MS analysis showed the 
reaction to be complete (3 d). H2O (5 mL) was added, and the aqueous layer was washed 
with ethyl acetate (3 x 5 mL). The combined organic phases were dried over MgSO4 and 
concentrated in vacuo to give a dark green oil. Recrystallization from hot MeOH gave 19 
as a white, fluffy powder (0.40 g, 57%); mp 71-72 
o
C; IR (KBr disc, cm
-1
) 2960, 2922, 
2870, 1615, 1467, 1408, 1341, 1270, 1183; UV-vis (CHCl3) λmax (ε) 268 nm (10500 L 
mol
-1 
cm
-1
); the compound does not fluoresce; m/z (EI-MS) 340 (25%, M
+
), 325 (100%, 
M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ 7.45 (1H, s), 7.26 (2H, s), 5.65 (1H, s), 3.72 
(4H, s) 2.37 (3H, s), 1.69 (4H, s) 1.28 (6H, s), 1.27 (6H, s), 1.02 (6H, s); 
13
C{
1
H} NMR 
125.67 MHz, CDCl3) δ 156.17, 144.83, 144.74, 141.79, 126.53, 124.28, 123.48, 72.43, 
35.53, 35.37, 34.67, 34.45, 32.19, 32.14, 22.27, 19.81; the resonance for the carbon 
attached to boron was not observed; 
11
B{
1
H} NMR (128.37 MHz, C6D6) 26.85, 
elemental analysis calcd. (%) for C22H33BO2: C 77.62, H 9.77; found: C 77.39, H 9.88. 
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5,5-Dimethyl-2-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-
propenyl]-[1,3,2]dioxaborinane (20). In a dry, N2 filled glovebox, B2neop2 (0.47 g, 2.1 
mmol), compound 12 (0.50 g, 2.1 mmol), and trans-[Rh(PPh3)2(CO)Cl] (70 mg, 0.1 
mmol) were dissolved in 4 mL of 3:1 toluene/MeCN and added to a thick walled glass 
tube fitted with a Young‟s tap. The reaction was heated at 80 oC until GC-MS analysis 
showed no further progress (7 d). H2O (5 mL) was added, and the aqueous layer was 
washed with ethyl acetate (3 x 5 mL). The combined organic phases were dried over 
MgSO4 and concentrated in vacuo to give a dark green oil. Recrystallization from hot 
MeOH gave 20 as a white, fluffy powder (0.36 g, 49%); mp 67-69 
o
C; IR (KBr disc, 
cm
-1
) 2961, 2926, 1634, 1496, 179, 1335, 1276, 1187, 1085; UV-vis (CHCl3) λmax (ε) 255 
nm (9100 L mol
-1 
cm
-1
); λem (CHCl3) 368 nm;  m/z (EI-MS) 354 (25%, M
+
), 339 (100%, 
M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ 7.05 (1H, s), 7.03 (1H, s), 5.18 (1H, s), 3.70 
(4H, s), 2.25 (6H, s), 1.66 (4H, s) 1.28 (6H, s), 1.27 (6H, s), 1.02 (6H, s); 
13
C{
1
H} NMR 
125.67 MHz, CDCl3) δ 159.28, 144.85, 143.33, 142.19, 130.95, 128.22, 125.64, 72.39, 
35.57, 35.55, 34.23, 34.20, 32.22, 32.21, 22.88, 22.32, 20.09; the resonance for the 
carbon attached to boron was not observed; 
11
B{
1
H} NMR (128.37 MHz, C6D6) 26.81, 
elemental analysis calcd. (%) for C23H35BO2: C 77.96, H 9.96; found: C 77.88, H 9.85. 
 
 
O
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4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-benzoic acid 
methyl ester (21). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (33 mg, 0.04 mmol), 
compound 17 (0.40 g, 1.1 mmol), 4-iodobenzoic acid methyl ester (0.24 g, 0.9 mmol), 
K3PO4·2H20 (0.57 g, 2.3 mmol) and degassed DMF (15 mL) were added to a thick walled 
glass tube fitted with a Young‟s tap. The tube was attached to a Schlenk line and 
degassed H2O (3 mL) was added via cannula. The mixture was heated at 80 
o
C for 2 d, at 
which time GC-MS analysis showed complete consumption of the starting materials. 
Dilute HCl(aq.) (2 mL) was added and the mixture was extracted with DCM (3 x 10 mL). 
The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was passed through a short silica gel column eluting 
with hexane and then 10% DCM/hexane and the solvent was removed in vacuo. 
Recrystallization from hot EtOH gave 21 as a white fluffy powder (280 mg, 84%); mp 
137-139 
o
C; IR (KBr disc, cm
-1
) 2951, 2920, 2857, 1706 (C=O), 1600, 1560, 1492, 1438, 
1388, 1361, 1275, 1182, 1110, 1046, 1016; UV-vis (CHCl3) λmax (ε) 309 nm (29500 L 
mol
-1 
cm
-1
); λem (CHCl3) 388 nm; m/z (EI-MS) 362 (90%, M
+
), 347 (100%, M
+
 - Me); 
1
H 
NMR (499.80 MHz, CDCl3)  8.04 (2H, d, J = 8.5 Hz), 7.46 (1H, d, J = 2.0 Hz), 7.43 
(2H, d, J = 8.5 Hz), 7.32 (1H, s), 7.31 (1H, d, J = 2.0 Hz), 6.82 (1H, s), 3.94 (3H, s), 2.30 
(3H, s), 1.72 (4H, s), 1.34 (6H, s), 1.31 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3)  
167.28, 145.06, 144.76, 143.54, 140.82, 140.08, 129.68, 129.28, 127.96, 126.79, 126.27, 
124.31, 123.57, 52.28, 35.74, 35.22, 34.60, 34.37, 32.12, 32.03, 17.91; HRMS calc for 
C25H31O2 ([M + H]
+
) 363.23186, found 363.23180. 
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3-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-benzoic acid 
methyl ester (22). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (33 mg, 0.04 mmol), 
compound 17 (0.40 g, 1.1 mmol), 3-iodobenzoic acid methyl ester (0.24 g, 0.9 mmol), 
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K3PO4·2H20 (0.57 g, 2.3 mmol) and degassed DMF (15 mL) were added to a thick walled 
glass tube fitted with a Young‟s tap. The tube was attached to a Schlenk line and 
degassed H2O (3 mL) was added via cannula. The mixture was heated at 80 
o
C for 2 d, at 
which time GC-MS analysis showed complete consumption of the starting materials. 
Dilute HCl(aq.) (2 mL) was added and the mixture was extracted with DCM (3 x 10 mL). 
The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was passed through a short silica gel column eluting 
with hexane and then 10% DCM/hexane and the solvent removed in vacuo. 
Recrystallization from hot EtOH gave 22 as a white fluffy powder (0.25 g, 75%); mp 86-
88 
o
C; IR (KBr disc, cm
-1
) 2952, 2920, 2856, 1717 (C=O), 1581, 1492, 1440, 1359, 1306, 
1287, 1250, 1201, 1106, 1085; UV-vis (CHCl3) λmax (ε) 284 nm (22800 L mol
-1 
cm
-1
); λem 
(CHCl3) 386 nm; m/z (EI-MS) 362 (90%, M
+
), 347 (100%, M
+
 - Me); 
1
H NMR (499.80 
MHz, CDCl3)  8.05 (1H, s), 7.92 (1H, d, J = 7.5 Hz), 7.55 (1H, d, J = 7.5 Hz), 7.46 (1H, 
s), 7.44 (1H, t, J = 7.5 Hz), 7.32 (1H, s), 7.31 (1H, t, J = 7.5 Hz), 6.82 (1H, s) 3.95 (3H, 
s), 2.28 (3H, s) 1.72 (4H, s), 1.35 (6H, s), 1.32 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, 
CDCl3) δ 167.59, 145.14, 144.67, 140.99, 139.17, 133.92, 130.57, 130.39, 128.56, 
127.73, 126.88, 126.17, 124.39, 123.66, 52.52, 35.51, 35.36, 34.72, 34.49, 32.25, 32.17, 
17.82; HRMS calc for C50H60O4Na ([M2Na]
+
) 747.43838, found 747.44029. 
 
O
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4-[2-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-benzoic 
acid methyl ester (23). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (28 mg, 0.03 mmol), 
compound 18 (0.30 g, 0.82 mmol), 4-iodobenzoic acid methyl ester (0.18 g, 0.68 mmol), 
K3PO4·2H2O (0.42 g, 1.7 mmol) and degassed DMF (15 mL) were added to a thick 
walled glass tube fitted with a Young‟s tap. The tube was attached to a Schlenk line and 
degassed H2O (3 mL) was added via cannula. The mixture was heated at 80 
o
C for 2 d, at 
which time GC-MS analysis showed complete consumption of the starting materials. 
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Dilute HCl(aq.) (2 mL) was added and the mixture was extracted with DCM (3 x 10 mL). 
The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was passed through a short silica gel column eluting 
with hexane and then 10% DCM/hexane and the solvent was removed in vacuo. 
Recrystallization from hot EtOH gave 23 as a white fluffy powder (0.22 g, 86 %); mp 
137-139 
o
C; IR (KBr disc, cm
-1
) 2957, 2918, 2851, 1714 (C=O), 1605, 1562, 1492, 1437, 
1411, 1361, 1278, 1182, 1111, 1016; UV-vis (CHCl3) λmax (ε) 288 nm (17500 L mol
-1 
cm
-
1
); λem (CHCl3) 380 nm; m/z (EI-MS) 376 (90%, M
+
), 361 (100%, M
+
 - Me); 
1
H NMR 
(499.80 MHz, CDCl3)  δ 8.05 (2H, d, J = 8 Hz), 7.45 (2H, d, J = 8 Hz), 7.13 (1H, s), 7.12 
(1H, s), 6.42 (1H, s), 3.94 (3H, s), 3.31 (3H, s), 1.70 (4H, s), 1.31 (6H, s), 1.30 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 167.40, 143.98, 143.31, 143.00, 142.59, 142.19, 
131.87, 129.85, 129.18, 128.63, 128.53, 128.11, 126.26, 52.41, 35.54, 35.39, 34.30, 
34.39, 32.27, 32.21, 20.69, 20.06;  HRMS calc for C26H33O2 ([M + H]
+
) 377.24695, 
found 377.24685. 
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3-[2-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-benzoic 
acid methyl ester (24). In a dry, N2 filled glovebox, Pd(dppf)Cl2 (285 mg, 0.03 mmol), 
compound 18 (0.30 g, 0.82 mmol), 3-iodobenzoic acid methyl ester (0.18 g, 0.68 mmol), 
K3PO4·2H20 (0.42 g, 1.7 mmol) and degassed DMF (15 mL) were added to a thick walled 
glass tube fitted with a Young‟s tap. The tube was attached to a Schlenk line and 
degassed H2O (3 mL) was added via cannula. The mixture was heated at 80 
o
C for 2 d, at 
which time GC-MS analysis showed complete consumption of the starting materials. 
Dilute HCl(aq.) (2 mL) was added and the mixture was extracted with DCM (3 x 10 mL). 
The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was filtered through a short silica gel column eluting 
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with hexane and then 10% DCM/hexane and the solvent was removed in vacuo. 
Recrystallization from hot EtOH gave 24 as a white fluffy powder (0.22 g, 86%); mp 91-
92 
o
C; IR (KBr disc cm
-1
) 2952, 2919, 2858, 1722 (C=O), 1582, 1496, 1440, 1360, 1292, 
1254, 1198, 1108, 1086; UV-vis (CHCl3) λmax (ε) 241 nm (24800 L mol
-1 
cm
-1
); λem 
(CHCl3) 383 nm; m/z (EI-MS) 376 (90%, M
+
), 361 (100%, M
+
 - Me); 
1
H NMR (499.80 
MHz, CDCl3)  δ 8.06 (1H, s), 7.92 (1H, d, J = 7.5 Hz), 7.56 (1H, d, J = 7.5 Hz), 7.46 (1H, 
t, J 7.5 Hz), 7.13 (1H, s), 7.12 (1H, s), 6.42 (1H, s), 3.95 (3H, s), 2.32 (3H, s), 2.20 (3H, 
s), 1.70 (4H, s), 1.32 (6H,s), 1.31 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 167.60, 
143.85, 142.98, 142.55, 141.05, 138.86, 133.76, 131.95, 130.41, 130.29, 128.59, 128.48, 
128.36, 127.76, 126.35, 52.53, 35.55, 35.52, 34.28, 34.27 32.27, 32.22, 20.42, 20.08; 
HRMS calcd for C26H33O2 ([M + H]
+
) 377.24751, found 377.24852. 
 
General experimental for Suzuki-Miyaura cross-couplings of aryl boronic esters at 
40 
o
C. 
In a dry, N2 filled glovebox, aryl boronate (0.32 mmol), Pd(dppf)Cl2 (5.2 mg, 0.007 
mmol), and base (0.64 mmol) were added to a thick wall glass tube fitted with a Young‟s 
tap. Degassed DMF (5 mL) and degassed H2O (1 mL) were added along with 2-
bromopropene (0.043 mL, 0.42 mmol). The tube was sealed and heated at 40 
o
C and the 
reaction was monitored by GC-MS. 
 
General experimental for Suzuki-Miyaura cross-couplings of aryl boronic esters at 
room temperature.  
In a dry, N2 filled glovebox, aryl boronate (0.32 mmol), Pd(dppf)Cl2 (5.2 mg, 0.007 
mmol), and base (0.64 mmol) were added to a screw top vial. Degassed DMF (5 mL) and 
degassed H2O (1 mL) were added along with 2-bromopropene (0.043 mL, 0.42 mmol). 
The vial was stirred at room temperature inside the glovebox and the reaction was 
monitored by GC-MS. 
 
General experimental for Suzuki-Miyaura cross-couplings of vinyl boronic esters at 
40 
o
C. 
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In a dry, N2 filled glovebox, vinyl boronate (0.28 mmol), 3-iodobenzoic acid methyl ester 
(0.065g, 0.25 mmol) Pd(dppf)Cl2 (4.5 mg, 0.006 mmol), and base (0.56 mmol) were 
added to a thick wall glass tube fitted with a Young‟s tap. Degassed DMF (5 mL) and 
degassed H2O (1 mL) were added. The tube was sealed and heated at 40 
o
C and the 
reaction was monitored by GC-MS 
 
General experimental for Suzuki-Miyaura cross-couplings of vinyl boronic esters at 
room temperature.  
In a dry, N2 filled glovebox, vinyl boronate (0.28 mmol), 3-iodobenzoic acid methyl ester 
(0.065g, 0.25 mmol) Pd(dppf)Cl2 (4.5 mg, 0.006 mmol), and base (0.56 mmol) were 
added to a screw top vial. Degassed DMF (5 mL), and degassed H2O (1 mL) were added. 
The vial was stirred at room temperature inside the glovebox and the reaction was 
monitored by GC-MS. 
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Table 2.3 Photophysical data for all compounds in CHCl3 
Compound λmax (nm) ε (L mol-1 cm-1) λem (nm)  (λex = λmax (abs)) 
TMN-Bpin (6) 243 2730 298 
TMN-Bneop (16) 241 8700 297 
TMN-isopropene (7) 246 10900 328 
PMN-isopropene (12) 252 4540 315 
PMN (9) 289 405 357 
TMN-I (15) 241 4800 does not fluoresce 
PMN-I (13) 241 6620 does not fluoresce 
PMN ketone (11) 296 1570 349 
PMN-Bpin (10a) 241 8240 304 
PMN-Bneop (14) 242 9450 305 
TMN Bpin VBE (17) 270 18600 344 
PMN Bpin VBE (18) 253 9500 324 
TMN Bneop VBE (19) 268 10500 does not fluoresce 
PMN Bneop VBE (20) 255 9100 368 
TTNPB-Me ester (21) 309 29500 388 
m-TTNPB-Me ester (22) 284 22800 386 
3-Me-TTNPB-Me ester (23) 288 17500 380 
3-Me-m-TTNPB-Me ester (24) 241, 268 24800, 16200 383 (λex 241nm), 383 (λex 268 nm) 
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Synthesis of tolan-, and biaryl-based retinoids via 
palladium-catalysed cross-couplings 
 
3.1 Introduction 
 
All-trans retinoic acid (ATRA), and its two naturally occurring isomers, 9-cis-retinoic 
acid (9cRA) and 13-cis-retinoic acid (13cRA) (Figure 3.1), are involved in the mediation 
of many biological processes, in both embryonic development and in adult life, 
particularly in the nervous system.
295
 Endogenous retinoids are essential for the 
mediation of cell proliferation, differentiation and apoptosis, and maintain these 
processes in both normal and tumour cells both in vivo and in vitro. 
 
CO2H
CO2H
CO2H
ATRA 13cRA 9cRA
 
 
Figure 3.1 Natural retinoids. 
 
The polyene chains of natural retinoids are excellent chromophores, which efficiently 
absorb light in the region of 300-400 nm (depending on the solvent). This makes these 
molecules particularly susceptible to photoisomerisation, leading to degradation into a 
mixture of retinoic acid isomers.
296
 The isomerisation of ATRA plays an important part 
in its metabolic pathways within cells, giving rise to 9cRA and 13cRA which possess 
different mechanisms of action,
297,298
 with Murayama et al. reporting that the different 
retinoic acid isomers differentially affected the ability of mammalian stem cells to 
differentiate along alternative lineages.
296
 
 
In addition, cellular responses may be determined by the concentrations of the different 
retinoic acid isomers present in solution. For example, the induction of the differentiation 
of pluripotent stem cells using retinoids is variable, resulting in the differential activation 
of key molecular pathways involved in tissue development in a concentration dependent 
manner.
299
 In turn, this variation has the potential to result in mixed proportions of 
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alternative differentiating cell types leading to increased culture heterogeneity. To reduce 
such variability in differentiation responses and improve experimental reproducibility, it 
is essential that compounds used for the induction of cellular differentiation exist in the 
same form and concentration every time. For compounds such as ATRA and its 
stereoisomers, this cannot be currently guaranteed, due to the high degree of 
susceptibility of these compounds to undergo isomerisation under the conditions used for 
sample preparation, storage of stock solution and in cell culture. 
 
Due to the diverse effects of RA isomers on cells, attempts have been made to limit the 
isomerisation and degradation of ATRA. A number of additives have been found to 
inhibit either the cis–trans interconversion or oxidation of natural retinoids, including 
bovine serum albumin (BSA), fibrogen, lysozyme, phosphatidylcholine, 
N-ethylmaleimide and vitamin C.
300
 However, the addition of such molecules to cell 
culture media is often not viable as such additives may themselves affect cell behaviour. 
In addition, none of these additives can completely prevent isomerisation and, for 
example, the use of BSA is not possible in serum-free culture media. 
 
An alternative is the synthesis of analogues of ATRA in which the unstable polyene chain 
of the linker unit is incorporated into one or more aromatic rings (arotinoids). As detailed 
in chapter 1 (section 1.1.3.4), a wide variety of different functionalities have been 
employed as linker units in arotinoids, with changes in linker structure allowing for 
selectivity between RAR and RXR as well as RAR isotypes to be controlled. 
 
Arotinoids possessing linker units based on disubstituted alkynes or biaryl units were 
chosen because it was envisaged that the use of these moieties as linker units would give 
retinoids with high degrees of resistance to both thermal and photochemical degradation. 
 
Comparison of ATRA and 9cRA with tolan-, and biaryl-based arotinoids (Figure 3.2) 
shows that para-substituted arotinoids appear similar to the natural retinoid ATRA, while 
their meta-substituted analogues may be considered to be potential 9cRA analogues. 
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(natural retinoid)
CO2H
ATRA             
(natural retinoid)
 
 
Figure 3.2 Arotinoid analogues (detailed in this work) of ATRA and 9cRA, R = H, Me. 
 
 
3.2 Synthetic retinoids based on the tolan structure 
 
Although substituted alkynes can be synthesised via a variety of methods, the 
Sonogashira reaction
301
 is one of the most effective methods due to the mild conditions 
employed and the high degree of functional group tolerance displayed. Thus, a short 
synthesis of tolan-based arotinoids was devised based upon Sonogashira cross-coupling 
of an aryl halide with a monoprotected alkyne, removal of the alkyne protecting group 
and subsequent Sonogashira reaction of the monosubstituted alkyne with a second aryl 
halide to give the tolan products (Scheme 3.1). 
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CO2H
CO2HX
P
X
1. Sonogashira cross-coupling
2. Deprotection
3. Sonogashira cross-coupling
X = halide
P = protecting group
+ +
 
 
Scheme 3.1 Retrosynthetic analysis of tolan-based retinoids via Sonogashira cross-couplings. 
 
Attempts to synthesise the desired aryl bromide via AlCl3-catalysed Friedel-Crafts 
dialkylation of bromobenzene with 2,5-dichloro-2,5-dimethylhexane, as described in the 
literature,
302
 were unsuccessful, as were reactions of 2,5-dichloro-2,5-dimethyl-hexane 
with iodobenzene or phenylethynyltrimethylsilane under the same conditions (Equation 
3.1). 
 
Cl
Cl
X XAlCl3
DCM, rt,18h
+
X = Br, I, CC-TMS  
 
Equation 3.1 Unsuccessful attempts to synthesise functionalised tetrahydronaphthalenes. 
 
 
Instead, bromination of the commercially available 1,1,4,4-tetramethyl-1,2,3,4-
tetrahydronaphthalene 1 was achieved using BF3·OEt2 and 1.8 equivalents of bromine in 
DCM at 0 
o
C to give 6-bromo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 2 in 
good yield (Equation 3.2).  
 
 
Br
1.8 equiv Br2
1.1 equiv BF3
.OEt2
DCM, 0 oC, 2 h, 78%
21  
 
Equation 3.2 Bromination of 1 with Br2/BF3·OEt2 to give 2. 
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Attempts to further increase yields by the use of more forcing conditions led to the 
formation of a dibrominated product, as evidenced by GC-MS (Figure 3.3). 
 
 
4 .0 0 6 .0 0 8 .0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
T im e -->
A b u n d a n c e
T I C :  jh b 5 5 a . D
 
Figure 3.3 GC (TIC) for the synthesis of 2 via bromination of 1 with BF3·OEt2. 
 
6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
m / z -->
A b u n d a n c e
S c a n  6 3 1  (6 .1 8 6  m in ):  jh b 5 5 a .D
2 5 1
1 3 0
1 7 2
1 4 1
1 1 5 1 5 7
2 6 6
5 7
2 0 9
7 7
9 1 1 0 2 1 9 5 2 2 1 2 3 51 8 36 7
 
Figure 3.4 MS of 2. 
 
The subsequent Sonogashira cross-coupling of 2 with 2-methy-3-butyn-2-ol or 
ethynyltrimethylsilane (TMSA) (Equation 3.3), carried out according to the literature 
procedure (2 mol % Pd(PPh3)2Cl2 and 2 mol % CuI in triethylamine at 78 
o
C for 18 h),
303
 
initially gave low conversions of <5%. Increased catalyst loadings (up to 10 mol %), 
under the same conditions, did not lead to improved conversions, and large amounts of 
black palladium precipitates were observed. The low activity of 2 in Sonogashira 
couplings, even under forcing conditions, suggests that the tetramethylated aliphatic ring 
of 2 is strongly ζ-donating and thus deactivating. However, a combination of PdCl2, PPh3 
Br
Br
Br1
2
Br
2
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and Cu(OAc)2, in a 1:5:1 ratio, which generates the active catalyst in situ, was found to 
be effective for the Sonogashira couplings of 2. 
 
The use of this catalyst system with 10 mol % Pd loadings in the couplings of 2 with both 
TMSA and 2-methy-3-butyn-2-ol gave 100% conversions in both cases giving 3, and 4, 
respectively, with no formation of black palladium precipitates observed. The reaction 
with TMSA was more rapid than that of 2-methy-3-butyn-2-ol with full conversion to the 
alkyne products requiring 18 hours and 3 days of heating, respectively (Equation 3.3).  
Br
OH
TMS
a 10 mol % PdCl2, 0.5 equiv PPh3, 10 mol % Cu(OAc)2, NEt3, 78 
oC, 3 d, 45%
b 10 mol % PdCl2, 0.5 equiv PPh3, 10 mol % Cu(OAc)2, NEt3, 78 
oC, 18 h, 81%
OHa
b
TMS
2
3
4
 
 
 
Equation 3.3 Sonogashira cross-couplings of 2 to give 3 and 4. 
 
 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
T i m e - - >
A b u n d a n c e
T I C :  j h b 4 9 d 1 . D
 
Figure 3.5 GC (TIC) of the Sonogashira reaction of 2 with 2-methyl-3-butyn-2-ol to give 3 after 72 h. 
 
 
OH
3
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6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
9 0 0 0 0 0
1 0 0 0 0 0 0
1 1 0 0 0 0 0
1 2 0 0 0 0 0
1 3 0 0 0 0 0
1 4 0 0 0 0 0
1 5 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  9 6 1  ( 8 . 0 7 2  m i n ) :  j h b 4 9 d 1 . D
2 5 5
2 7 0
1 6 5
1 8 1 1 9 51 5 5 2 3 7
1 4 11 1 5 1 2 8 2 1 3
5 9 2 2 5
9 17 7 1 0 4
 
Figure 3.6 MS of 3. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
T i m e - - >
A b u n d a n c e
T I C :  j h b 5 2 b . D
 
Figure 3.7 GC (TIC) of the Sonogashira reaction of 2 with TMSA to give 4 after 18 h. 
 
6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
8 0 0 0 0 0
1 0 0 0 0 0 0
1 2 0 0 0 0 0
1 4 0 0 0 0 0
1 6 0 0 0 0 0
1 8 0 0 0 0 0
2 0 0 0 0 0 0
m / z -->
A b u n d a n c e
S c a n  8 8 0  (7 . 6 0 9  m in ):  jh b 5 2 b . D
2 6 9
2 8 4
7 3
2 1 1
2 3 9
2 2 51 9 71 6 5 2 5 31 7 91 5 25 9 1 1 19 7 1 2 7 1 4 18 6
 
Figure 3.8 MS of 4. 
 
In light of the low activity of 2, more reactive coupling partners were required. The use of 
the iodide analogue of 2 (previously detailed in Chapter 2, compound 15) allowed for the 
OH
3
TMS
TMS diyne 4
TMS
4
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reaction to be carried out at room temperature, using of 1 mol% Pd(PPh3)2Cl2 and 1 mol 
% CuI as catalysts, with full conversion to 4 observed after 12 hours (Equation 3.4). 
 
I
TMS
TMSA
1 mol % Pd(PPh3)2Cl2
1 mol % CuI
NEt3, rt, 12 h, 88% 4
 
 
Equation 3.4 Mild Sonogashira cross-coupling to give 4.  
 
TMS-protected alkyne 4 was desilylated by treatment with KOH in Et2O / MeOH to give 
5 (Equation 3.5). Deprotection of 3 with KOH in refluxing toluene was sluggish and, in 
the light of the higher reactivity of TMSA in Sonogashira cross-couplings with bromide 
2, and the more facile deprotection of 4, the use of 3 was not pursued further. 
 
.  
TMS
KOH, MeOH, Et2O
rt, 2 h, 74%
4 5  
 
Equation 3.5 Desilylation of 4 with KOH to give acetylene 5. 
 
4 .0 0 6 .0 0 8 .0 0 1 0 .0 0 1 2 .0 0 1 4 .0 0 1 6 .0 0 1 8 .0 0 2 0 .0 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
T im e -->
A b u n d a n c e
T IC : jh b 6 1 b .D
 
Figure 3.9 GC (TIC) for the desilylation of 4 with KOH to give 5. 
 
5
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4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0 3 8 0 4 0 0 4 2 0
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
4 0 0 0 0 0
4 5 0 0 0 0
5 0 0 0 0 0
5 5 0 0 0 0
6 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  5 6 0  ( 5 . 7 8 0  m i n ) :  j h b 6 1 b . D
1 9 7
1 5 5
1 1 5
1 3 9
2 1 35 7
7 6 1 8 1
9 9 4 2 4
 
Figure 3.10 MS of 5. 
 
Monoclinic single crystals of 5 (P21/c) grew from pure liquid 5 upon standing. The 
alkyne triple bond distance C(15)-C(16) was found to be 1.1789(16) Å (Figure 3.11). 
 
Figure 3.11 Molecular structure of alkyne 5. Thermal ellipsoids are drawn at the 50% probability level. 
 
Terminal alkyne 5, was coupled with 4-iodomethylbenzoate with a 1 mol % loading of 
both Pd(PPh3)2Cl2 and CuI in neat NEt3 at room temperature to give retinoid methyl ester 
6 in a high yield (Equation 3.6). 
 
5
1 mol % Pd(PPh3)2Cl2
1 mol % CuI
NEt3, rt, 18 h, 87% 6
I
CO2Me
CO2Me
+
 
Equation 3.6 Sonogashira cross-coupling of 5 with 4-iodomethylbenzoate to give 6. 
5
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4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
9 0 0 0 0 0
1 0 0 0 0 0 0
1 1 0 0 0 0 0
1 2 0 0 0 0 0
1 3 0 0 0 0 0
T im e - - >
A b u n d a n c e
T I C :  jh b 1 4 4 a . D
 
Figure 3.12 GC (TIC) for the Sonogashira cross-coupling of 5 with 4-iodomethylbenzoate to give 6. 
 
 
6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 6 8 0  ( 1 2 . 1 8 1  m in ) :  j h b 1 4 4 a . D
3 3 1
3 4 6
2 1 5
2 8 9
2 5 72 2 8
2 7 51 2 91 1 3 3 1 52 0 2 2 4 15 9 1 6 5 1 8 9
3 0 29 5 1 5 2
7 7
 
Figure 3.13 MS of 6. 
 
Triclinic single crystals of para-retinoid ester 6 (P-1) were grown from a concentrated 
solution of 6 in MeOH at -20 
o
C. The interplanar angle between rings i and ii is 69.3
o
, 
while that between ring ii and the methoxycarbonyl group is 6.4
o
. The torsion angle C(7)-
C(6)···C(17)-C(22) is 66.2(2)
 o
 (Figure 3.14). 
CO2Me
5
6
CO2Me
6
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Figure 3.14 Molecular structure of compound 6. Thermal ellipsoids are drawn at the 50% probability 
level.
304
 
 
Hydrolysis of 6 with concentrated aqueous NaOH in refluxing THF gave the target 
compound 7 in high yield (Equation 3.7) after acidification. The synthesis of 7 directly 
could be achieved via the Sonogashira cross-coupling of 5 with 4-iodobenzoic acid under 
the same conditions described for the synthesis of 6. However, yields were lower than for 
the 2 step process and both the work up and purification of the product proved 
troublesome. 
 
1) 20% w/w NaOH/H2O
THF, 70 oC, 18 h,
2) HCl
CO2H
6
CO2Me
7   72%
 
 
Equation 3.7 Hydrolysis of 6 with aqueous hydroxide to give 7. 
 
 
 
3.2.2 Synthesis of 3-methylated retinoids based on the tolan structure 
 
                                                 

The molecular structures of 2, its iodide analogue, 4, and the meta-analogue of 6 were also determined. 
Crystals of these compounds were grown by Ms E. B. Cartmell and Dr. J. C. Collings. 
i
ii
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The replacement the of proton in the 3-position of certain arotinoids with larger 
substituents (i.e., Me) results in substantial changes in the binding affinities for RARs and 
RXRs and in the toxicity. This effect, often termed the α-methyl effect, is believed to 
result from the increase in the dihedral angle between the plane of the hydrophobic unit 
and that of the linker unit due to unfavourable steric interactions between the 
3-substituent and the linker unit.
305
 The adoption of this twisted conformation (more 
similar to that of 9cRA than to ATRA) results in an increased selectivity for RXR 
binding over RAR binding and reduced toxicity (which is associated with pathways 
mediated by RAR activation).
306
 In addition, the toxicity of retinoids with 3-alkyl 
substituents may also be reduced by their more facile oxidative metabolism, which 
predominantly occurs in allylic / benzylic positions in retinoids.
307
 Thus, by comparing 3-
methylated retinoids with linear and non-linear linker units it may be possible to 
determine the extent of the contributions of conformational and metabolic effects to the 
change in biological activity observed upon the addition of a 3-methyl group to 
arotinoids. 
 
A short synthesis of 3-methylated tolan-based arotinoids was devised. Again, this was 
based upon the Sonogashira cross-coupling of an aryl halide with a monoprotected 
alkyne, removal of the alkyne protecting group and subsequent Sonogashira reaction of 
the monosubstituted alkyne with a second aryl halide to give the tolan products (Scheme 
3.2).   
 
CO2H
CO2HX
P
X
1. Sonogashira cross-coupling
3. Deprotection
4.  Sonogashira cross-coupling
X = halide
P = protecting group
+ +
 
 
Scheme 3.2 Retrosynthetic analysis for the 3-methylated EC retinoid skeleton via Sonogashira 
cross-couplings. 
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The desired iodide (detailed in Chapter 2, compound 13) was synthesised by the 
iodination of 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphthalene (chapter 2, compound 
9) with a combination of I2/HIO4 in acetic acid. Sonogashira cross-coupling with TMSA 
with 1 mol % of Pd(PPh3)2Cl2 and CuI catalysts gave the desired TMS-protected alkyne 8 
in excellent yield. 
 
I
TMS
TMSA
1 mol % Pd(PPh3)2Cl2
1 mol % CuI
NEt3, rt, 18h, 97%
8  
 
Equation 3.8 Synthesis of 8 via Sonogashira cross-coupling. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
T i m e - - >
A b u n d a n c e
T I C :  J H B 2 2 2 B . D
 
Figure 3.15 GC (TIC) for the synthesis of 8 via Sonogashira cross-coupling. 
 
2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
9 0 0 0 0 0
1 0 0 0 0 0 0
1 1 0 0 0 0 0
1 2 0 0 0 0 0
1 3 0 0 0 0 0
1 4 0 0 0 0 0
1 5 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  9 1 5  ( 8 . 1 9 9  m in ) :  J H B 2 2 2 B . D
2 8 3
2 9 8
7 3
2 2 5
4 3 2 5 32 0 91 6 5 2 3 91 9 51 7 95 9
1 1 1 1 5 2 2 6 72 9 1 3 49 71 5
 
Figure 3.16 MS of 8. 
 
TMS
8
TMS
8
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Desilylation of compound 8 was achieved with NaOH in MeOH / Et2O to give the 
terminal alkyne 9
308
 in excellent yield. 
 
TMS
0.67 equiv NaOH
MeOH/Et2O, rt, 2 h, 91%
8 9 
 
Equation 3.9 Desilylation of 8 with NaOH to give 9. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
T i m e - - >
A b u n d a n c e
T I C :  j h b  P M N C C H  2 0 0 9  1 . D
 
Figure 3.17 GC (TIC) for the desilyation of 8 to give 9 after 2 h. 
5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0 2 1 0 2 2 0 2 3 0
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
6 0 0 0 0
7 0 0 0 0
8 0 0 0 0
9 0 0 0 0
1 0 0 0 0 0
1 1 0 0 0 0
1 2 0 0 0 0
1 3 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  7 3 3  ( 6 . 7 6 8  m i n ) :  j h b  P M N C C H  2 0 0 9  1 . D
2 1 1
2 2 6
1 6 9
1 5 5
1 8 1
1 9 61 2 8 1 4 11 1 55 7 8 97 6
1 0 26 5
 
Figure 3.18 MS of 8. 
 
Terminal alkyne 9 underwent Sonogashira cross-couplings with 3-, and 4-iodo-
methylbenzoate in the presence of 1 mol % of Pd(PPh3)2Cl2 and CuI catalysts at ambient 
temperature to give the 3-methylated retinoid esters in good yields. 
9
9
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CO2Me
CO2Me
a. p-I-C6H4-CO2Me, 1 mol % Pd(PPh3)2Cl2, 1 mol % CuI, NEt3, rt, 18 h, 77%
b. m-I-C6H4-CO2Me, 1 mol % Pd(PPh3)2Cl2, 1 mol % CuI, NEt3, rt, 18 h, 71%
a
b
9
10
11
 
 
Equation 3.10 Sonogashira cross-couplings of 9 with iodomethylbenzoates to give 10 and 11. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
T im e -->
A b u n d a n c e
T I C :  jh b 2 2 4  2 a 2 . D
 
Figure 3.19 GC (TIC) for the synthesis of 10 from 9 and 4-iodomethylbenzoate after 18 h. 
 
2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
9 0 0 0 0 0
1 0 0 0 0 0 0
1 1 0 0 0 0 0
1 2 0 0 0 0 0
1 3 0 0 0 0 0
1 4 0 0 0 0 0
1 5 0 0 0 0 0
1 6 0 0 0 0 0
1 7 0 0 0 0 0
1 8 0 0 0 0 0
1 9 0 0 0 0 0
2 0 0 0 0 0 0
2 1 0 0 0 0 0
2 2 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 8 1 1  ( 1 3 . 7 0 2  m i n ) :  j h b 2 2 4  2 a 2 . D
3 4 5
3 6 0
3 0 32 2 9 3 2 9
2 7 1
2 8 62 4 42 0 21 6 54 3 1 8 11 2 0 1 3 61 0 15 9 7 72 7
 
Figure 3.20 MS of 10. 
 
10
CO2Me
10
CO2Me
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4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
2 0 0 0 0 0 0
4 0 0 0 0 0 0
6 0 0 0 0 0 0
8 0 0 0 0 0 0
   1 e + 0 7
 1 . 2 e + 0 7
 1 . 4 e + 0 7
 1 . 6 e + 0 7
 1 . 8 e + 0 7
   2 e + 0 7
 2 . 2 e + 0 7
 2 . 4 e + 0 7
 2 . 6 e + 0 7
 2 . 8 e + 0 7
   3 e + 0 7
 3 . 2 e + 0 7
 3 . 4 e + 0 7
 3 . 6 e + 0 7
 3 . 8 e + 0 7
   4 e + 0 7
 4 . 2 e + 0 7
 4 . 4 e + 0 7
 4 . 6 e + 0 7
T im e - - >
A b u n d a n c e
T I C :  j h b  P M N  E C 1 9  M e . D
 
Figure 3.21 GC (TIC) for the synthesis of 11 from 9 and 3-iodomethylbenzoate after 18 h. 
 
4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 2 2 0 2 4 0 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0 3 8 0 4 0 0 4 2 0 4 4 0 4 6 0
0
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5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 5 7 1  ( 1 1 . 5 5 8  m i n ) :  j h b  P M N  E C 1 9  M e . D
3 4 5
2 3 9
3 0 3
2 7 12 1 5
1 6 51 2 0 1 8 91 4 21 0 15 9
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Figure 3.22 MS of 11. 
 
 
Orthorhombic single crystals of 10 (Pccn) were grown from a concentrated EtOH 
solution at -20 
o
C (Figure 3.23), while monoclinic single crystals of 11 (P21/c) were 
grown via slow evaporation of a concentrated EtOH/Et2O solution at room temperature 
(Figure 3.24). 
 
For 10, the interplanar angle between rings i and ii 16.3
o
, and that between ring ii and the 
methoxycarbonyl group is 7.7
o
. For 11 the interplanar angle between rings i and ii is 5.3
o
, 
and that between ring ii and the methoxycarbonyl group is 5.5
o
. 
 
11
CO2Me
11
CO2Me
218 
 
 
Figure 3.23 Molecular structure of compound 10. Thermal ellipsoids are drawn at the 50% probability 
level. 
 
Figure 3.24 Molecular structure of compound 11. Thermal ellipsoids are drawn at the 50% probability 
level. 
 
Retinoid methyl esters 10 and 11 were hydrolysed with LiOH at ambient temperature in a 
mixture of THF and H2O to give their acid derivatives 12 and 13, respectively, in good 
yields (Equation 3.11). 
 
ii
i
i
ii
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CO2H
CO2H
a. LiOH, THF/H2O rt, 18 h, 76%
b. LiOH, THF/H2O rt, 18 h, 73%
a
b
12
13
CO2Me
CO2Me
10
11
 
 
Equation 3.11 Hydrolysis of 10 and 11 with LiOH to give 12 and 13. 
 
3.3 Synthesis of retinoid esters based on the biaryl structure 
 
Biaryl-based arotinoids, such as TTNN,
309,310
 have been shown to possess high activities 
in a variety of screens for retinoidal activity, such as the TOC (tracheal organ cells) 
assay. In addition, biaryl moieties can be efficiently constructed by Suzuki-Miyaura 
cross-couplings making these compounds excellent targets for synthesis using the 
combined aromatic C-H borylation / cross-coupling approach for retinoid synthesis 
previously applied to the TTNPB series in Chapter 2. 
 
Building upon the synthesis of 3-methylated and non-methylated 1,1,4,4-tetramethyl 
1,2,3,4-tetrahydronaphthalene boronate esters  a, b, c and d (detailed in Chapter 2, as 
compounds 6, 16, 10a and 14, respectively) (Figure 3.25) rapid syntheses of a range of 
biaryl retinoid esters were envisaged utilising Suzuki-Miyaura cross-couplings of these 
useful building blocks. 
 
B
O
O
B
O
O
B
O
O
B
O
O
a c db  
 
Figure 3.25 Boronate ester building blocks for retinoid synthesis. 
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For the synthesis of the non-methylated biaryl retinoid esters 14, 15 and 16, 
pinacolboronate ester a (Chapter 2, compound 6) was utilised due to its ease of synthesis 
(via Ir-catalysed C-H borylation with B2pin2) and its marginally higher reactivity, 
compared to its neopentaneglycolato ester analogue b. 
 
The pinacol boronate ester underwent Suzuki-Miyaura cross-coupling with 3-, and 4-
bromo-cinnamic acid methyl esters and 6-bromonaphthalene-2-carboxylic acid methyl 
ester to give the retinoid esters 14, 15 and 16, respectively, in high yields (Equation 
3.12). The reactions were carried out in the presence of 5 mol % Pd(dppf)Cl2 catalyst and 
2 molar equivalents of K3PO4·2H2O base in a combination of DMF/H2O at 80 
o
C. The 
reactions were heated for 2 days, at which time analysis by in situ GC-MS showed all 
reactions to be complete. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equation 3.12 Synthesis of biaryl retinoid esters 14, 15 and 16 via Suzuki-Miyaura cross-couplings. 
 
 
B
O
O
CO2Me
CO2Me
CO2Me
5 mol % Pd(dppf)Cl2
2 equiv K3PO4
.2H2O
5:1 DMF/H2O, 80 
oC, 2 d
+
Br
R
16     87%
14     84%
15     88%
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4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
2 2 0 0 0 0
2 4 0 0 0 0
2 6 0 0 0 0
2 8 0 0 0 0
3 0 0 0 0 0
3 2 0 0 0 0
3 4 0 0 0 0
T i m e - - >
A b u n d a n c e
T I C :  J H B  C E B 1 6  M e  2 0 0 9  3 b . D
 
Figure 3.26 GC (TIC) for the synthesis of 14 from boronate ester a. 
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0
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1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
3 0 0 0 0
3 5 0 0 0
4 0 0 0 0
4 5 0 0 0
5 0 0 0 0
5 5 0 0 0
6 0 0 0 0
6 5 0 0 0
7 0 0 0 0
7 5 0 0 0
8 0 0 0 0
m / z - - >
A b u n d a n c e
S c a n  1 7 9 6  ( 1 2 . 8 4 4  m i n ) :  J H B  C E B 1 6  M e  2 0 0 9  3 b . D
3 3 3
3 4 9
2 5 9 2 9 12 1 5
1 8 91 1 5 2 4 11 5 15 7 9 67 7 4 0 51 3 5 3 1 5 4 2 9
 
Figure 3.27 MS of 14. 
 
4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
8 0 0 0 0 0
1 0 0 0 0 0 0
1 2 0 0 0 0 0
1 4 0 0 0 0 0
1 6 0 0 0 0 0
1 8 0 0 0 0 0
2 0 0 0 0 0 0
T im e - - >
A b u n d a n c e
T I C :  jh b  C E B 1 7  M e  2 0 0 9  3 b . D
 
Figure 3.28 GC (TIC) for the synthesis of 15 from boronate ester a. 
 
CO2Me
14
CO2Me
14
CO2Me
15
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Figure 3.29 MS of 15. 
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Figure 3.30 GC (TIC) for the synthesis of 16 from boronate ester a. 
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Figure 3.31 MS of 16. 
 
 
For the synthesis of 3-methylated biaryl retinoid esters, the neopentaneglycolato boronate 
ester d was utilised as a precursor. Although compound d is marginally less reactive than 
CO2Me
15
CO2Me
16
CO2Me
16
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its pinacol boronate ester analogue c, the synthesis of d from the corresponding aryl-
iodide via Pd-catalysed Miyaura borylation with B2neop2 is much more rapid than the 
corresponding borylation with B2pin2 to give c (18 hours at 80 
o
C versus 4 days at 80 
o
C, 
respectively), making the synthesis from arene to retinoid ester via an iodination / 
borylation / Suzuki-Miyaura cross-coupling sequence much more rapid (4 days versus 7 
days). 
 
Neopentane glycolate boronate ester d underwent Suzuki-Miyaura cross-coupling with 3-
, and 4-bromo-cinnamic acid methyl esters and 6-bromonaphthalene-2-carboxylic acid 
methyl ester to give the retinoid esters 17, 18 and 19, respectively, in high yields 
(Equation 3.13). The reactions were carried out in the presence of 5 mol % Pd(dppf)Cl2 
catalyst and 2 molar equivalents of K3PO4·2H2O based in a combination of DMF/H2O at 
80 
o
C. The reactions were heated for 2 days, at which time analysis by in situ GC-MS 
showed all reactions to be complete. 
 
B
CO2Me
CO2Me
CO2Me
5 mol % Pd(dppf)Cl2
2 equiv K3PO4
.2H2O
5:1 DMF/H2O, 80 
oC, 2 d
+
Br
R
19     83%
17     84%
18     80%
O
O
 
 
Equation 3.13 Synthesis of biaryl retinoid esters 17, 18 and 19 via Suzuki-Miyaura cross-couplings of d. 
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Figure 3.32 GC (TIC) for the synthesis of 17 from boronate ester d. 
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Figure 3.33 MS of 17. 
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Figure 3.34 GC (TIC) for the synthesis of 18 from boronate ester d. 
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Figure 3.35 MS of 18. 
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Figure 3.36 GC (TIC) for the synthesis of 19 from boronate ester d. 
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Figure 3.37 MS of 19. 
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The biaryl retinoid esters 14 – 19 were hydrolysed with aqueous LiOH at ambient 
temperature to give their corresponding carboxylic acids in moderate to good yields 
(Equation 3.14). 
 
CO2H
CO2H
CO2H
5:1 THF/H2O, rt, 3 d
R = H    20      72% 
R = Me  21      69%
R
R
R
CO2Me
CO2Me
CO2Me
R
R
R
LiOH
R = H    22     62% 
R = Me  23     57%
R = H    24     70% 
R = Me  25     75%  
 
Equation 3.14 Hydrolysis of biaryl retinoid esters 14 – 19. 
 
3.4 Conclusions 
 
Two series of highly rigid arotinoids have been synthesised via combinations of aromatic 
iodinations and palladium-catalysed C-C and C-B forming reactions, giving the products 
with good to high yields. Preliminary results
304
 have shown that compound 7 and its 
meta-analogue are highly effective in inducing the differentiation of the human 
embryonal carcinoma stem cell line, TERA2.cl.SP12, with 7 leading to the formation of 
neuronal cells (similar to the effects of ATRA) while its meta-analogue led to the 
formation of „plaques‟ of epithelial cells showing a marked difference in selectivity 
between the para and meta isomers.  
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In contrast to the stilbene-based arotinoids (TTNPB series) detailed in Chapter 2, the 
incorporation of ortho-methyl groups on the arene ring of the hydrophobic terminus does 
not result in any conformational change in the alkynyl compounds, as observed by 
comparisons of the molecular structures and λmax values of compounds differing only by 
the presence of an ortho-methyl group. As a result, these compounds can be used to 
assess the effects (if any) of increasing the steric bulk of the hydrophobic terminus by 
incorporation of this ortho-methyl group, and further work is currently underway to 
evaluate the ability of these compounds to induce the differentiation of the human 
embryonal carcinoma stem cell line, TERA2.cl.SP12. 
 
3.5 Experimental 
 
All reactions were carried out under a dry nitrogen atmosphere using standard Schlenk 
techniques or in an Innovative Technology Inc. System 1 double-length glove box. 
Glassware was oven dried before transfer into the glove box. Hexane was dried over 
sodium/benzophenone was distilled under nitrogen. The solvents DMF, and DMSO and 
H2O were degassed by 3 freeze-pump-thaw-cycles. B2pin2 and B2neop2 were kindly 
supplied as gifts by AllyChem Co. Ltd., Frontier Scientific Inc. and NetChem. Inc. 
Hydrochloric acid was obtained from Fisher Scientific and all other compounds were 
obtained from Aldrich Chemical Company, tested for purity by GCMS and used without 
further purification. NMR spectra were recorded at ambient temperature on Varian 
Systems 700 (
1
H, 
13
C{
1
H}) Varian Inova 500 (
1
H, 
13
C{
1
H}), Varian C500 (
1
H, 
13
C{
1
H}), 
Bruker 400 Ultrashield (
1
H, 
13
C{
1
H}) and Bruker AC200 (
13
C{
1
H}) instruments. Proton 
and carbon spectra were referenced to external SiMe4 via residual protons in the 
deuterated solvents or solvent resonance respectively. IR spectra were recorded on a 
Perkin-Elmer Paragon 500 FT-IR spectrometer. UV-vis and fluorescence measurements 
were recorded in CHCl3. UV-vis absorption spectra and extinction coefficients were 
obtained on a Hewlett-Packard 8453 diode array spectrophotometer using standard 1 cm 
quartz cells. Fluorescence spectra were recorded on a Horiba Jobin-Yvon Fluoromax-3 
spectrophotometer. The spectra of dilute solutions with absorbance maxima of less than 
0.1 were recorded using conventional 90 degree geometry. The emission spectra were 
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fully corrected using the manufacturer‟s correction curves for the spectral response of 
emission optical components. Elemental analyses were conducted in the Department of 
Chemistry at Durham University using an Exeter Analytical Inc. CE-440 Elemental 
Analyser. GC-MS analyses were performed on an Agilent 6890 Plus GC equipped with a 
5973N MSD and an Anatune Focus robotic liquid handling system / autosampler. A 
fused silica capillary column (10 m or 12 m, cross-linked 5% phenylmethylsilicone) was 
used, and the oven temperature was ramped from 50 
o
C to 280 
o
C at a rate of 20 
o
C/min. 
UHP grade helium was used as the carrier gas. The screw-cap autosampler vials used 
were supplied by Thermoquest Inc. and were fitted with Teflon / silicone / Teflon septa 
and 0.2 mL micro inserts. HRMS spectra were recorded in the Department of Chemistry 
at Durham University using a Thermo Finnigan LTQ FT Ultra Hybrid mass spectrometer. 
 
Br
 2 
 
6-Bromo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (2).
302
 To a solution of 
1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene (10.0 g, 53.0 mmol) in DCM (60 mL) 
at 0 
o
C under N2 was added 1.8 eq. of Br2 (15.58 g, 97.5 mmol). BF3.Et2O (8.27 g, 58.3 
mmol) in DCM (10 mL) was added dropwise over 2 h. The reaction mixture was diluted 
with 40/60 EtOAc/hexane (150 mL) and washed with saturated Na2SO3 solution (100 
mL), saturated NaHCO3 solution (100 mL), and H2O (100 mL). The organic layer was 
dried over MgSO4, filtered and the solvents were removed in vacuo to give a dark brown 
oil. Kugelrohr distillation (120 
o
C, 8 x 10
-3
 mbar) gave the product as pale yellow crystals 
(11.0 g, 78%); mp 43-45 
o
C; EI-MS m/z: 266 (30% M
+
), 251 (100%, M
+
 - Me); 
1
H NMR
 
(400.13 MHz, CDCl3)  7.40 (1H, d, J = 3 Hz), 7.21 (1H, d, J = 3 Hz), 7.18 (1H, s), 1.67 
(4H, s), 1.27 (6H, s), 1.26 (6H, s); 
13
C{
1
H} NMR (100.13 MHz, CDCl3)  147.63, 
144.09, 129.67, 128.88, 128.66, 119.62, 35.11, 35.10, 34.70, 34.30, 31.96 (two peaks 
overlapped); anal. calcd for C14H19Br: C 62.93; H 7.17; found: C 62.81; H 7.16.  
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Si
 3 
 
 
Trimethyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)-silane (3). 
PdCl2 (75 mg, 0.43 mmol), Cu(OAc)2 (77 mg, 0.43 mmol), 1 (1.14 g, 4.30 mmol) and 
PPh3 (0.56 g, 2.14 mmol) were placed in a 250 mL Schlenk flask under N2. Dry, 
degassed NEt3 (100 mL) was added via cannula and ethynyltrimethylsilane (0.7 mL 5.14 
mmol) was added via syringe. After 18 h at 70 
o
C, the NEt3 was evaporated and the 
residue was passed through a short silica gel column (hexane as eluent) to give the crude 
product as a viscous, pale yellow oil after evaporation which slowly solidified to give an 
off-white solid which was recrystallised from ethanol to give 3 (1.0 g, 81%); mp 51-52 
o
C; EI-MS m/z: 284 (25%, M
+
), 269 (100%, M
+
-Me); 
1
H NMR
 
 (400.13 MHz, CDCl3) 
7.22 (1H, s), 7.02 (2H, s), 1.47 (4H, s), 1.07 (6H, s), 1.07 (6H, s), 0.05 (9H, s); 13C{1H} 
NMR (100.61 MHz, CDCl3) 145.94, 145.10, 130.45, 129.31, 126.71, 120.31, 106.20, 
93.51, 35.23, 35.14, 34.54, 34.39, 31.96, 31.89, 0.31; anal. calcd. for C19H28Si: C 80.21, 
H 9.92; found: C 80.04, H 9.90. 
 
Synthesis of 3 from 6-iodo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene  
6-Iodo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (3.14 g, 10.0 mmol), 
Pd(PPh3)2Cl2 (0.07 g, 0.1 mmol) and CuI (0.02 g, 0.1 mmol) were placed in a 250 mL 
Schlenk flask under N2. Dry, degassed NEt3 (150 mL) was added via cannula under N2 
and ethynyltrimethylsilane (1.18 g, 12 mmol) was added via syringe. The reaction was 
stirred under N2 at room temperature, until analysis by GCMS showed the reaction to be 
complete (12 h). The NEt3 solvent was removed in vacuo and the residue was passed 
through a short silica gel column, eluting with hexane. Evaporation of the solvent gave 
the crude product as a pale yellow oil which slowly solidified to give an off-white solid. 
Recrystallisation from hot EtOH gave 3 (2.50 g, 88%). All spectroscopic and analytical 
properties were identical to those reported above. 
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OH
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2-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-but-3-yn-2-ol 
(4). PdCl2 (0.331 g, 1.87 mmol), Cu(OAc)2 (0.274 g, 1.87 mmol), 1 (5.0 g, 18.71 mmol) 
and PPh3 (2.45 g, 9.35 mmol) were placed in a 500 mL Schlenk flask, and the flask was 
evacuated and back-filled with N2 gas (3x). NEt3 (150 mL) was added via cannula, 
followed by 2-methylbut-3-yn-2-ol (4.72 g, 56.13 mmol). The solution was stirred under 
N2 at 70 
o
C for 3 d. The NEt3 was evaporated and the residue was passed through a short 
silica gel column (hexane, then 10% EtOAc/hexane as eluent). The EtOAc/hexane 
solution was washed with 1M HCl solution (100 mL), dried (MgSO4) and evaporated to 
give 4 as an off-white solid (2.25 g, 45%); mp 107–109 oC; EI-MS m/z: 236 (90%, M+), 
205 (100%, OH and Me loss); 
1
H NMR
 
(499.76 MHz, CDCl3)  7.36 (1H, s), 7.24 (1H, 
d, J  = 8.0 Hz), 7.21 (1H, d, J = 8.0 Hz), 2.05 (1H, s), 1.67 (4H, s), 1.62 (6H, s), 1.27 (6H, 
s), 1.26 (6H, s); 
13
C{
1
H} NMR (126 MHz, CDCl3) 145.6, 145.1, 130.1, 128.9, 126.8, 
119.8, 92.8, 82.8, 65.8, 35.2, 35.1, 34.5, 34.4,  31.9, 31.9, 31.8; m/z (EI) 270 (M
+
); 
HRMS (ES
+
) calcd. for C19H26ONa ([M + Na]
+
) 293.18759, found 293.18776, and 
HRMS (ES
+
) calcd. for C19H25 ([M − OH]
+
) 253.19508, found 253.19522. 
 
 
5 
 
6-Ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (5). To a solution of 3 
(1.42 g, 5 mmol) in MeOH (50 mL) and Et2O (50 mL), was added NaOH (0.14 g, 3.5 
mmol) in H2O (2 mL). After 4 h, the mixture was extracted with Et2O (30 mL), washed 
with H2O (3 x 30 mL), dried (MgSO4) and evaporated to give 5 as an oil which slowly 
solidified to give a white solid (0.78 g, 74%); mp 48–49 oC; IR(KBr disc, cm−1) 2105 
(C≡C); 1H NMR (199.99 MHz, CDCl3)  7.47 (1H, s), 7.27 (2H, s), 3.03 (1H, s), 1.70 
(4H, s), 1.29 (6H, s), 1.26 (6H, s); 
13
C{
1
H} NMR (100.61 MHz, CDCl3) δ 146.1, 145.1, 
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130.5, 129.2, 126.6, 119.1, 84.3, 75.9, 34.9, 34.8, 34.3, 34.2, 31.8, 31.7; m/z (EI-MS): 
212 (M
+
); anal. calcd. for C16H20: C 90.51, H 9.49; found: C 90.27, H 9.57. 
 
CO2Me
 6 
 
4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)-benzoic acid 
methyl ester (6). CuI (0.03 g, 0.14 mmol), 4-iodobenzoic acid methyl ester (3.59 g, 13.7 
mmol) and Pd(PPh3)2Cl2 (0.09 g, 0.14 mmol) were placed in a 500 mL Schlenk flask 
under N2 and 5 (3.50 g, 16.48 mmol) was added. Dry, degassed Et3N (200 mL) was 
added via cannula and the reaction mixture was stirred under N2 until GCMS analysis 
showed the reaction to be complete (18 h). Et3N was removed in vacuo and the remaining 
crude solid purified via passage through a silica plug, eluting with hexane (100 mL), then 
10% DCM/hexane. Removal of solvent and drying in vacuo gave a crude solid. 
Recrystallisation from hot EtOH gave the product as a white crystalline solid; (4.13 g, 
87%); mp 122 
o
C; R (KBr disc, cm−1) 2207 (C≡C), 1712 (C=O); UV-vis (CHCl3) λmax 
310 nm ( 26400 M−1cm−1; λem (CHCl3) 362 nm; m/z (EI-MS) 346 20% M
+
), 331 (100% 
M
+
-Me); 
1
H NMR (400.13 MHz, CDCl3) 8.03 (2H, d, J = 9.0 Hz), 7.59 (2H, d, J = 9.0 
Hz), 7.51 (1H, s), 7.31 (2H, s), 3.94 (3H, s), 1.71 (4H, s), 1.28 (12H, s);
 13
C{
1
H} NMR 
(100.61 MHz, CDCl3)  166.83, 146.34, 145.41, 131.67, 130.31, 129.69, 129.43, 129.00, 
128.61, 126.98, 119.84, 93.30, 87.23, 52.39, 35.16, 35.09, 34.61, 34,45, 31.99, 31.90; 
anal. calcd. for C24H26O2 C, 83.20; H, 7.56; found: C, 83.03; H, 7.59. 
 
CO2H
 7 
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4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)-benzoic acid (7). 
A solution of 6 (0.35 g, 1 mmol) in THF (20 mL) was treated with aqueous 20% NaOH 
(20 mL). After heating at 70 
o
C for 20 h, the reaction mixture was diluted with Et2O (150 
mL) and water (150 mL), then 1 M HCl solution was added until mixture reached pH 1. 
The organic layer was separated, dried (MgSO4) and evaporated to give an off-white 
powder, which was recrystallised from MeCN to give the product 7 as a white crystalline 
solid (0.24 g, 72%); mp 254–256 oC;IR (KBr disc, cm−1) 2205 (C≡C), 1681 (C=O); UV-
vis (CHCl3) λmax 310 nm ( 26900 M
−1
cm
−1
; λem (CHCl3) 365 nm; (ES-MS) m/z 377 
(20%, MNa2), 331 (100%, [M-H]
-
); 
1
H NMR (400.13 MHz, DMSO-d6) 8.09 (2H, d, J = 
8.5 Hz), 7.62 (2H, d, J = 8.5 Hz), 7.51 (1H, s), 7.31 (2H, s), 1.68 (4H, s), 1.31 (12H, s); 
13
C{
1
H} NMR (125.67 MHz, CDCl3) 171.49, 146.46, 145.43, 131.76, 130.35, 130.33, 
129.56, 129.02, 128.38, 127.01, 119.69, 93.85, 87.76, 35.10, 35.04, 34.62, 34.46, 31.98, 
31.89; HRMS (ES
-
) calcd. for C23H23O2 331.16926 [(M − H)
-
], found 331.16949. 
 
SiMe3
8 
 
Trimethyl-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)- 
silane (8). Pd(PPh3)2Cl2 (0.21 g, 0.31 mmol) CuI (58 mg, 0.31 mmol) and  6-iodo-
1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene (10.0 g, 30.5 mmol) were placed in 
a 1 L Schlenk flask under N2. Dry, degassed Et3N (500 mL) was added via cannula and 
ethynyltrimethylsilane (5.17 mL, 36.6 mmol) was added via syringe. The mixture was 
stirred under N2 until GCMS analysis showed the reaction to be complete (18 h). The 
solvent was removed in vacuo and the residue was filtered through a SiO2 plug eluting 
with hexane (300 mL). Removal of the solvent in vacuo gave a clear oil. Addition of 
MeOH (5 mL) and cooling gave 8 as analytically pure white crystals (8.82 g, 97%); mp 
77-78 
o
C; IR (KBr disc, cm
-1
) 2963, 2926, 2860, 2143, 1493, 1457, 1362, 1247; m/z (EI-
MS) 354 (100%, M
+
 - Me), 339 (25%, M
+
); 
1
H NMR (499.80 MHz, CDCl3) δ 7.37 (1H, 
s), 7.10, (1H, s), 2.37, (3H, s), 1.65, (4H, s), 1.25 (6H, s), 1.24 (6H, s), 0.25 (9H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 146.02, 142.54, 137.65, 130.58, 127.73, 120.48, 
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105.02, 97.04, 35.34, 35.32, 34.54, 34.18, 32.12, 32.02, 20.62, 0.50; anal. calcd for 
C20H30Si: C 80.46, H 10.13; found: C 80.29, H 10.17. 
 
 
9 
 
6-Ethynyl-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene (9). Compound 8 (6.0 
g, 20.1 mmol) and NaOH (0.53 g, 13.4 mmol) were dissolved in a 50/50 mixture of Et2O 
and MeOH (100 mL) with 1 mL of H2O. The mixture was stirred for 2 h at which time 
GCMS analysis showed the reaction to be complete. H2O (100 mL) and hexane (100 mL) 
were added and the product was extracted into the organic layer. The organic layer was 
dried over MgSO4, filtered and the solvent removed in vacuo to give a white solid. 
Recrystallisation from MeOH gave 9 as an analytically pure white powder (0.41 mg, 91 
%); mp 45-47 
o
C (lit. 41-43 
o
C
308
); IR (KBr disc, cm
-1
) 2963, 2926, 2861, 2143, 1493, 
1458, 1391, 1247; m/z (EI-MS) 226 (25%, M
+
), 211 (100%, M
+
 - Me); 
1
H NMR (499.80 
MHz, CDCl3) δ 7.42 (1H, s), 7.13 (1H, s), 3.20 (1H, s), 2.40 (3H, s), 1.66 (4H, s) 1.27 
(6H, s), 1.26 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 146.32, 142.67, 137.72, 
131.161, 127.84, 119.49, 83.38, 79.91, 35.28, 35.27, 34.55, 34.16, 32.12, 32.01, 20.59; 
anal. calcd for C17H22: C 90.20, H 9.80; found: C 89.95, H 9.80. 
 
O
O
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4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)-benzoic acid 
methyl ester (10). Pd(PPh3)2Cl2 (29 mg, 0.042 mmol), CuI (8 mg, 0.004 mmol), 
4-iodobenzoic acid methyl ester (1.1 g, 4.2 mmol) and compound 9 (1.0 g, 4.4 mmol) 
were placed in a 250 mL Schlenk flask under N2. Dry, degassed Et3N (100 mL) was 
added via cannula. The reaction was stirred under N2 for 3 d. The solvent was removed in 
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vacuo and the residue was filtered through a SiO2 plug eluting with hexane (200 mL) and 
then with 50:50 DCM/hexane (200 mL). The DCM/hexane fraction was evaporated in 
vacuo to give a pale brown solid. Recrystallisation from EtOH gave white needles (0.12 
g, 77%); mp 135-137; IR (KBr disc, cm
-1
)  2921, 2857, 1711 (C=O), 1602, 1433, 1287, 
1108; UV-vis (CHCl3) λmax 317 nm (ε) 25700 L mol
-1 
cm
-1
; λem (CHCl3) 378 nm;  m/z 
(EI-MS) 360 (50%, M
+
), 345 (100%, M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ  8.01 
(2H, d, J = 8.5 Hz), 7.58 (2H, d, J = 8.5 Hz), 7.45 (1H, s), 7.16 (1H, s), 3.93 (3H, s), 2.46 
(3H, s), 1.68 (4H, s), 1.29 (6H, s) 1.28 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 
166.99, 146.52, 142.89, 137.43, 131.69, 130.63, 129.84, 129.49, 128.94, 127.97, 120.04, 
92.36, 91.72, 52.57, 35.29, 34.62, 34.24, 32.16, 32.10 32.02, 20.73; anal. calcd. for 
C25H28O2: C 83.29, H 7.83; found: C 82.83, H 7.67. 
 
O
O
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3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)-benzoic acid 
methyl ester (11). Pd(PPh3)2Cl2 (29 mg, 0.042 mmol), CuI (8 mg,0.0042 mmol), 
3-iodobenzoic acid methyl ester (1.1 g, 4.21 mmol) and compound 9 (1.0 g, 4.42 mmol) 
were placed in a 250 mL Schlenk flask under N2. Dry, degassed Et3N (100 mL) was 
added via cannula. The reaction was stirred under N2 for 3 d. The solvent was removed in 
vacuo and the residue filtered through a SiO2 plug eluting with hexane (200 mL) and 
50/50 DCM/hexane (200 mL). The DCM/hexane fraction was evaporated in vacuo to 
give a pale brown solid. Recrystallisation from EtOH to gave white needles (0.11 g, 
71%); mp 115-117; IR (KBr disc, cm
-1
) 2956, 2926, 2862, 1725 (C=O), 1439, 1280, 
1256; UV-vis (CHCl3) λmax 290 nm (ε) 22000 L mol
-1 
cm
-1
; λem (CHCl3) 370 nm;  m/z 
(EI-MS) 360 (50%, M
+
), 345 (100%, M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ  8.04 
(1H, s), 7.82 (1H, d, J = 7.5 Hz), 7.70 (1H, d, J = 7.5 Hz), 7.46 (1H, s), 7.33 (1H, t, J = 
7.5 Hz) 7.16 (1H, s), 2.46 (3H, s), 3.94 (3H, s), 2.46 (3H, s), 1.68 (4H, s), 1.29 (6H, s) 
1.28 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 166.89, 146.23, 142.79, 137.34, 
135.97, 132.88, 130.71, 130.57, 129.22, 128.79, 127.91, 124.63, 120.20, 91.33, 90.13, 
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52.64, 35.31, 34.59, 34.23, 32.17, 32.10, 32.03, 20.76; anal. calcd. for C25H28O2: C 83.29, 
H 7.83; found: C 83.03, H 7.36. 
 
OH
O
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4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylethynyl)-benzoic acid 
(12). LiOH·H2O (17.5 mg, 0.42 mmol) and 10 (0.10 g, 0.28 mmol) were placed in a large 
screw top vial. THF (5 mL) and H2O (1 mL) were added and the solution stirred at room 
temperature until analysis via tlc showed the reaction to be complete. Et2O (30 mL) was 
added and the mixture washed with dilute HCl(aq.) (30 mL), and H2O (2 x 30 mL). The 
organic layer was dried with MgSO4, filtered and the solvent removed in vacuo. 
Recrystallisation from MeCN gave the product as a white powder (0.73 mg, 76%); mp 
220-222 
o
C; UV-vis (CHCl3) λmax 319 nm (ε) 26100 L mol
-1 
cm
-1
; λem (CHCl3) 381 nm; 
m/z (ES
+
-MS) 692 (2M
+
); 
1
H NMR (499.80 MHz, DMSO-d6) δ  7.96 (2H, d, J = 8.0 Hz), 
7.65 (2H, d, J = 8.0 Hz), 7.45 (1H, s), 7.27 (1H, s), 2.40 (3H, s), 1.62 (4H, s), 1.23 (12H, 
s); 
13
C{
1
H} NMR 125.67 MHz, DMSO-d6) δ 167.47, 146.68, 142.97, 137.45, 132.03, 
130.97, 130.48, 130.28, 128.36, 127.80, 119.67, 92.21, 92.14, 35.14, 35.10, 34.25, 32.17, 
32.06, 20.64; anal. calcd. for C24H26O2: C 83.20, H 7.56; found: C 83.23, H 8.04. 
 
 
O
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3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylethynyl)-benzoic acid 
(13). LiOH·H2O (17.5 mg, 0.42 mmol) and compound 11 (0.10 g, 0.28 mmol) were 
placed in a large screw top vial. THF (5 mL) and H2O (1 mL) were added and the 
solution stirred at room temperature until analysis via tlc showed the reaction to be 
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complete. Et2O (30 mL) was added and the mixture washed with dilute HCl(aq.) (30 mL), 
and H2O (2 x 30 mL). The organic layer was dried with MgSO4, filtered and the solvent 
removed in vacuo. Recrystallisation from MeCN gave the product as a white powder (71 
mg, 73%); mp 206-207 
o
C; UV-vis (CHCl3) λmax 290 nm (ε) 23000 L mol
-1 
cm
-1
; λem 
(CHCl3) 376 nm; m/z (ES
+
-MS) 692 (M
+
);  
1
H NMR (499.80 MHz, DMSO-d6) δ  8.03 
(1H, s), 7.93 (1H, d, J = 7.5 Hz), 7.76 (1H, d, J = 7.5 Hz), 7.54 (1H, t, J = 7.5 Hz), 7.44 
(1H, s), 7.24 (1H, s), 2.39 (3H, s), 1.60 (4H, s), 1.22 (12H, s); 
13
C{
1
H} NMR 125.67 
MHz, DMSO-d6) δ 166.55, 145.69, 136.47, 135.13, 131.37, 129.70, 129.17, 127.54, 
123.16, 119.10, 91.04, 89.49, 34.46, 34.42, 33.91, 33.51, 31.44, 19.90; anal. calcd. for 
C24H26O2: C 83.20, H 7.56; found: C 83.09, H 8.00. 
 
O
O
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3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]-acrylic acid 
methyl ester (14). Pd(dppf)Cl2 (23 mg, 0.03 mmol), compound a (0.20 g, 0.64 mmol), 
K3PO4·2H2O (0.29 g, 1.16 mmol) and 3-(4-bromo-phenyl)-acrylic acid methyl ester (0.14 
g, 0.58 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along 
with DMF (10 mL) and H2O (2 mL) in a dry, N2 filled, glovebox. The mixture was 
heated at 80 
o
C until GCMS analysis showed the reaction to be complete (2 d). Dilute 
HCl (aq.) (2 mL) was added and the mixture was extracted with Et2O (3 x 10 mL); the 
organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was filtered through a silica plug, eluting with hexane 
and then 10% DCM/hexane, and the solvent was removed in vacuo. Recrystallisation 
from hot EtOH gave the product as a white fluffy powder (180 mg, 84%); mp 167-169 
o
C; IR (KBr disc, cm
-1
) 2956, 2922, 2857, 1711 (C=O), 1638, 1313, 1193m 1171; UV-vis 
(CHCl3) λmax 307  nm (ε)  28400 L mol
-1 
cm
-1
; λem (CHCl3) 396 nm; m/z (EI-MS) 333 
(100%, M
+
 - Me), 348 (20%, M
+
); 
1
H NMR (499.80 MHz, CDCl3) δ 7.75 (1H, d, J = 16.0 
Hz), 7.60 (2H, d, J = 9.0 Hz), 7.58 (2H, d,  J = 9.0 Hz), 7.53 (1H, d, J = 2.0 Hz), 7.40 
(1H, d, J =  9.0 Hz), 7.37 (1H, dd, J = 9.0, 2.0 Hz), 6.46 (1H, d, J = 16.0 Hz), 3.82 (3H, 
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s), 1.72 (4H, s), 1.34 (6H, s), 1.32 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 
167.70, 145.59, 144.96, 144.71, 143.60, 137.42, 133.07, 128.65, 127.59, 127.31, 125.35, 
124.46, 117.44, 51.85, 35.24, 35.13, 34.58, 34.35, 32.06, 32.08; HRMS (ES
+
) calcd. for 
C24H29O2 ([M + H]
+
) 349.21621, found 349.21628. 
 
O
O
15 
 
 
3-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]-acrylic acid 
methyl ester (15). Pd(dppf)Cl2 (23 mg, 0.028 mmol), compound a (0.20 g, 0.64 mmol), 
K3PO4·2H2O (0.29 g, 1.16 mmol) and 3-(3-bromo-phenyl)-acrylic acid methyl ester (0.14 
g, 0.58 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along 
with DMF (10 mL) and H2O (2 mL) in a dry, N2 filled, glovebox. The mixture was 
heated at 80 
o
C until GCMS analysis showed the reaction to be complete (2 d). Dilute 
HCl (aq.) (2 mL) was added and the mixture was extracted with Et2O (3 x 10 mL); the 
organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was filtered through a silica plug, eluting with hexane 
and then 10% DCM/hexane, and the solvent was removed in vacuo. Recrystallisation 
from hot EtOH gave the product as a white fluffy powder (0.178 g, 88%); mp 163-165 
o
C; IR (KBr disc, cm
-1
) 2956, 2921, 2856, 1709 (C=O), 1637, 1313, 1170; UV-vis 
(CHCl3) λmax 268 nm (ε) 14400 L mol
-1 
cm
-1; λem (CHCl3) 396 nm;  m/z (EI-MS) 333 
(100%, M
+
 - Me), 348 (20%, M
+
); 
1
H NMR (499.80 MHz, CDCl3) δ 7.78 (1H, d, J = 16.0 
Hz), 7.70 (1H, s), 7.59 (1H, d, J = 8.0 Hz), 7.51 (2H, m). 7.45 (1H, t, J = 8.0 Hz), 7.40 
(1H, d, J = 8.0 Hz), 7.37 (1H, dd, J = 8.0, 2.0 Hz), 6.47 (1H, d, J = 16.0 Hz), 3.82 (3H, s), 
1.72 (4H, s), 1.34 (6H, s), 1.32 (6H, s); 
13
C{
1
H} NMR 125.67 MHz, CDCl3) δ 167.61, 
145.58, 145.13, 144.71, 142.44, 137.79, 134.86, 129.35, 129.24, 127.29, 127.05, 126.54, 
125.40, 124.55, 118.08, 51.90, 35.24, 35.14, 34.57, 34.31, 32.07, 32.00; HRMS (ES
+
) 
calcd. for C24H28O2Na ([M + Na]
+
) 371.19815, found 371.19816. 
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5',5',8',8'-Tetramethyl-5',6',7',8'-tetrahydro[2,2']binaphthalenyl-6-carboxylic acid 
methyl ester (16). Pd(dppf)Cl2 (23 mg, 0.028 mmol), compound a (0.20 g, 0.64 mmol), 
K3PO4·2H2O (0.29 g, 1.16 mmol) and 2-bromo-naphthalene-6-carboxylic acid methyl 
ester (0.15 g, 0.58 mmol) were placed in a thick walled glass tube fitted with a Young‟s 
tap along with DMF (10 mL) and H2O (2 mL) in a dry, N2 filled, glovebox. The mixture 
was heated at 80 
o
C until GCMS analysis showed the reaction to be complete (2 d). 
Dilute HCl (aq.) (2 mL) was added and the mixture was extracted with Et2O (3 x 10 mL); 
the organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was filtered through a silica plug, eluting with hexane 
and then 10% DCM/hexane, and the solvent was removed in vacuo. Recrystallisation 
from hot EtOH gave the product as a white fluffy powder (0.196 g, 87%); mp 169-170; 
IR (KBr disc, cm
-1
) 2955, 2922, 2857, 1706 (C=O), 1476, 1293, 1222, 1094; UV-vis 
(CHCl3) λmax 266 nm (ε) 34500 L mol
-1 
cm
-1
; λem (CHCl3) 378 nm; m/z (EI-MS) 347 
(100%, M
+
 - Me), 372 (20%, M
+
); 
1
H NMR (699.73 MHz, CDCl3) δ 8.63 (1H, s), 8.08 
(1H, dd, J = 9.0, 2.0 Hz), 8.04 (1H, s), 8.01 (1H, d, J = 9.0 Hz), 7.94 (1H, d, J = 9.0 Hz), 
7.80 (1H, dd, J = 9.0, 2.0 Hz), 7.65 (1H, d, J = 2.0 Hz), 7.49 (1H, dd, J = 9.0, 2.0 Hz), 
7.44 (1H, d, J = 9.0 Hz), 3.99 (3H, s), 1.75 (4H, s), 1.38 (6H, s), 1.35 (6H, s); 
13
C{
1
H} 
NMR δ 167.44, 145.68, 145.93, 141.48, 137.83, 136.00, 131.63, 130.98, 129.87, 128.46, 
127.39, 127.26, 126.70, 125.79, 125.74, 125.38, 124.89, 52.39, 35.29, 35.17, 34.63, 
34.37, 32.11, 32.01; HRMS (ES
+
) calcd. for C26H28O2Na, ([M + Na]
+
) 395.19815, found 
395.19813. 
 
 
239 
 
O
O
17 
 
3-[4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]-acrylic acid 
methyl ester (17). Pd(dppf)Cl2 (23 mg, 0.028 mmol), compound d (0.20 g, 0.64 mmol), 
K3PO4·2H2O (0.29 g, 1.16 mmol) and 4-(3-bromo-phenyl)-acrylic acid methyl ester (0.14 
g, 0.58 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along 
with degassed DMF (10 mL) and H2O (2 mL) in a dry, N2 filled, glovebox. The mixture 
was heated at 80 
o
C until GCMS analysis showed the reaction to be complete (2 d). 
Dilute HCl (aq.) (2 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was filtered through a silica plug with hexane and 
then 10% DCM/hexane and the solvent was removed in vacuo. Recrystallisation from hot 
EtOH gave the product as a fluffy, white powder (0.17 g, 80%); mp 152-153; IR (KBr 
disc, cm
-1
) 2965, 2922, 2856, 1714 (C=O), 1634, 1491, 1314, 1169; UV-vis (CHCl3) λmax 
307 nm (ε) 29600  L mol-1 cm-1; λem (CHCl3) 400 nm; m/z (EI-MS) 362 (20%, M
+
), 347 
(100%, M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ 7.74 (1H, d, J = 16.0 Hz), 7.57 (2H, 
d, J = 9.0 Hz), 7.37 (2H, d, J = 9.0 Hz), 7.19 (1H, s), 7.16 (1H, s), 6.47 (1H, d, J = 16.0 
Hz), 3.83 (3H, s), 2.26 (3H, s), 1.71 (4H, s), 1.33 (6H, s), 1.29 (6H, s); 
13
C{
1
H} NMR 
125.67 MHz, CDCl3) δ 167.71, 142.83, 144.60, 144.56, 142.77, 138.40, 132.78, 132.29, 
130.07, 128.63, 127.99, 127.95, 117.55, 51.89, 35.27, 35.26, 34.16, 34.13, 32.04, 32.01, 
20.36; HRMS (ES
+
) calcd. for C25H31O2 ([M + H]
+
) 363.23186, found 363.23189.  
 
O
O
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3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]-acrylic acid 
methyl ester (18). Pd(dppf)Cl2 (23 mg, 0.028 mmol), compound d (0.20 g, 0.64 mmol), 
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K3PO4·2H2O (0.29 g, 1.16 mmol) and 3-(3-bromo-phenyl)-acrylic acid methyl ester (0.14 
g, 0.54 mmol) were placed in a thick walled glass tube fitted with a Young‟s tap along 
with degassed DMF (10 mL) and H2O (2 mL) in a dry, N2 filled, glovebox. The mixture 
was heated at 80 
o
C until GCMS analysis showed the reaction to be complete (2 d). 
Dilute HCl (aq.) (2 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried over MgSO4 and 
concentrated in vacuo. The mixture was filtered through a silica plug with hexane and 
then 10% DCM/hexane and the solvent was removed in vacuo. Recrystallisation from hot 
EtOH gave the product as a fluffy, white powder (0.17 g, 83%); mp 121-122; IR (KBr 
disc, cm
-1
) 2953, 2924, 2857m 1714 (C=O), 1639, 145, 1322, 1170; UV-vis (CHCl3) λmax 
267 nm (ε) 25600 L mol-1 cm-1; λem (CHCl3) 378 nm; m/z (EI-MS) 362 (20%, M
+
), 347 
(100%, M
+
 - Me); 
1
H NMR (399.60 MHz, CDCl3) δ 7.74 (1H, d, J = 16.0 Hz), 7.49, (2H, 
m), 4.40 (2H, ov m), 7.21 (1H, s), 7.16 (1H, s), 6.47 (1H, d, J = 16.0 Hz), 3.82 (3H, s), 
2.24 (3H, s), 1.72 (4H, s), 1.34 (6H, s), 1.29 (6H, s); 
13
C{
1
H} NMR 50.29 MHz, CDCl3) 
δ 167.82, 145.22, 144.69, 143.34, 142.97, 138.09, 134.56, 132.49, 131.69, 129.39, 
128.02, 128.76, 128.19, 126.59, 118.28, 52.04, 35.54, 35.53, 34.36, 34.33, 32.26, 32.23, 
20.47; HRMS (ES
+
) calcd. for C25H30O2Na ([M + Na]
+
) 385.21434, found 385.21492. 
 
 
O
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3’,5',5',8',8'-Tetramethyl-5',6',7',8'-tetrahydro[2,2']binaphthalenyl-6-carboxylic 
acid methyl ester (19). Pd(dppf)Cl2 (23 mg, 0.28 mmol), compound d (0.20 g, 0.64 
mmol), K3PO4·2H2O (0.29 g, 1.16 mmol) and 6-bromo-naphthalene-2-carboxylic acid 
methyl ester  (0.15 g, 0.58 mmol) were placed in a thick walled glass tube fitted with a 
Young‟s tap along with degassed DMF (10 mL) and H2O (2 mL) in a dry, N2 filled, 
glovebox. The mixture was heated at 80 
o
C until GCMS analysis showed the reaction to 
be complete (2 d). Dilute HCl (aq.) (2 mL) was added and the mixture was extracted with 
Et2O (3 x 10 mL). The organic phase was washed with dilute HCl(aq.) (3 x 10 mL), dried 
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over MgSO4 and concentrated in vacuo. The mixture was filtered through a silica plug 
with hexane and then 10% DCM/hexane and the solvent was removed in vacuo. 
Recrystallisation from hot EtOH gave the product as a fluffy, white powder (0.19 g, 
84%); mp 162-163 
o
C;
 
IR (KBr disc, cm
-1
) 2954, 2918, 2853, 1709 (C=O), 1436, 1295, 
1128, 1096; UV-vis (CHCl3) λmax 302 nm (ε) 16200 L mol
-1 
cm
-1
; λem (CHCl3) 369 nm; 
m/z (EI-MS) 386 (20%, M
+
), 372 (100%, M
+
 - Me); 
1
H NMR (499.80 MHz, CDCl3) δ 
8.64 (1H, s), 8.08 (1H, dd, J = 9.0, 2.0 Hz), 7.98 (1H, d, J = 9.0 Hz), 7.89 (1H, d, J = 9.0 
Hz), 7.82 (1H, s), 7.56 (1H, dd, J = 9.0, 2.0 Hz), 7.25 (1H, s), 7.24 (1H, s), 4.00 (3H, s), 
2.29, (3H, s), 1.73 (4H, s), 1.35 (6H, s), 1.31 (6H, s); 
13
C{
1
H} NMR (125.67 MHz, 
CDCl3) δ 167.49, 144.58, 142.59, 142.53, 138.74, 135.60, 132.51, 131.35, 131.00, 
129.01, 128.97, 128.62, 128.36, 128.28, 128.83, 127.32, 125.63, 52.40, 35.30, 35.29, 
34.19, 34.17, 32.18, 32.14, 20.41; HRMS (ES
+
) calcd. for C27H31O2 ([M + H]
+
) 
387.23186, found 387.23155. 
 
General procedure for the hydrolysis of retinoid esters 14 – 19 with LiOH. To a 
large, screw top vial equipped with a stirred bar was added a solution of the retinoid 
methyl ester in 5:1 THF/H2O (6 mL) and LiOH monohydrate (3.0 equiv. w.r.t, retinoid 
ester). The mixture was stirred at room temperature until analysis via tlc showed the 
reaction to be complete (3 days). Et2O (30 mL) was added and the mixture was washed 
with dilute HCl(aq.) (30 mL), and H2O (2 x 30 mL). The organic layer was dried with 
MgSO4, filtered and the solvent was removed in vacuo. Recrystallisation from MeCN 
gave the products as white powders. 
 
CO2H
20 
 
3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-phenyl]-acrylic acid 
(20). 
The reaction was performed on a 0.18 mmol scale. 
242 
 
(43 mg, 72%); mp 275-277 
o
C;
 
IR (KBr disc, cm
-1
) 2953, 2920, 1675, 1626, 1420, 1310, 
1181, 1107; m/z (ES
-
) 333 ([M – H]-); 1H NMR (400.13 MHz, DMSO-d6) δ 7.56 (5H, ov, 
m), 7.46 (1H, s), 7.31 (2H, ov, s), 6.38 (1H, d, J = 16.0 Hz), 1.64 (4H, s), 1.27 (6H, s), 
1.24 (6H, s); 
13
C{
1
H} NMR (100.67 MHz, DMSO-d6) δ 166.92, 144.00, 143.33, 142.50, 
141.49, 135.63, 131.81, 127.28, 125.89, 123.53, 122.86, 117.47 two aromatic/vinylic 
carbon resonances are overlapped, 33.70, 33.58, 33.02, 32.80, 30.64, 30.54; anal. calcd. 
for C23H26O2: C 82.60, H 7.84; found: C 81.97, H 8.02. 
 
CO2H
21 
 
3-[4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-phenyl]-acrylic acid 
(21). 
The reaction was performed on a 0.28 mmol scale. 
(66 mg, 69%); mp 235-238 
o
C;
 
m/z (ES
-
) 347 ([M – H]-); 1H NMR (400.13 MHz, DMSO-
d6) δ 7.70 (2H, d, J = 8.0 Hz), 7.60 (1H, d, J = 16.0 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.20 
(1H, s), 7.09 (1H, s), 6.54 (2H, d, J = 16.0 Hz), 2.17 (3H, s), 1.63 (4H, s), 1.25 (6H, s), 
1.22 (6H, s); 
13
C{
1
H} NMR (100.67 MHz, DMSO-d6) δ 168.48, 150.38, 149.63, 144.15, 
142.47, 138.36, 136.57, 134.78, 132.06, 130.02, 128.72, 128.43, 127.66, 35.28 (two 
carbon environments), 34.22, 34.16, 32.21 (two carbon environments), 20.50; anal. calcd. 
for C24H28O2: C 82.72, H 8.10; found: C 82.41, H 8.36. 
 
 
CO2H
22 
 
3-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-phenyl]-acrylic acid 
(22). 
The reaction was performed on a 0.12 mmol scale. 
(24 mg, 62%); mp 207-208 
o
C; m/z (ES
-
) 333 ([M – H]-); 1H NMR (400.13 MHz, 
DMSO-d6) δ 12.20 (1H, br), 7.73 (1H, s), 7.66 (1H, d J = 16.0 Hz), 7.54 (1H, tr J = 7.5 
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Hz), 7.49 (2H, m), 7.41 (1H, tr, J = 7.5 Hz), 7.33 (2H, ov, s), 6.49 (1H, d J = 16.0 Hz), 
1.66 (4H, s), 1.29 (6H, s), 1.25 (6H, s); 
13
C{
1
H} NMR 100.61 MHz, DMSO-d6) δ 166.30, 
143.52, 142.59, 142.49, 140.07, 135.48, 133.34, 127.76, 126.90, 125.47, 125.03, 124.76, 
123.25, 122.67, 117.94, 33.37, 33.22, 32.66, 32.38, 30.28, 30.20; anal. calcd. for 
C23H26O2: C 82.60, H 7.84; found: C 81.97, H 8.02. 
 
CO2H
23 
 
3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-phenyl]-acrylic acid 
(23). 
The reaction was performed on a 0.21 mmol scale. 
(42 mg, 57%); mp 170-172 
o
C; m/z (ES
-
) 347 ([M – H]-); 1H NMR (400.13 MHz, 
DMSO-d6) δ 7.58 (3H, ov, m), 7.44 (1H, t, J = 8.0 Hz), 7.33 (1H, d, J = 8.0 Hz), 7.20 
(1H, s), 7.09 (1H, s), 6.56 (1H, d, J = 16.0 Hz), 2.16 (3H, s), 1.65 (4H, s), 1.25 (6H, s), 
1.24 (6H, s); 
13
C{
1
H} NMR (100.67 MHz, DMSO-d6) δ 168.85, 144.23, 142.85, 142.63, 
138.68, 134.96, 132.34, 131.45, 129.40, 128.83, 127.98, 126.79, 125.66, 125.11 two 
aromatic/vinylic carbon resonances are overlapped, 35.38, 35.34, 34.29. 34.25, 32.30 
(two carbon environments), 20.56; anal. calcd. for C24H28O2: C 82.72, H 8.10; found: C 
82.83, H 7.67. 
OH
O
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5',5',8',8'-Tetramethyl-5',6',7',8'-tetrahydro[2,2']binaphthalenyl-6-carboxylic acid 
(24). 
The reaction was performed on a 0.13 mmol scale. 
(33 mg, 70%); m/z (ES
-
) 357 ([M – H]-); mp 280-282 oC (lit. 287.5-288.5 oC); 1H NMR 
(499.76 MHz, DMSO-d6) δ 13.06 (1H, br, s), 8.62 (1H, s), 8.26 (1H, s), 8.18 (1H, d, J = 
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9.0 Hz), 8.08 (1H, d, J = 9.0 Hz), 7.99 (1H, d, J = 9.0 Hz), 7.91 (1H, d, J = 9.0 Hz), 7.74 
(1H, s), 7.56 (1H, d, J = 8.0 Hz), 7.46 (1H, d, J = 8.0 Hz), 1.69 (4H, s), 1.34 (6H, s), 1.29 
(6H, s); 
13
C{
1
H} NMR (126.67 MHz, DMSO-d6) δ 167.50, 145.13, 144.34, 140.14, 
136.78, 135.40, 131.23, 130.30, 129.89, 128.51, 127.87, 127.24, 126.12, 125.56, 125.08, 
124.72, 124.51, 34.74, 34.55, 34.17, 33.91, 31.69, 31.60; anal. calcd. for C25H26O2: C 
83.76, H 7.31; found: C 83.32, H 7.09. 
OH
O
25 
 
3',5',5',8',8'-Tetramethyl-5',6',7',8'-tetrahydro[2,2']binaphthalenyl-6-carboxylic acid 
(25). 
The reaction was performed on a 0.08 mmol scale. 
(22 mg, 75%); mp 260-263 
o
C (lit.
310
 263-265 
o
C);
 
m/z (ES
-
) 371 ([M – H]-); 1H NMR 
(400 MHz, DMSO-d6) δ 8.64 (1H, s), 8.14 (1H, d, J = 9.0 Hz), 8.04 (1H, d, J = 9.0 Hz), 
7.99 (1H, d, J = 9.0 Hz), 7.92 (1H, s), 7.59 (1H, d, J = 9.0 Hz), 7.24 (1H, s), 7.19 (1H, s), 
2.20 (3H, s), 1.63 (4H, s), 1.27 (6H, s), 1.24 (6H, s); 
13
C{
1
H} NMR (125.67 MHz, 
DMSO-d6) δ 167.56, 143.80, 142.06, 141.61, 138.19, 134.95, 131.87, 130.92, 128.95, 
128.60, 128.29, 127.89, 127.57, 127.30, 125.46, two aromatic peaks are believed to be 
overlapped, 34.71, 34.70, 33.68, 33.62, 31.65 two carbon resonances overlapped, 19.97; 
anal. calcd. for C26H28O2: C 83.83, H 7.58; found: C 83.39, H, 7.55.  
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Mild and selective formation of vinylboronate esters via the 
Rh-catalysed dehydrogenative borylation of alkenes 
 
4.1 Introduction 
 
Vinyl boronate esters (VBEs)
311
 are useful intermediates in organic chemistry, having 
been employed as precursors to aldehydes and vinyl halides, and can undergo transition 
metal-catalysed additions to a range of electrophiles. VBEs can be synthesised by a 
variety of methods including: (a) lithiation of vinyl halides and subsequent trapping with 
trialkylborates,
312
 (b) palladium-catalysed borylation of vinyl halides,
313
 (c) 
transmetallation of vinyl metal reagents,
314
 (d) hydrozirconation of 1-borylalkynes,
315
 (e) 
cross-metathesis of terminal alkenes with pinacolvinylboronate,
316
 (f) hydrogenation of 1-
borylalkynes,
317
 (g) transfer of a boryl group between two alkenes,
318
 (h) hydroboration 
of alkynes,
319
 and (i) transition metal-catalysed diboration of alkynes with diboron 
reagents.
320
 However, the majority of these methods involve the preactivation of the vinyl 
group (a-f) or are unsuitable for the synthesis of β,β-disubstituted vinylboronates (h-i). 
Thus, the dehydrogenative borylation of alkenes
321
 (Scheme 4.1), in which a vinyl C-H 
bond is replaced by a C-B bond, is an attractive alternative to these methods as it does not 
require the preactivation of the substrate, and is suitable for the synthesis of VBEs from 
β,β-disubstituted alkenes.  
 
 catalyst
 HB(OR)2 / B2(OR)4
R1
R2
H
R1
R2
B(OR)2 + H2 or HB(OR)2
R3 R3  
Scheme 4.1 Catalytic dehydrogenative borylation of alkenes.  
 
The formation of VBE products has been observed as a side reaction in 
rhodium-catalysed diborations
321a
 and hydroborations of alkenes.
321b,c
 Combinations of 
phosphine free Rh(I)
321d-g
 catalysts and boranes have been shown to give 1:1 mixtures of 
VBEs and hydrogenation products while Ru catalysts
321g,n,o
 (not phosphine free) give 
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mixtures of VBEs and products resulting from hydroboration and hydrogenation. 
Significant amounts of VBE products were observed in the Rh(PPh3)3Cl-catalysed 
reactions of 1,1-disubstituted alkenes and catecholborane.
321b,c 
In the majority of cases it 
has been demonstrated, or is believed, that the reaction occurs through 1,2-insertion of 
the alkene substrate, followed by β-hydride elimination to give the VBE product.321a-t 
Alternatively, VBE formation can occur by the direct oxidative addition of a vinylic C-H 
bond, followed by C-B reductive elimination.
321u,v
 For the majority of dehydrogenative 
borylation reactions, the concomitant hydrogenation and/or hydroboration of the substrate 
leads to the formation of unwanted by-products and remains a major obstacle to the 
realisation of effective dehydrogenative borylations of unactivated alkenes. In 2003, it 
was reported that trans-[Rh(PPh3)2(CO)Cl] (1) catalyses the dehydrogenative borylation 
of a range of vinylarenes,
321k,l
 to give E-VBEs  with high levels of chemo-, and 
stereoselectivity and a dehydrogenative borylation reaction catalysed by 1 has recently 
been utilised as a key step in the stereoselective synthesis of TTNPB retinoids.
322 
However, dehydrogenative borylations involving 1 require temperatures of 80 
o
C and 
prolonged reaction times in order to give acceptable conversions. Also, the nature of the 
catalytic cycle and active species were not determined for reactions involving 1. Thus, in 
order to realize an efficient synthesis of VBEs from unactivated alkenes, there is a need 
for catalysts which are stable and display high activities under mild conditions. In 
addition, elucidation of the catalytic cycle would give information on the factors 
determining the activity of the catalysts and allow for the future development of more 
efficient catalysts for this reaction. 
 
 4.2 Results and discussion 
 
Although reactions of rhodium(I) phosphine complexes with boranes and diboron 
reagents have been studied extensively,
323
 the Rh-boryl complex postulated to be the 
active catalyst in reactions involving 1 has not been identified. Whereas trans-
[Ir(PPh3)2(CO)Cl] oxidatively adds HBcat (cat = 1,2-O2C6H4),
324
 no reaction was 
observed between the rhodium analogue 1 and either B2pin2 or B2cat2.
323d 
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In light of the acceleration, in the presence of basic additives, of the transmetallation of 
diboron, and organoboron reagents to transition metal centers
325,326,327,328,329
 the 
borylation of 2-phenylpropene with B2pin2 catalysed by 1 in the presence of oxygen 
containing bases (1.1 equiv w.r.t, Rh) was investigated (Table 4.1). Reactions were 
performed in 3:1 C6D6/CD3CN, a solvent combination which was previously shown to be 
especially effective for 1-catalysed dehydrogenative borylations.
321k,l 
 
Table 4.1 Dehydrogenative borylations of 2-phenylpropene with B2pin2 in the presence 
of bases 
Ph Ph
B
O
O
1 equiv B2pin2
5 mol % trans-[Rh(PPh3)2(CO)Cl] (1)
5.5 mol % base
3:1 C6D6/CD3CN, 18 h, N2
H
 
Entry base temp 
o
C conversion %
a 
1 none 20 5 
2 none 45 43 
3 KO(t)Bu 45 65 
4 KOAc 45 43 
5 KOH 45 77 
6 KOH 20 28 
Reactions were analysed after 18 h by in situ 
1
H NMR and GC-MS. 
a
Conversions were determined by 
comparison of the integrals of the resonances of the vinylic protons of 2-phenylpropene and the E-VBE 
product by 
1
H NMR. Product identities and conversions were confirmed by GC-MS analysis. 
 
 
Reactions performed in the presence of KOH and KO(t)Bu showed enhanced activity 
(w.r.t, 1 alone), with KOH found to be the most effective. In addition, the reaction with 1 
and 5.5 mol % KOH gave 28% conversion to the VBE product after 18 h at room 
temperature, whereas the use of 1 without additional base showed very low activity (ca. 1 
turnover). Reasoning that the additive reacts with 1 to form a Rh-OR species in situ, 
although other pathways are possible,
329c,330
 a range of Rh(I) complexes bearing different 
anionic and neutral ligands (Table 4.2) were screened as catalyst precursors for the 
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dehydrogenative borylation of 2-phenylpropene with B2pin2 in a 3:1 mixture of 
C6D6/CD3CN.
321k,l 
The activity of 6, the well known hydroformylation catalyst,
331
 was 
also examined.  
 
Table 4.2 Rh-catalysed dehydrogenative borylations of 2-phenylpropene with B2pin2 
after 18h.  
Rh
OC
Ph3P O
PPh3
O
H Ph3P Rh
PPh3
PPh3
H
CO
Rh
OC
Ph3P O
PPh3
O
Ph
Rh
OC
Ph3P Cl
PPh3
Rh
OC
P Cl
PtBu3
Rh
OC
Ph3P CltBu3
N
N
Mes
Mes1 2 3
4 5 6
Ph
Ph
B
O
O
1 equiv B2pin2
5 mol % Rh-complex 1 - 6
3:1 C6D6/CD3CN, N2
H
 
entry Rh-complex temp 
o
C conversion %
a 
1 1 20 5 
2 1 45 43 
3 1 80 71 
4 2 20 8 
5 2 45 23 
6 2 80 89 
7 3
b 
20 1 
8 3
b
 45 12 
9 3
b
 80 36 
10 4 20 11 
11 4 45 57 
12 4 80 88 
13 5 20 10 
14 5 45 51 
14 5 80 84 
16 6 20 32 
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17 6 45 48 
18 6 80 87 
Reactions were analysed after 18 hours by in situ 
1
H NMR and GC-MS.
  a
Conversions were determined 
by comparison of the integrals of the vinylic protons signals of 2-phenylpropene and the E-VBE 
products by 
1
H NMR. 
b
Conversion determined by comparison of the integrals of 2-phenylpropene, 
B2pin2 and VBE product peaks in the GC (TIC) trace.  
 
All of the Rh(I) complexes examined catalysed the dehydrogenative borylation reaction, 
with VBE products formed with high selectivity. At 80 
o
C, the complexes 1, 2, 4, 5 and 6 
gave similar results, within experimental error. At lower temperatures, the effect of 
exchanging chloride for hydride or oxy-anions was more pronounced, with complexes 4, 
5, and 6 exhibiting increased catalytic activity in comparison to Rh-Cl complexes 1, 2 
and 3, suggesting that the ease of the initial transmetallation (Rh-X + B-B → Rh-B + B-
X) process may be important for high catalytic activity by increasing the rate of catalyst 
initiation.  
 
The activity of 6 was further examined (Table 4.3) for a range of substrates including 
monosubstituted alkenes (Entries 1-4), 1,1-disubstituted alkenes (Entries 5-8) and cyclic 
alkenes (Entries 9-12). Monosubstituted substrates were borylated at 45 
o
C in order to 
reduce the formation of products resulting from further borylation of the VBE products, a 
process which yields saturated or unsaturated bis-boronates or even tris-
boronates,
320a,320k,320l,332
 while the less reactive 1,1-, and 1,2-disubstituted alkenes were 
borylated at 80 
o
C. 
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Table 4.3 Dehydrogenative borylation of alkenes with B2pin2 catalysed by 6 
R2
R1
R2
R1
B
O
O
1 equiv B2pin2, 5 mol % 6
3:1 C6D6/CD3CN
18 h, N2
H
R3 R3
 
Entry substrate temp 
o
C
 
Yield 
% 
Isolated VBE 
product 
HB 
%
a
 
VBE  
%
a
 
VBBE 
%
a
 
1 
Ph  
45 31 Ph
Bpin
7a 10 53 36 
2 p-MeO-C6H4
 
45 28 
Ar
Bpin
7b 
27 60 13 
3 Hex  45 n.d. - 35 11
 
51 
4 p-MeO-C6H4
 
45 n.d. - 6 26 18
 
5 
Ph  
80 85
b 
Ph
Bpin
7c 
0 84 0 
6 
 
80 92
b 
Bpin7d 
trace 73 0 
7 
 
80 73 Bpin7e 
trace >98 0 
8 
Ph
Ph
 
80 89
b 
Ph
Ph
Bpin
7f 
0 84 0 
9 
 
80 n.d. - 0 trace 0 
10 
 
80 n.d. - 0 trace 0 
11  80 n.d. 
Bpin
7g 
trace 30 0 
 Reactions were carried out with 5 mol % 6 and 1 equiv of B2pin2 in 3:1 C6D6/CD3CN at 45 
o
C or 80 
o
C, 
and analysed by in situ 
1
H NMR and GC-MS after 18 hours. 
a
% conversion to each product type at 18 h. 
HB = hydroboration. VBBE = vinyl-bis-boronate ester. For entries 1, 2 and 7, isolated yields are for the 
VBE product after 18 h reaction. 
b
For 5, 6 and 8, isolated yields are for the VBE product after 42 h 
reaction, i.e. when the reaction is complete, rather than after 18 h. n.d. = not determined.  
253 
 
Borylations of styrene and 4-vinylanisole (entries 1 and 2) were found to be rapid, with 
full consumption of both the alkene and B2pin2 observed after 18 hours. VBE products 
were formed with moderate selectivities, along with significant amounts of vinyl bis-
boronate ester (VBBE) products, resulting from the further dehydrogenative borylation of 
the VBE products. The borylation of 1-octene led to full consumption of the substrate 
after 18 h giving a complex mixture of hydroboration, VBE and VBBE products (due to 
double bond migration in either, or both, the substrate or products), with VBBEs being 
the major product type. 4-Allylanisole gave a single VBE product along with a mixture of 
isomeric hydroboration and VBBE products. In contrast, reactions of 1,1-disubstituted 
alkenes were more selective, giving VBEs and only trace amounts of hydroboration 
products. This high degree of chemo-, and stereoselectivity is in contrast to Heck 
reactions of 1,1-disubstituted alkenes
333
 such as 2-phenylpropene which typically give 
mixtures of allylic and vinylic products with poor E/Z selectivities. In both cases, 
borylation of 1,1-dialkyl-substituted alkenes (entries 6 and 7) led to the selective 
formation of the exocyclic VBE product, over the endocyclic allylboronate ester. For 
indene, previously found to be extremely unreactive,
321k,l
 30% conversion to the 
synthetically useful 2-borylated product 7g (vida infra) was observed after 18 h. This 
compares to 19% conversion after 148 h using 1 as a catalyst precursor.
321l
 In the 
reactions of cyclohexene and cyclooctene, only trace amounts of VBE products were 
observed after 18 h. The low reactivity of cyclic substrates
321m
 may result from the 
difficulty of achieving planarity between the β-hydride and rhodium moieties leading to 
an unfavourable β-hydride elimination process or the poor binding of cyclohexene and 
cyclooctene to rhodium. 
 
The use of 3:1 toluene/MeCN or C6D6/CD3CN was previously found to be highly 
effective at minimizing side product formation in the dehydrogenative borylation of 4-
vinyl anisole with 1, however, MeCN retards the rate of the reaction.
321k
 In light of the 
high selectivities exhibited in the borylations of 1,1-disubstituted substrates, the 
borylation of 2-phenylpropene with B2pin2 and 5 mol % 6 at 45 
o
C in different solvents 
(Table 4.4) was examined. 
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Table 4.4  Dehydrogenative borylation of 2-phenylpropene in different solvents 
Ph Ph
B
O
O
1 equiv B2pin2, 5 mol % 6
45 oC, N2
H
 
entry solvent  % VBE at 4 h 
1 Hexane 57 
2 Toluene 61 
3 Benzene 57 
4 MTBE 70 
5 THF 15 
6 3:1 benzene/MeCN 22 
Reactions were carried out with 5 mol % 6 and 1 equiv of B2pin2 at 45 
o
C, and analysed periodically by 
1
H NMR and GC-MS. % conversions were determined by comparisons of the integrals of NMR 
resonances corresponding to 2-phenylpropene and the E-VBE product. Product identities and 
conversions were confirmed by comparison with the substrate and VBE peaks in the GC/MS (TIC) 
trace. 
 
Reactions performed in non-coordinating solvents showed increased rate w.r.t, the use of 
3:1 C6D6/CD3CN. MTBE (Me-O-(t)Bu) was found to be the most effective solvent 
followed by hexane, toluene and benzene. In contrast to MBTE, reactions performed in 
the more strongly coordinating ether, THF, showed the lowest activity. 
It has recently shown that MTBE is an excellent solvent for a one-pot, single solvent 
process involving Ir-catalysed arene or heteroarene C-H borylation
334,335
 followed by 
Suzuki-Miyaura cross-coupling. The high activity displayed by 6 in MTBE led us to 
explore a one-pot, single solvent dehydrogenative borylation/Suzuki-Miyaura 
cross-coupling sequence for the direct functionalisation of indene. 2-Arylindenes are 
highly desirable products due to their use as ligands in organometallic chemistry, 
especially in the Zr-catalysed polymerization of propene,
336
 but current methods for their 
synthesis are limited by side reactions related to the high basicity of the arylmetal 
reagents used,
337
 the need for preactivation of the 2-position,
338
 or a lack of selectivity for 
2-functionalisation.
339
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H B
O
O
R
8a R = CO2Me, 78%
a
8b R = F, 83%a
a c
a. 1 equiv B2pin2, 5 mol % 6, MTBE, 80 
oC, 42 h
b. 1 equiv B2pin2, 1.5 mol % [Ir(OMe)COD]2, 3 mol % dtbpy MTBE, 45 
oC, 18 h
c. 0.85 equiv p-I-C6H4-R, 3 mol % Pd(dppf)Cl2
.DCM, 2 equiv. K3PO4
.2H2O, H2O (20% v/v), 80 
oC
a Isolated yields; b Conversions by 1H NMR spectroscopy
H B
O
Oa
7g 70%a
H B
O
Ob
34%b
H
H
B
O
O
58%b
 
 
Equation 4.1 Borylation of indene and synthesis of 2-arylindenes via one-pot, single 
solvent C-H borylation/Suzuki-Miyaura cross-coupling. 
 
Ir-catalysed borylation
335
 with 1.5 mol % [Ir(μ-OMe)COD]2 / 3 mol % 4,4‟-di-tert-2,2‟-
bipyridine as catalyst was investigated, and found to give a mixture of products resulting 
from vinylic C-H borylation at the 2-position and aromatic C-H borylation at the 5- and 
6-positions. In contrast, borylation of indene with 5 mol % 6 and B2pin2 in MTBE at 80 
o
C led to full conversion to 7g after 42 h. After addition of Ar-I, Pd(dppf)Cl2·CH2Cl2, 
K3PO4·2H2O and H2O to the completed Rh-catalysed  reactions, heating (80 
o
C) gave the 
2-arylindene products in good yields (Equation 4.1) offering an efficient alternative 
route to these products. 
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4.3 Investigations into the mechanism of the dehydrogenative borylation 
reaction 
 
Borylations of 2-phenylpropene with 1 equivalent of B2pin2 and 20 mol % of 4 or 6 as the 
catalyst precursor were performed in 3:1 C6D6/CD3CN at 20 
o
C and analysed by in situ 
1
H, 
31
P{
1
H} and 
11
B NMR spectroscopy after 6 hours. 
 
 
Figure 4.1 162 MHz 
31
P{
1
H} NMR spectrum of the borylation of 2-phenylpropene with 20 mol % of 6 in 
3:1 C6D6/CD3CN after 6 h at 20 
o
C. 
 
For the use of 6 as the catalyst precursor, in situ 
31
P{
1
H} NMR spectroscopy showed 6 to 
be the main phosphine containing species present (Figure 1), along with a doublet at 37.8 
ppm (JRh-P = 196 Hz) corresponding to the known dimer [Rh(-CO)(PPh3)2]2 9
340,341 
and a 
small, broad peak at 30.5 ppm. 
 
Ph3P Rh
PPh3
PPh3
H
CO
JRh-P = 154 Hz
6
[Rh(PPh3)2(-CO)]2 9
JRh-P = 196 Hz
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Figure 4.2 162 MHz 
31
P{
1
H} NMR spectrum of the borylation of 2-phenylpropene with 20 mol % of 4 in 
3:1 C6D6/CD3CN after 6 h at 20 
o
C. 
 
In contrast, in situ 
31
P{
1
H} NMR spectra
 
of the same reaction with 4 instead of 6 did not 
display the doublet corresponding to 4. Peaks corresponding to 6 and 9 were observed, as 
well as a broad peak at 31.5 ppm (Figure 4.2). Although 6 can be synthesised from 4 in 
the presence of PPh3,
342
 solutions of 4 in C6D6/MeCN showed no formation of 6 after 18 
hours at room temperature, suggesting that 6 is formed from 4 via a process involving 
B2pin2 and 2-phenylpropene. 
 
Reactions of 4 and 6 with stoichiometric amounts of B2pin2 in 3:1 C6D6/CD3CN at 20 
o
C 
resulted in the formation of HCOO-Bpin and HBpin, respectively, as observed by 
11
B 
NMR spectroscopy, suggesting that transmetallation had occurred. It is possible that 
HBpin and HCOO-Bpin are formed via oxidative addition of the B-B bond, followed by 
rapid reductive elimination; however, the lack of reactivity displayed by 1 under the same 
conditions (vide supra) suggests otherwise. It should be noted that no 
11
B NMR signal 
corresponding to any Rh-boryl species was observed in the 
11
B NMR spectra. Marder, 
Norman et al. have reported that they were unable to observe a resonance for the boryl 
group of [Rh(dppe)2(Bcat)] in the 
11
B NMR spectrum, presumably because it is 
extremely broad.
323d
 In situ 
31
P{
1
H} NMR spectra of the reaction of 4 or 6 with B2pin2 
Ph3P Rh
PPh3
PPh3
H
CO
JRh-P = 154 Hz
6
[Rh(PPh3)2(-CO)]2 9
JRh-P = 196 Hz
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did not reveal any resonances which could be attributed to the expected Rh(I) monoboryl 
complex trans-[Rh(PPh3)2(CO)Bpin]. Instead, a new 
31
P signal at 37.8 ppm (JRh-P = 196 
Hz) was observed, corresponding to [Rh(-CO)(PPh3)2]2 9 (Scheme 4.2) and its intensity 
was found to increase with time. 
 
To investigate whether the rhodium boryl complex was consumed via reaction with the 
arene solvent, solutions of 4 and 6 with 10 equivalents of B2pin2 were stirred in benzene 
at room temperature and were then analysed by 
31
P{
1
H} NMR spectroscopy and in situ 
GC-MS. Reactions of 6 were found to contain small amounts of 9 as well as residual 6 as 
the major phosphorus-containing species, while reactions of 4 resulted in its complete 
consumption within 4 hours, with 9 being the major phosphorus-containing species 
observed by 
31
P{
1
H} NMR spectroscopy. Analysis of the reaction mixtures by in situ 
GC-MS showed the formation of substoichiometric amounts of C6H5-Bpin. However, 
performing the reactions in C6D6 did not lead to the formation of C6D5-Bpin, nor did 
analogous reactions in toluene give tolyl-Bpin. Instead C6H5-Bpin was formed in all 
cases, indicating that the source of the C6H5 fragment is not the solvent, but most likely 
the PPh3 ligands which may be undergoing P-C bond cleavage. However, due to the 
small amounts of arylboronate ester products observed, any further mechanistic 
speculation is unwarranted at present. 
As borylation of the solvent was not observed, it is proposed that the rhodium boryl 
species, in the absence of substrate, is consumed by reaction with unreacted 4 or 6 to 
yield additional HCOO-Bpin or HBpin, respectively, and 9 (Scheme 4.2). Such 
bimolecular reductive elimination processes have been previously observed in the 
reaction of trans-[Rh(PPh3)2(CO)(p-C6H4Me)] with 6 to give toluene and 9.
340 
 
Rh
Ph3P
OC PPh3
Bpin
Rh
Ph3P
Ph3P
O
C
O
C
Rh
PPh3
PPh3
 9
4
- HCOOBpin
Rh
Ph3P
OC PPh3
O
O H
B2pin2
- HCOOBpin
4   
 
Scheme 4.2 Proposed formation of 9 from 4. 
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As previously noted, 9 and 6 are observed by 
31
P{
1
H} NMR in borylations of 
2-phenylpropene with B2pin2 using 4, 5 and 6 as catalyst precursors. For reactions with 4 
and 5, these catalyst precursors are not observed by in situ 
31
P{
1
H} NMR during the 
reaction. However, for reactions with 6, 6 is observed as the major species. In order to 
assess whether 6 or 9 might be the catalytically active species, a solution of 9 was 
prepared by reacting 4 with 10 equivalents of B2pin2 in C6D6 at room temperature. Full 
consumption of the starting material was observed after 4 hours. Addition of HBpin (10 
equiv) and stirring for 18 h at 20 
o
C
 
generated the rhodium hydride complex 6, along with 
an unidentified product (a broad peak at 30.5 ppm). Addition of 2-phenylpropene (10 
equiv) to a solution of 9 and B2pin2 led to the formation of the VBE product with 50% 
conversion after 18 hours at 20 
o
C. Analysis by in situ 
11
B NMR spectroscopy showed 
that HBpin had been formed, while the 
31
P{
1
H} NMR spectrum of the reaction mixture 
showed the presence of 6, as well as 9.  This suggests that 9 is not an inactive side product 
of catalyst breakdown, but is able to react with B2pin2 and HBpin to give species capable 
of catalysing the dehydrogenative borylation of alkenes.  
 
Rh
Ph3P
Ph3P
O
C
O
C
Rh
PPh3
PPh3
9
10 equiv HBpin
C6D6, 18 h, 20 
oC
Ph3P Rh
PPh3
PPh3
H
CO 6
unidentified
products
+
1 equiv B2pin2
10 mol % 9
C6D6, 18 h, 20 
oC
B
O
O
50% conversion  
Scheme 4.3 Reactions of 9. 
 
Compound 9 has been reported to undergo bimetallic oxidative addition of H2 in the 
presence of excess PPh3 to give 2 equivalents of HRh(PPh3)3CO 6, to undergo oxidative 
cleavage in the presence of I2
343
 and to mediate the reductive coupling of alkyl halides to 
give trans-[Rh(PPh3)2(CO)X] and the dialkyl coupling products.
344
 In addition, the 
bimetallic oxidative addition of B2cat2 to an isoelectronic bimetallic Ni
I
 complex has 
recently been reported by Mindiola and coworkers (Scheme 4.4).
345
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iPr2P
iPr2P
Ni Ni
PiPr2
PiPr2
N
N
N Ni
PiPr2
PiPr2
Bcat
B2cat2 2
 
Scheme 4.4 Bimetallic oxidative addition of B2cat2 to a dimeric Ni
I
 complex. 
 
Analysis of a control experiment (in which the borylation of 2-phenylpropene with B2pin2 
in C6D6 at 20 
o
C was catalysed by 10 mol % 6) by in situ GC-MS and 
31
P{
1
H} NMR 
spectroscopy showed 6 to be the major phosphine containing species present after 18 
hours, with small amounts of 9 observed. Both the conversions and product selectivities 
for the reactions catalysed by 10 mol % 6 and 5 mol % 9 are similar, suggesting that both 
6 and 9 give rise to the same catalytically active species.  
 
Based on the above observations, a catalytic cycle is proposed for the dehydrogenative 
borylation of alkenes catalysed by Rh(PPh3)n(CO)X catalyst precursors (Scheme 4.5).  
 
Transmetallation of trans-[Rh(PPh3)2(CO)X] with B2pin2 would give the Rh(I) boryl 
complex  trans-[Rh(PPh3)2(CO)Bpin]. This is much more efficient when X = OR or 
O(C=O)R than when X = Cl, as is established for other metal centres.
325-329
 The same 
rhodium compound could also be formed from HRh(PPh3)3CO via the initial dissociation 
of PPh3 and subsequent reaction with B2pin2, forming HBpin as the byproduct. Reaction 
of trans-[Rh(PPh3)2(CO)Bpin] with trans-[Rh(PPh3)2(CO)X] or trans-[Rh(PPh3)2(CO)H] 
would give XBpin or HBpin, respectively, along with [Rh(μ-CO)(PPh3)2]2 9. Dissociation 
of PPh3 from trans-[Rh(PPh3)2(CO)Bpin], followed by binding and 1,2 insertion of the 
alkene substrate into the rhodium-boron bond would give a coordinatively unsaturated 
tertiary alkyl-rhodium complex. Subsequent diastereoselective β-hydride elimination321o 
and coordination of PPh3 would release the VBE product and regenerate 
[Rh(PPh3)2(CO)H], completing the catalytic cycle. In contrast to Rh(PPh3)3Cl-catalysed 
additions of HB(OR)2/B2(OR)2 to alkenes and alkynes,
321a,346
 the proposed catalytic cycle 
does not involve  oxidative addition of HB(OR)2/B2(OR)2 to Rh(I), due to the strongly 
electron-withdrawing effects of the carbonyl ligand. 
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PPh3
1, 4, 5, etc.
1, 4, 5 etc.
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Scheme
 
4.5 Proposed catalytic cycle for the Rh(PPh3)n(CO)X/H-catalysed dehydrogenative borylation of 
alkenes with B2pin2. 
 
4.4 Conclusions 
 
The use of the commercially available hydroformylation catalyst HRh(PPh3)3CO 6 allows 
for the mild, stereoselective C-H borylation of alkenes to give (E)-VBE products in one 
step and has been utilised in the one-pot synthesis of 2-arylindenes from the parent 
hydrocarbon. This represents the first catalytic dehydrogenative borylation of unactivated 
alkenes which proceeds under mild conditions without the formation of large amounts of 
unwanted hydrogenation and hydroboration products. Combined multinuclear NMR and 
GC-MS studies of stoichiometric and catalytic reactions have identified two viable 
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catalyst resting states. A catalytic cycle is proposed, in which the active rhodium-boryl 
complex is formed via transmetallation of rhodium hydride or carboxylate with the 
diboron reagent rather than oxidative addition of the B-B bond and subsequent reductive 
elimination of B-X. Further applications of this reaction are under investigation.  
 
4.5 Experimental 
 
All reactions were carried out under a dry nitrogen atmosphere using standard Schlenk 
techniques or in an Innovative Technology Inc. System 1 double-length glove box. 
Glassware was oven dried before transfer into the glove box. Hexane was dried over 
sodium / benzophenone and acetonitrile and benzene were dried over CaH2 and both were 
distilled under nitrogen. The solvents H2O and anhydrous MTBE were degassed by 3 
freeze-pump-thaw-cycles. Toluene was dried and deoxygenated by passage through 
columns of activated alumina and BASF-R311 catalyst under Ar pressure using a locally 
modified version of the Innovative Technology Inc. SPS-400 solvent purification system. 
THF was dried by passage through columns of activated alumina under Ar pressure using 
the same system and then degassed by 3 freeze-pump-thaw-cycles. 
Trans-[Rh(PPh3)2(CO)Cl] 1,
347 
trans-[Rh(Pt-Bu3)2(CO)Cl] 2,
348
 
trans-[Rh(PPh3)2(CO)OOCH] 4,
349
 HRh(PPh3)3CO 6,
350
 were synthesised by literature 
procedures. Trans-[Rh(PPh3)(iMes)(CO)Cl]
351
 3 was a gift from Prof Antonio M. 
Echavarren, Fundaciό Privida Institut Català D‟investigaciό Química (ICIQ). B2pin2 was 
supplied as a gift by AllyChem Co. Ltd., Frontier Scientific Inc. and NetChem Inc. 
Hydrochloric acid was obtained from Fisher Scientific and all other compounds were 
obtained from Aldrich Chemical Company, tested for purity by 
1
H NMR and GC-MS, 
degassed and used without further purification. NMR spectra were recorded at ambient 
temperature on Varian Inova 500 (
1
H, 
13
C{
1
H}), Varian C500 (
1
H, 
13
C{
1
H}, 
31
P{
1
H}, 
19
F), Bruker 400 Ultrashield (
1
H, 
13
C{
1
H},
11
B and 
11
B{
1
H}) instruments. Proton and 
carbon spectra were referenced to external SiMe4 via residual protons in the deuterated 
solvents or solvent resonances, respectively. 
11
B NMR spectra were referenced to 
external BF3∙OEt3. Elemental analyses were conducted in the Department of Chemistry at 
Durham University using an Exeter Analytical Inc. CE-440 Elemental Analyser. GC-MS 
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analyses were performed on an Agilent 6890 Plus GC equipped with a 5973N MSD and 
an Anatune Focus robotic liquid handling system / autosampler. A fused silica capillary 
column (10 m or 12 m, cross-linked 5% phenylmethylsilicone) was used, and the oven 
temperature was ramped from 50 
o
C to 280 
o
C at a rate of 20 
o
C/min. UHP grade helium 
was used as the carrier gas. The screw-cap autosampler vials used were supplied by 
Thermoquest Inc. and were fitted with Teflon / silicone / Teflon septa and 0.2 mL micro 
inserts.  
 
Unless otherwise specified the vinylboronate ester products were synthesised via the 
following methods. 
 
Method A: synthesis of VBEs via Rh-catalysed dehydrogenative borylation. In dry, 
N2-filled glovebox, a solution of alkene, B2pin2 (1.0 equiv) and HRh(PPh3)3CO 6 (5 mol 
%) in 3:1 C6D6/CD3CN was added to a thick-walled glass tube which was then sealed. 
The mixture was heated at the appropriate temperature and monitored by in situ 
1
H NMR 
and GC-MS. Reactions were performed on a 0.2 mmol scale in 1 mL of solvent or on a 
0.4 mmol scale in 2 mL of solvent. Unless otherwise specified, the products were purified 
in the following manner. The solvent was removed in vacuo and the residue was 
dissolved in 3:2 hexanes/CH2Cl2 and passed through a silica plug. The solvent was 
removed in vacuo to give a crude product that was purified via silica gel chromatography 
(hexanes to 1:1 CH2Cl2/hexanes, gradient elution). 
 
Method B: synthesis of VBEs via Ir-catalysed dehydrogenative borylation. In dry, 
N2-filled glovebox, alkene (0.5 mmol) was added to a premixed solution of 
[Ir(OMe)COD]2 (1.5 mol %, 5.0 mg, 7.5 µmol), dtbpy (3 mol %, 4.0 mg, 1.5 µmol mol) 
and B2pin2 (1.0 equiv 127 mg, 0.5 mmol) in MTBE (1.2 mL). Additional MTBE (1 mL) 
was added, and the solution was transferred to a thick-walled glass tube which was then 
sealed. The mixture was heated at the appropriate temperature and monitored by in situ 
1
H NMR and GC-MS. The solvent was removed in vacuo and the residue was dissolved 
in 3:2 hexanes/CH2Cl2 and passed through a silica plug. The solvent was removed in 
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vacuo to give a crude product that was purified via silica gel chromatography (hexanes to 
1:1 CH2Cl2/hexanes, gradient elution). 
 
Synthesis of 4,4,5,5-tetramethyl-2-styryl-[1,3,2]dioxaborolane
316b, 321g
 (7a) via 
method A (0.2 mmol scale). The reaction with styrene was heated at 45 
o
C and found to 
be complete within 18 h. Chromatographic purification gave a clear oil (15 mg, 31%); 
1
H 
NMR (400.13 MHz, CDCl3)  7.50 (m, 2H), 7.40 (d, J = 16.0 Hz, 1H), 7.27 (m, 3H), 
6.10 (d, J = 16.0 Hz, 1H), 1.24 (s, 12H); 
13
C{
1
H} NMR (100.59 MHz, CDCl3)  149.65, 
137.64, 129.02, 128.71, 127.20, 83.49, 24.97 (the resonance for the carbon attached to the 
boron atom was not observed); 
11
B NMR (128.38 MHz, CDCl3)  30.13 (s, br); m/z (EI-
MS) 230 (M
+
, 80%), 215 ([M – Me]+, 40%), 130 ([M – MeC(O)CMe3]
+
, 100%. 
 
Synthesis of 2-[2-(4-methoxy-phenyl)-vinyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaboro- 
lane
321g
 (7b) via method A (0.2 mmol scale). The reaction with 4-vinyl anisole was 
heated at 45 
o
C and found to be complete within 18 h. Chromatographic purification gave 
a clear oil (15 mg, 28%); 
1
H NMR (400.13 MHz, CDCl3)  7.43 (d, J = 8.0 Hz, 2H), 7.36 
(d, J = 16.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 2H), 6.04 (d, J = 16.0 Hz 1H), 3.82 (s, 3H), 
1.30 (s, 12H); 
13
C{
1
H} NMR (100.59 MHz, CDCl3)  160.43, 149.18, 130.55, 126.59, 
114.10, 83.33, 55.40, 26.95 (the resonance for the carbon attached to the boron atom was 
not observed); 
11
B NMR (128.38 MHz, CDCl3)  30.34 (s, br); m/z (EI-MS) 260 (M
+
, 
100%), 245 ([M – Me]+, 15%), 160 ([M - MeC(O)CMe3]
+
, 70%. 
 
Synthesis of 4,4,5,5-tetramethyl-2-(2-phenyl-propenyl)-[1,3,2]dioxaborolane
321l
 (7c) 
via method A (0.2 mmol scale). The reaction with 2-phenyl propene was heated at 80 
o
C 
and found to be complete within 42 h. Chromatographic purification gave a clear oil (42 
mg, 85 %); 
1
H NMR (400.13 MHz, CDCl3)  7.49 (m, 2H), 7.28 (m, 3H), 5.76 (s, 1H), 
2.41 (s, 3H), 1.32 (s, 12H); 
13
C{
1
H} NMR (100.59 MHz, CDCl3)  157.93, 143.93, 
128.28, 128.06, 125.95, 83.08, 25.04, 20.24 (the resonance for the carbon attached to the 
boron atom was not observed); 
11
B NMR (128.38 MHz, CDCl3)  30.15 (s, br); m/z (EI-
MS) 244 (M
+
, 90%), 229 ([M – Me]+, 25%), 144 ([M - MeC(O)CMe3]
+
, 100%, HRMS 
for C15H21BO2 calcd: 244.1749, found: 244.1752. 
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Synthesis of 2-(2,2-diphenyl-vinyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
321l, 352
 
(7d) via method A (0.2 mmol scale). The reaction with 2,2-diphenylethene was heated at 
80 
o
C and found to be complete within 42 h. Chromatographic purification gave a clear 
oil (55 mg, 89%); 
1
H NMR (400.13 MHz, CDCl3)  7.33 (m, 4H), 7.28 (m, 6H), 6.00 (s, 
1H), 1.16 (s, 12H); 
13
C{
1
H} NMR (100.59 MHz, CDCl3)  159.91, 143.22, 141.98, 
129.97, 128.16, 128.122, 127.74, 127.67, 83.28, 24.75 (the resonance for the carbon 
attached to the boron atom was not observed); 
11
B NMR (128.38 MHz, CDCl3)  30.20 
(s, br); m/z (EI-MS) 306 (M
+
, 50 %), 291 ([M – Me]+, 10%), 190 ([Ph2CCHB]
+
, 100%. 
 
Synthesis of 2-cyclohexylidenemethyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
316b, 
321l
 (7e) via method A (0.2 mmol scale). The reaction with methylene cyclohexane was 
performed at 80 
o
C and was found to be complete within 42 h. Chromatographic 
purification gave a clear oil (41 mg, 92%); 
1
H NMR (400.13 MHz, CDCl3)  5.00 (s, 
1H), 2.50 (m, 2H) 2.18 (m, 2H) 1.57 (m, 6H), 1.24 (s, 12H); 
13
C{
1
H} NMR (100.59 
MHz, CDCl3)  167.03, 82.65, 40.23, 33.34, 28.83, 28.59, 26.57, 24.96 (the resonance 
for the carbon attached to the boron atom was not observed); 
11
B NMR (128.38 MHz, 
CDCl3)  29.79 (s, br); m/z (EI-MS) 222 (M
+
, 10 %), 207 ([M - Me]
+
, 15%), 165 (][M - 
OCMe2]
+
) (100%), HRMS for C13H23
10
BO2 calcd: 222.1906, found: 222.1899. 
 
Synthesis of 2-cyclopentylidenemethyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
316g, 
321l
 (7f) via method A (0.2 mmol scale). The reaction with methylene cyclopentane was 
performed at 80 
o
C and was found to be complete within 42 h. Chromatographic 
purification gave a clear oil (30 mg, 73%) containing trace amounts of three isomeric 
products (7f2-4) and the hydroboration product (7f5), as determined by GC-MS; 
1
H 
NMR (400 MHz, CDCl3) δ 5.27 (t, J = 4.0 Hz, 1H), 2.52 (t, J = 7.0 Hz, 2H), 2.36 (t, J = 
7.0 Hz, 2H), 1.73 – 1.59 (m, 4H), 1.25 (s, 12H);  13C{1H} NMR (100.59 MHz, CDCl3)  
172.09, 82.68, 37.17, 33.43, 26.97, 26.03, 25.05 (the resonance for the carbon attached to 
the boron atom was not observed); 
11
B NMR (128.38 MHz, CDCl3)  29.74 (s, br); m/z 
(EI-MS) 208 (M
+
, 10 %), 193 ([M - Me]
+
, 15%), 151 (][M - OCMe2]
+
) (100%). 
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Synthesis of 2-(1H-inden-2-yl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
3201l, 337
 (7g) 
via a modification of method A (0.4 mmol scale). The reaction with indene was 
performed in MTBE (2 mL) at 80 
o
C and was found to be complete within 42 h. 
Chromatographic purification gave an off-white solid (67 mg, 70%); mp 67–69 oC (lit28 
73-74 
o
C); 
1
H NMR (400.13 MHz, CDCl3)  7.85 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 7.5 Hz, 
1H), 7.27 (m overlapped, 2H), 7.21 (t, J = 7.5 Hz, 1H), 3.47 (s, 2H), 1.36 (s, 12H); 
13
C{
1
H} NMR (100.59 MHz, CDCl3)  149.14, 146.93, 143.95, 126.32, 124.40, 123.54, 
122.87, 83.64, 40.75, 25.05 (the resonance for the carbon attached to the boron atom was 
not observed); 
11
B NMR (128.38 MHz, CDCl3)  29.47 (s, br); m/z (EI-MS) 242 (M
+
, 80 
%), 227 ([M – Me]+, 20%), 142 ([indenyl-B-O]+, 100%). 
 
Synthesis of 2-(4-fluoro-phenyl)-1H-indene
353
 (8a) (0.4 mmol scale). The synthesis of 
7g was performed as above. Once the consumption of the starting materials had been 
confirmed by GC-MS analysis, the reaction vessel was transferred to a dry, N2 filled 
glovebox and opened. 4-Fluoro-1-iodobenzene (75 mg, 0.34 mmol, 0.85 equiv w.r.t, 7g), 
Pd(dppf)Cl2
.
CH2Cl2 (10 mg, 0.012 mmol), K3PO4∙2H2O (198 mg, 0.8 mmol) and 
degassed H2O (0.5 mL) were added, the vessel was sealed and heated at 80 
o
C
 
until 
analysis by in situ GC-MS showed the reaction to be complete (3 h). The reaction 
mixture was diluted in CH2Cl2 (20 mL) and washed with H2O (3 x 20 mL), the organic 
layer was dried (MgSO4), filtered and the solvent removed in vacuo to give a crude 
product that was purified by silica gel chromatography (hexanes to 1:1 CH2Cl2/hexanes, 
gradient elution) to give the product as a off-white solid (59 mg, 83% w.r.t, aryl iodide); 
mp 155-156 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.64 – 7.56 (m, 2H), 7.47 (d, J = 7.5 Hz, 
1H), 7.40 (d, J = 7.5 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.19 (td, J = 7.5, 1.0 Hz, 1H), 7.16 
(s, 1H), 7.11 – 7.03 (m, 2H), 3.77 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 163.69, 161.23, 
145.45, 143.12, 132.47, 132.43, 127.39, 127.31, 126.84, 126.43, 126.41, 124.94, 123.80, 
121.11, 115.87, 115.65, 77.48, 77.16, 76.84, 39.30; 
19
F NMR (376 MHz, CDCl3) δ -
114.77 to -114.81 (m); m/z (EI-MS) 210 (M
+
, 100%), 191 ([M - F]
+
, 10%). 
 
Synthesis of 4-(1H-inden-2-yl)-benzoic acid methyl ester (8b) (0.4 mmol scale). The 
synthesis of 7g was performed as above. Once the consumption of the starting materials 
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had been confirmed by GC-MS analysis, the reaction vessel was transferred to a dry, N2 
filled glovebox and opened. 4-Iodomethylbenzoate (89 mg, 0.34 mmol, 0.85 equiv w.r.t, 
7g), Pd(dppf)Cl2
.
CH2Cl2 (10 mg, 0.012 mmol), K3PO4∙2H2O (198 mg, 0.8 mmol) and 
degassed H2O (0.5 mL) were added, the vessel was sealed and heated at 80 
o
C
 
until 
analysis by in situ GC-MS showed the reaction to be complete (3 h). The reaction 
mixture was diluted in CH2Cl2 (20 mL) and washed with H2O (3 x 20 mL), the organic 
layer was dried (MgSO4), filtered and the solvent removed in vacuo to give a crude 
product that was purified by silica gel chromatography (hexanes to 1:1 CH2Cl2/hexanes, 
gradient elution) to give the product as a white solid (66 mg, 78% w.r.t, aryl iodide); mp 
191-192 
o
C; IR (solid) 2357, 2327, 2060, 1952, 1711 (vC=O), 1425, 1275, 1175, 1098; 
1
H 
NMR (400.13 MHz, CDCl3)  8.04 (d, J = 9.0 Hz, 2H), 7.69 (d, J = 9.0 Hz, 2H), 7.50 (d, 
J = 7.5 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.36 (s, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.23 (dt, J 
= 7.5, 1.0 Hz, 1H), 3.93 (s, 3H), 3.82 (s, 2H); 
13
C{
1
H} NMR (100.59 MHz, CDCl3)  
167.00, 145.30, 145.04, 143.52, 140.43, 130.18, 129.19, 128.90, 126.95, 125.61, 125.53, 
123.94, 121.64, 52.22, 39.10; m/z (EI-MS) 250 (M
+
, 100%), 219 ([M
+
 - MeO], 35%); 
HRMS for C17H18O2 calcd: 251.1072, found: 251.1066. 
 
Formation of  [Rh(PPh3)2(μ-CO)]2 9 from trans-[Rh(PPh3)2(CO)OOCH] 4 and 
B2pin2. Trans-[Rh(PPh3)2(CO)OOCH] 4 (40 mg, 0.057 mmol) and B2pin2 (145 mg, 0.57 
mmol) were dissolved in C6D6 (1 mL). A colour change from yellow to dark red was 
observed within 5 minutes. Analysis by 
31
P{
1
H} NMR spectroscopy after four hours 
showed the complete consumption of 4 and the formation of 9 (δ 37.75, dd, JRh-P = 196 
Hz, JRh-Rh-P = 12 Hz) along with a broad doublet (δ 30.5 ppm, JRh-P = 120 Hz). Analysis of 
the reaction at 18 hours showed no additional change in the 
31
P{
1
H} NMR spectrum.
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Figure 4.3 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of 4 and B2pin2 (10 equiv) in C6D6 after 4 h at 
20 
o
C. 
 
Figure 4.4 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of 4 and B2pin2 (10 equiv) in C6D6 after 18 h 
at 20 
o
C. 
 
[Rh(PPh3)2(-CO)]2 9
JRh-P = 196 Hz
[Rh(PPh3)2(-CO)]2 9
JRh-P = 196 Hz
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Figure 4.5 128 MHz 
11
B NMR spectrum of the reaction of 4 and B2pin2 (10 equiv.) in C6D6 after 18 h at 20 
o
C. 
 
Formation of [Rh(PPh3)2(μ-CO)]2 9 from HRh(PPh3)3CO 6 and B2pin2. 
HRh(PPh3)3CO 6 (26 mg, 0.03 mmol) and B2pin2 (73 mg, 0.29 mmol) were dissolved in 
C6D6 (0.5 mL). A slow colour change from yellow to dark orange was observed within 
~1 hour. The mixture was analysed after 18 h at 20 
o
C by 
31
P{
1
H} NMR spectroscopy, 
showing partial consumption of 6 and the formation of 9 (δ 37.75, d, JRh-P = 196 Hz).  
Analysis by 
11B NMR spectroscopy showed the formation of HBpin (δ 28.1, d, JH-B = 
173 Hz). 
 
HCOO-Bpin
B2pin2
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Figure 4.6 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of 6 and B2pin2 (10 equiv.) in C6D6 after 18 h 
at 20 
o
C. 
 
Figure 4.7 128 MHz 
11
B NMR spectrum of the reaction of 6 and B2pin2 (10 equiv.) in C6D6 after 18 h at 20 
o
C. 
 
Reaction of 9 with pinacolborane (HBpin). Trans-[Rh(PPh3)2(CO)OOCH] 4 (40 mg, 
0.057 mmol) and B2pin2 (145 mg, 0.57 mmol) were dissolved in C6D6 (1 mL), the 
solution was left for 18 h at 20 
o
C, at which time analysis by 
31
P{
1
H} NMR spectroscopy 
showed the complete conversion of 4 into 9. Pinacolborane (82 μL, 0.57 mmol) was 
JRh-P = 154 Hz
Ph3P Rh
PPh3
PPh3
H
CO
6
[Rh(PPh3)2(-CO)]2 9
JRh-P = 196 Hz
B2pin2
HBpin
JH-B 173 Hz
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added. After 18 hours at 20 
o
C, the mixture was analysed by 
31
P{
1
H} and 
11
B NMR 
spectroscopy. 
 
Figure 4.8 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of HBpin with 9 and B2pin2 in C6D6 after 18 h 
at 20 
o
C. 
 
 
Figure 4.9 128 MHz 
11
B NMR spectrum of the reaction of HBpin with 9 and B2pin2 in C6D6 after 18 h at 
20 
o
C. 
 
JRh-P = 154 Hz
Ph3P Rh
PPh3
PPh3
H
CO
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Dehydrogenative borylation of 2-phenylpropene in the presence of 5 mol % 9. 
Trans-[Rh(PPh3)2(CO)OOCH] 4 (40 mg, 0.057 mmol) and B2pin2 (145 mg, 0.57 mmol) 
were dissolved in C6D6 (1 mL), the solution was left for 18 h at 20 
o
C, at which time 
analysis by 
31
P{
1
H} NMR spectroscopy showed the complete conversion of 4 into 9. 2-
phenylpropene (60 μL, 0.57 mmol) was added. After 18 hours at 20 oC, the mixture was 
analysed by 
31
P{
1
H} and 
11
B NMR spectroscopy and by GC-MS and the reaction was 
found to be 50% complete by GC-MS. 
 
 
Figure 4.10 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of 2-phenylpropene with 9 and B2pin2 in 
C6D6 after 18 h at 20 
o
C. 
 
[Rh(PPh3)2(-CO)]2 9
JRh-P = 196 Hz
Ph3P Rh
PPh3
PPh3
H
CO
JRh-P = 154 Hz
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Figure 4.11 128 MHz 
11
B NMR spectrum of the reaction of 2-phenylpropene with 9 and B2pin2 in C6D6 
after 18 h at 20 
o
C. 
 
2 . 0 0 4 . 0 0 6 . 0 0 8 . 0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 0 0 0 0 0 0
   1 e + 0 7
 1 . 1 e + 0 7
 1 . 2 e + 0 7
 1 . 3 e + 0 7
 1 . 4 e + 0 7
 1 . 5 e + 0 7
 1 . 6 e + 0 7
 1 . 7 e + 0 7
 1 . 8 e + 0 7
T i m e - - >
A b u n d a n c e
T I C :  j h b  3 9 2  2 a 2 . D
 
Figure 4.12 GC (TIC) of the reaction of 2-phenylpropene with 9 and B2pin2 in C6D6 after 18 h at 20 
o
C. 
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Figure 4.13 EI-MS of the peak at 7.3 minutes for the reaction of 2-phenylpropene with 9 and B2pin2 in 
C6D6 after 18 h at 20 
o
C. 
 
The reaction was analysed further by 
31
P{
1
H} and 
11
B NMR spectroscopy after the 
borylation reaction was complete, as determined by in situ 
1
H NMR spectroscopy (3 d). 
The broad peak at 30.5 ppm was now the major phosphorus-containing species present in 
solution, suggesting that in the absence of substrate catalyst breakdown occurs. 
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Figure 4.14 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of 2-phenylpropene with 9 and B2pin2 in 
C6D6 after 3 d at 20 
o
C. 
 
Dehydrogenative borylation of 2-phenylpropene in the presence of 10 mol % 6. A 
solution of HRh(PPh3)3CO 6 (26 mg, 0.029 mmol) and B2pin2 (70 mg, 0.29 mmol) and 2-
phenylpropene (30 μL, 0.29 mmol) in C6D6 (0.5 mL) was prepared. After 18 hours at 20 
o
C, the mixture was analysed by 
31
P{
1
H} and 
11
B NMR spectroscopy and by GC-MS and 
the reaction was found to be 65% complete by GC-MS. 
 
Figure 4.15 162 MHz 
31
P{
1
H} NMR spectrum of the reaction of 2-phenylpropene with 6 and B2pin2 in 
C6D6 after 18 h at 20 
o
C. 
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Figure 4.16 128 MHz 
11
B NMR spectrum of the reaction of 2-phenylpropene with 6 and B2pin2 in C6D6 
after 18 h at 20 
o
C. 
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Figure 4.17 GC (TIC) of the reaction of 2-phenylpropene with 6 and B2pin2 in C6D6 after 18 h at 20 
o
C. 
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Figure 4.18 EI-MS of the peak at 7.3 minutes for the reaction of 2-phenylpropene with 6 and B2pin2 in 
C6D6 after 18 h at 20 
o
C. 
 
 Synthesis of trans-[Rh(PPh3)2(CO)O2CPh] 5 and related data. The compound was 
synthesised by the method of Robinson et al.
354
 In a dry, N2 filled glovebox 
HRh(PPh3)3CO (200 mg, 0.21 mmol) and benzoic acid (500 mg, 4.1 mmol) were added 
to a thick walled glass tube fitted with a Young‟s tap. Degassed ethanol (10 mL) was 
added, the vessel was sealed and heated under reflux for 30 mins. The mixture was 
cooled and the precipitate was filtered under N2. The crude solid was recrystallised from 
EtOH/DCM at -20 
o
C and dried in vacuo to give the product as a bright yellow solid; 
yield 107 mg, 62%; 
1
H NMR (400 MHz, C6D6) δ 7.95 (m, 14H), 7.00 (m, 21H); 
31
P{
1
H} 
NMR (162 MHz, C6D6) δ 32.91 (d, JRh-P = 136 Hz); IR (solid) 1958 (CO), 1816 
(asymOCO), 1352 (symOCO); elemental anal. Calcd for C44H35O3P2Rh·CH3OH: C, 
66.84; H, 4.86, found C, 65.71; H, 4.47. 
 
 
Bpin
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Figure 4.19 400 MHz 
1
H NMR spectrum of compound 5 in C6D6. 
 
 
Figure 4.20 162 MHz 
31
P{
1
H} NMR spectrum of compound 5 in C6D6. 
 
Triclinic single crystals (Pī) of compound 5 were grown from a solution in a 1:1 mixture 
of MeOH/DCM at -20 
o
C. Compound 5 was characterised by a single-crystal X-ray 
structure determination.
355
  
Rh
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Figure 4.21 X-ray molecular structure of trans-[Rh(PPh3)2(CO)(O2CPh)]·MeOH (5), showing thermal 
ellipsoids at the 50% probability level and the disorder of the methanol molecule and the PPh3 phenyl ring.  
 
The rhodium atom adopts a square-planar coordination geometry with a slight tetrahedral 
distortion. The benzoate ligand is monodentate, the un-coordinated oxygen atom 
accepting a hydrogen bond from the disordered methanol molecule of crystallization. The 
carboxylate plane is inclined by 68° to the mean coordination plane of Rh and by 19° to 
the adjacent phenyl ring. Bond distances (Å) and angles (°): Rh−P(1) 2.3377(6), Rh−P(2) 
2.3216(6), Rh−O(1) 2.066(1), Rh−C(8) 1.808(2), O(1)-C(7) 1.284(2), O(2)-C(7) 
1.245(2), P(1)-Rh-P(2) 170.26(2), O(1)-Rh-C(8) 176.93(6), Rh-O(1)-C(7) 117.9(1). Bond 
distances are similar to those in trans-[Rh(PPh3)2(CO)(O2CR)] analogues, where R = H 
(compound 4),
344
 Me
356
 and CF3.
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Future work 
 
5.1 Future work relating to Chapter 2 
 
Although the synthesis of the TTNPB series of retinoid was successfully completed, 
possibilities for improving the work exist. In particular, the Pd-catalysed borylation 
reactions of aryl iodides with B2pin2 or B2neop2 could be coupled with subsequent 
Suzuki-Miyaura cross-couplings to give the cross coupled products directly from the aryl 
iodides in two-step, one-pot procedures. In addition, work in Chapter 4 has demonstrated 
that Rh-catalysed dehydrogenative borylations of alkenes can be performed in MTBE and 
followed by Suzuki-Miyaura cross-couplings to give the cross-coupled products in a one-
pot procedure. Applying this to the synthesis of the TTNPB retinoids would allow for the 
syntheses to be carried out in two one-pot procedures from the parent arene or aryl 
iodide. 
 
 
5.2 Future work relating to Chapter 3 
 
Similarly, the syntheses of biaryl-based retinoid esters could be performed by one-pot 
borylation/Suzuki-Miyaura cross-coupling sequences, while the tolan-based retinoid 
esters could possibly be synthesised in a one-pot sequence consisting of a Sonogashira 
reaction between aryl iodides and TMSA, in situ desilyation of the protected alkyne 
products and addition of a second aryl halide and subsequent Sonagashira cross-coupling 
to give the retinoid ester products. 
 
5.3 Future work relating to Chapter 4 
 
Chapter 4 details the development of second generation catalysts for the synthesis of 
vinyl boronate esters (VBEs) from unactivated alkenes. In this work it is established that 
287 
 
the anionic ligand in the rhodium complex is lost in the catalyst initiation step and that 
catalyst initiation is rapid when the anionic ligand is OR or H. The low activity exhibited 
by trans-[Rh(PPh3)(iMes)(CO)Cl] compared to  trans-[Rh(PPh3)2(CO)Cl] shows that 
catalytic activity can be altered by changing the dative ligand. Thus, to further improve 
catalytic activity a range of HRh(PR3)3(CO) complexes should be screened to assess the 
effects of phosphine structure on catalytic activity. 
 
In addition a catalytic system that gave VBEs as the sole products from styrenes and 
other mono-substituted terminal olefins would be desirable as the current system, though 
highly active and selective for the borylation 1,1-disubstituted alkenes and indene, is 
poorly selective for VBE formation from styrenes. 
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